

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

1

FUNCTIONAL GASTROINTESTINAL DISORDERS  
PUBLIC MEETING ON  
PATIENT-FOCUSED DRUG DEVELOPMENT

Monday, May 11, 2015

Food and Drug Administration  
White Oak Campus  
10903 New Hampshire Avenue  
Silver Springs, MD 20993

Facilitator: DR. SARA EGGERS Reported

by: Michael Farkas,

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

2

1	C O N T E N T S	
2	Speaker	Page
3	Dr. Donna Griebel	5
4	Dr. Theresa Mullin	11
5	Dr. Laurie Muldowney	17
6	Dr. Sara Eggers	25
7	Tanya Taylor	39
8	Cynthia Bens	44
9	Carrie Reily	52
10	Bettemarie Bond	59
11	Anne Sirota	111
12	Lynn Wolfson	117
13	Julian Chilson	124
14	Meredith Holt	128
15	Carol Pasinkoff	131
16	Tegan Gaekano	175
17	Marilyn Geller	178
18	Ellen Komichers	179
19	Carissa Haston	180
20	Nancy Ginter	184
21	Kelly Brezoczky	187
22		

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

3

1	APPEARANCES CONTINUED	
2	Ritu Verma	190
3	Mary Berger	192
4	Bruce Zagnit	192
5	Debbie Fisher	196
6	Raymond Panus	197
7	Dr. Andrew Mulberg	199
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

4

1 P R O C E E D I N G S

2 DR. EGGERS: Welcome everyone. My name  
3 is Sara Eggers and I'm in the Office of Strategic  
4 Programs here within the Center for Drug  
5 Evaluation and Research here at FDA. I'm going to  
6 be the discussion facilitator today and I am  
7 delighted that we are finally here at the meeting.  
8 I'm especially delighted, since my voice came back  
9 on Saturday. This would have been a physically  
10 impossible task for me to do, because I lost my  
11 voice. So, if I start to lose it in the middle of  
12 today, just let me know and I'll try to speak  
13 closer to the microphone and someone can bring me  
14 some water if they see me struggling.

15 Our meeting today is part of our  
16 agency's Patient-Focused Drug Development  
17 Initiative, which is focused on gathering patient  
18 perspective on functional GI disorders. We'll  
19 hear some more background about that in a little  
20 bit. And Donna Griebel is going to come up and  
21 give some opening remarks in a few minutes, but  
22 first I'm going to ask my colleagues at the FDA

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

5

1 table to go through and say your name and where  
2 you are located within the agency and push the red  
3 button to turn the mike on.

4 DR. GRIEBEL: I'm Donna Griebel. I'm  
5 the Division Director in the Division of  
6 Gastroenterology and Inborn Errors Products.

7 DR. MULBERG: Good afternoon, Andrew  
8 Mulberg, Division Deputy in Gastroenterology and  
9 Inborn Errors Products.

10 DR. MULDOWNNEY: I'm Laurie Muldowney,  
11 and I'm a clinical reviewer within the same  
12 division.

13 DR. MULLIN: Hi, I'm Theresa Mullin, and  
14 I direct the Office of Strategic Programs and and  
15 the Center for Drugs.

16 DR. DIMICK: Lara Dimick, and I'm also a  
17 Medical Reviewer in the GI Division.

18 DR. VENKATARAMAN: Preeti Venkataraman,  
19 also a Clinical Reviewer in the same division.

20 DR. KOVACS: Sarrit Kovacs, Study  
21 Endpoints Reviewer in Office of New Drugs.

22 DR. EGGERS: Thank you very much. And

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

6

1 we will learn your names in a little bit, as we go  
2 through the discussion, so I would like to thank  
3 those of you who are in person, and also to the  
4 folks that are on the web. We have a very, very  
5 strong turnout on our web and participating by web  
6 today. There will be every opportunity for those  
7 on the web as well.

8           We have a full agenda this afternoon.  
9 We'll first spend a little bit of time setting the  
10 context and have my FDA colleagues provide some  
11 background on our initiative and on the functional  
12 GI disorders. And then we're going to get into the  
13 whole purpose for our discussion, which is  
14 listening to you. I will go over the meeting  
15 format and the process before we get into that  
16 discussion.

17           Our two main topics are the disease  
18 symptoms that matter most to patients, followed by  
19 patient perspective on current approaches to  
20 treating functional GI disorders. We have time  
21 set aside for open public comment this afternoon.  
22 While the primary focus of our discussion is

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

7

1 really dialog with patients living with functional  
2 GI disorders, open public comment gives anyone a  
3 chance to offer a perspective or experience or a  
4 comment at the end of the meeting. So, anyone can  
5 comment. And to participate, you'll sign up at  
6 the registration desk, if you haven't already.  
7 We'll close that registration sign-up at the  
8 break, and it's a first come, first served. The  
9 time allotment will probably be on the order of  
10 two minutes.

11           There is a kiosk with food and  
12 beverages, and restrooms are located behind the  
13 kiosk toward the back wall in that lobby and then  
14 all the way to the right. We're going to take a  
15 15-minute break somewhere between 2:45 and three  
16 o'clock. It says 2:45 on your agenda, but I think  
17 our first discussion is going to be jam packed,  
18 and so we'll let it slip a bit into that. So, by  
19 three o'clock we'll be taking a break, but please  
20 feel free at any time -- this is a very informal  
21 setting and informal meeting. Get up when you  
22 need to, do whatever you need to and make

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

8

1 yourselves comfortable, and let us know if there's  
2 anything that you need. The meeting is being  
3 transcribed and a live webcast is being recorded  
4 and will be archived on our website. And with  
5 that, I would like to turn it over to Donna who  
6 will give some welcoming remarks.

7 DR. GRIEBEL: Good afternoon. And I  
8 welcome you as well to this Patient-Focused Drug  
9 Development meeting on functional GI disorders.  
10 You've already heard that I'm Donna Griebel. I'm  
11 the Division Director in the Division of  
12 Gastroenterology and Inborn Errors Products. Our  
13 division is the division in the Office of New  
14 Drugs that reviews drugs that are intended to  
15 treat functional GI disorders. We're grateful to  
16 all of you patients and patient advocates who came  
17 to the White Oak Campus to be here with us today  
18 in the audience. And as well, I understand that  
19 we are joined by many, many more via web.

20 Today's meeting is one in a series of  
21 what we're calling FDA's Patient-Focused Drug  
22 Development Meetings. Theresa Mullin will be



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

9

1 talking a bit more about this initiative in a few  
2 minutes. Functional GI disorders are common  
3 disorders. They're characterized by persistent  
4 and recurrent GI symptoms and occur as a result of  
5 abnormal functioning of the upper and lower GI  
6 tract. Disorders within this group include  
7 irritable bowel syndrome, gastroparesis, chronic  
8 persistent symptomatic gastroesophageal reflux  
9 disease that persists despite standard therapeutic  
10 interventions, and chronic idiopathic  
11 constipation. Dr. Laurie Muldowney from our  
12 division will be providing a bit more background  
13 information on these disorders in a few minutes.

14           This is a very important meeting to us.  
15 We fully understand that functional GI disorders  
16 are serious conditions and that there is a great  
17 need for treatments for these disorders. It's  
18 FDA's responsibility to ensure that the benefits  
19 of a drug outweighs its risks. Therefore, having  
20 this kind of dialog is extremely valuable for us.  
21 What we hear from you today can help us understand  
22 how patients view benefits and how they view the

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

10

1 risk of treatments for these disorders. We want  
2 to hear from you today about the different ways  
3 your symptoms affect your daily life. It's also  
4 important to hear from you what you value in a  
5 treatment for functional GI disorders and what you  
6 would like to see in future treatments.

7           It's important to remember that FDA is  
8 just one part of the drug development process. We  
9 do not represent the boots on the ground who are  
10 actually doing the drug development or conducting  
11 the clinical trials. Drug companies working with  
12 researchers and patient communities are the ones  
13 who conduct the trials and submit applications for  
14 new drugs to the FDA. We at FDA work closely with  
15 drug companies throughout the drug development  
16 process. We have frequent meetings with  
17 companies. We discuss early clinical trial  
18 designs. We discuss the results of those early  
19 clinical trials to give input on what the designs  
20 for the so-called pivotal trials that will be  
21 submitted to support the application for approval.  
22 We also look at the safety results from those

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

11

1 trials and early safety information from animal  
2 data.

3 I know there are a lot of  
4 representatives from industry, academia, and  
5 others in the room and on the web. We thank you  
6 all for being here and being a part of this  
7 meeting as well. We believe this meeting will be  
8 a valuable source of information for you, too.

9 So, again, welcome everyone. I'll now  
10 turn it over to Theresa Mullin who will talk about  
11 our broader efforts in Patient-Focused Drug  
12 Development.

13 DR. MULLIN: Thank you, Donna. And good  
14 afternoon again. And as Donna said, I'm going to  
15 just tell you a little bit more about this  
16 initiative that we've undertaken, that this  
17 functional GI disease meeting is a part of this  
18 initiative for us. As Donna was saying, you know,  
19 FDA's job is to assess whether the benefits  
20 outweigh the risks for a given application, a  
21 given new drug and a disease. And we get the  
22 evidence submitted to us by the sponsor, the so-

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

12

1 called sponsor, the company sponsoring that  
2 application. And they collect that information in  
3 the clinical trials that they run. But what's  
4 very critical for us to understand is the context  
5 of this disease, and really, the severity of this  
6 disease and the degree to which there's an unmet  
7 medical need. That the treatments that are  
8 currently available and on the market already, how  
9 well do they meet that need? How well do they  
10 treat that disease and that severity? And what we  
11 realized is that patients -- well, you might think  
12 this is kind of a, why did it take the lightbulb  
13 this long to go on, but, you know, the patients  
14 are in a very unique position to inform that,  
15 because patients are the ones who experience the  
16 disease. They are the ones who are going to use  
17 the treatment. Any benefits to be gained, they  
18 will be experiencing any risks they will  
19 experience, and they're uniquely positioned to  
20 tell us about the severity of the disease and  
21 what's the most impactful aspects of the disease  
22 for them, and whether or not the treatments that

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

13

1 are available, if any, are effective.

2           And so, we wanted a more systematic way  
3 to get this kind of information. We have a very  
4 good patient representative program, but we can  
5 only -- we involve patients as individuals  
6 representing the whole community of patients. And  
7 they are helping us in looking at particular drug  
8 applications, particular matters, as the  
9 government calls it. And we also have to do some  
10 conflict of interest screening for that because of  
11 that particularity. We wanted to get a more  
12 widespread input from patients experiencing a  
13 disease, and that's why we set up these meetings.  
14 And so, getting the information in this kind of by  
15 disease and not by particular drug enables us to  
16 have a larger meeting like the one we're having  
17 today. And those of you who have come -- and  
18 thank you very much for coming to this meeting and  
19 being in the room and for joining us on the  
20 webcast. Your perspective on this disease really  
21 helps us to understand the context and make those  
22 better-informed decisions both in the development

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

14

1 programs and companies coming in to talk about  
2 drugs in development, and when we're looking at  
3 applications.

4           So, we set this up, this Patient-Focused  
5 Drug Development, that's the name we use to refer  
6 to these meetings as a way to kind of pilot this  
7 idea of trying to get information in, you know, in  
8 the context of the disease, not in the context of  
9 a particular drug application. And we're  
10 committed to do at least 20 of these meetings,  
11 each in a different disease area over the five  
12 years of this program or the reauthorized PDUFA  
13 program that goes from fiscal year 2013 to 2017.  
14 And so, we started in September of 2012 right  
15 before our new fiscal year, '13 was to start. Put  
16 out a list of diseases, got public comment, got a  
17 lot of comment on that. And the first 16 of the  
18 diseases we're covering in the first three years  
19 were in response to that process of getting public  
20 input on our list revising it and putting it out  
21 there. And this is the list that we had for the  
22 first three years. And as you can see, we're

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

15

1 working our way through the lists that we had to  
2 date, and here we are today covering our  
3 functional GI disorders meeting. And so, as I  
4 said, we really focus on the severity and what's  
5 it like to live with this disease? What are the  
6 most important impacts? And what are your  
7 experiences with current treatments? And Sara  
8 showed you that our two sessions are organized  
9 around those two themes. We start out with that,  
10 but we also ask the review division when our  
11 office is trying to help coordinate these meetings  
12 and setting them up, what other questions do you  
13 want to ask? It's a very special and unique  
14 opportunity for us to hear from patients with a  
15 disease about other aspects, maybe clinical trial  
16 participation, trade-offs that they think --  
17 questions that the review division would like  
18 answers to, like to hear from patients about.  
19 This is a golden opportunity to ask questions like  
20 that as well. So, we tailor the meetings a little  
21 bit to the particular aspects of the disease and  
22 treatments associated with that disease. And we

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

16

1 find that patient advocacy groups and others have  
2 -- and actively helping us get the word out about  
3 the meetings ahead of time has helped us to really  
4 make them a success because of the increased  
5 participation.

6           And finally, what do we produce? At the  
7 end of these meetings, which we have the meeting,  
8 we have the webcast, we have a wonderful  
9 discussion here. We hear from a very rich set of  
10 panelists and their perspectives. We also have  
11 our docket. We leave open an electronic docket,  
12 so any documents or other information that people  
13 want to submit to us during or after the meeting,  
14 we leave that open for at least a month or so, so  
15 we can get that information in. We put all that  
16 together in what we call the Voice of the Patient  
17 Report. And if you go to our website, you'll see  
18 the reports that we have posted there to date for  
19 the meetings we've already had. And we think  
20 these reports are helpful to our review divisions  
21 as a sort of a reference set they can go back and  
22 look at later, especially as applications come in



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

17

1 associated with that disease. Industry sponsors  
2 have told us it's useful. And actually, we've  
3 heard from patients who have had the diseases that  
4 we've already had meetings about. And they have  
5 said the reports have actually been very helpful  
6 to them as well. We see them as maybe also a  
7 kickoff of a way to look at more systematic  
8 collection of this information that might even be  
9 done during clinical trials and used as part of  
10 that evidence base for deciding about whether the  
11 benefits exceed the risks.

12                   And with that, I'd like to turn the mike  
13 over to Laurie to tell you more about the  
14 background on the disease, thank you.

15                   DR. MULDOWNNEY: My name is Laurie  
16 Muldowney, again, and I'm a Clinical Reviewer  
17 within the Division of Gastroenterology and Inborn  
18 Error Products. And I want to thank everybody for  
19 coming today to provide us with really helpful and  
20 important insights as to what it's like to live  
21 day to day with a functional gastrointestinal  
22 disorder. Before we turn the floor over to you

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

18

1 all, I was asked to just provide some brief  
2 background on some of the disorders that are  
3 represented today.

4           So, functional GI disorders is really a  
5 term used to describe a group of chronic GI  
6 disorders in which patients experience symptoms,  
7 but there's generally no anatomic or structural  
8 abnormality. So, these diseases can affect  
9 anywhere from the esophagus to the rectum, and  
10 they're typically characterized by a chronic  
11 course, and often with very unpredictable symptoms  
12 that can be disabling to patients. There's still  
13 a lot to learn about the underlying cause of  
14 functional GI disorders. These are not  
15 psychological disorders. The signs and symptoms  
16 are thought to relate to a number of issues,  
17 including abnormal intestinal motility, abnormal  
18 intestinal perception, or abnormal brain/gut  
19 communication. Because there are no objective  
20 measures, though, for example, generally no  
21 abnormalities on a colonoscopy, the diagnosis is  
22 really based on patient signs and symptoms.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

19

1           There are approximately 45 functional  
2 gastrointestinal disorders. And this is based on  
3 the Rome III criteria. So, the Rome criteria were  
4 established by an international group of experts  
5 in order to standardize the diagnosis and the  
6 classification for functional GI disorders. I've  
7 listed some of them here. Of course, this is not  
8 an inclusive list, and Donna mentioned several of  
9 these before. Irritable bowel syndrome, which can  
10 further be subdivided into constipation or  
11 diarrhea predominant or a mixed subtype. Chronic  
12 idiopathic constipation, functional dyspepsia,  
13 gastroparesis, and and functional abdominal pain,  
14 again, are just some examples. Importantly, there  
15 is a lot of overlap between these conditions and  
16 many, many patients we know suffer from two or  
17 more functional GI disorders.

18           They're incredibly common, so some  
19 estimates suggest that at any one time, two out of  
20 every five people in the United States are  
21 affected by a functional GI disorder. And  
22 importantly, they impact across every demographic

1 category. So, across age, gender, race,  
2 ethnicity, and socio-economic status. I've  
3 included some prevalence numbers here for some of  
4 the disorders that I believe are represented  
5 today, but as you can see, particularly irritable  
6 bowel syndrome, functional dyspepsia, and  
7 functional constipation, which we also call  
8 chronic idiopathic constipation, are very, very  
9 common.

10           So, I mentioned before that some of the  
11 symptoms are thought to relate to abnormal  
12 intestinal perception and abnormal brain/gut  
13 communication, so this slide just really shows  
14 sort of that brain/gut communication that I  
15 mentioned. When we talk about abnormal intestinal  
16 perception, we're basically just implying that  
17 normal activities of the GI tract, so intestinal  
18 contractions, normal things that we expect to  
19 happen, cause pain or discomfort, whereas a  
20 patient who is not suffering from a functional  
21 gastrointestinal disorder would not perceive that  
22 as painful.

1 Abnormal brain/gut communication is  
2 referring to what we call the enteric nervous  
3 system or the little brain in the gut. And this  
4 is really just a set of nerves throughout the GI  
5 tract that send signals to the central nervous  
6 system and vice versa. So, in patients with  
7 functional gastrointestinal disorders, these  
8 interactions are impaired and patients experience  
9 pain, nausea, and other symptoms when they  
10 shouldn't.

11 So, some of the common signs and  
12 symptoms that you all are very well familiar with,  
13 pain, heartburn, abdominal distention and  
14 bloating, nausea and vomiting, constipation and  
15 diarrhea. We also see urgency, decreased  
16 appetite, swallowing difficulties and  
17 incontinence. And again, I know that's not an  
18 inclusive list, but just some of the common signs  
19 and symptoms that are seen.

20 So, we understand that these conditions  
21 can have a significant impact on an individual's  
22 quality of life. Patients are impacted, not only

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

22

1 physically, but socially and emotionally as well.  
2 And misunderstanding, even in the medical  
3 community, can lead to misdiagnosis, unnecessary  
4 testing, incorrect procedures or treatments, and  
5 worse outcomes for patients.

6           So, what are the costs for functional  
7 gastrointestinal disorders? It's difficult to  
8 estimate the costs, because a lot of what is seen  
9 is done in an outpatient basis. But I've seen  
10 numbers ranging from one and a half to ten billion  
11 for direct costs. And when we think about direct  
12 costs, we're basically talking about costs for  
13 doctors' visits, for hospitalizations and  
14 surgeries, and for medications, so things that are  
15 directly related to that diagnosis. But indirect  
16 costs are really even more astounding with  
17 estimates of up to 20 billion. So, that's  
18 including the cost of lost work days, lost school  
19 days, those types of things, in addition to the  
20 costs of actually seeing your doctor and taking  
21 your medications.

22           It's difficult to cover the full

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

23

1 spectrum of treatments when we're talking about  
2 such an array of disorders, but I was asked to  
3 provide sort of an overview of some treatment  
4 options. In general, dietary management is  
5 commonly used for these conditions, and there are  
6 a number of over-the-counter drugs that are  
7 commonly used. Antidiarrheals or promotility  
8 agents can be used to treat the diarrhea or  
9 constipation associated with some of these  
10 disorders. Proton pump inhibitors and H2 blockers  
11 are classes that are often used to treat  
12 heartburn-related symptoms. There are  
13 prescription therapies available for some. We  
14 understand that it is limited and there's a need  
15 for new and more options for these disorders, but  
16 lubiprostone and linaclotide are both indicated to  
17 treat irritable bowel syndrome with constipation  
18 as well as chronic idiopathic constipation.  
19 Metoclopramide, of course, is indicated for  
20 gastroparesis, and alosetron is indicated for  
21 irritable bowel syndrome with diarrhea, but is  
22 limited in that it's only actually indicated for

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

1 women and it has some restrictions because of some  
2 safety concerns.

3           Off-label medication use, of course,  
4 patients are sometimes prescribed antidepressants.  
5 And there are also a few therapies such as  
6 Zelnorm, domperidone, and cisapride, to name a  
7 few, which are not approved therapies for a  
8 variety of reasons, but which can be accessed  
9 through special programs for patients who have  
10 failed other treatment options. And finally, in  
11 gastroparesis, specifically, gastric electrical  
12 stimulation has been used and sometimes feeding  
13 tubes are necessary.

14           So, patient-reported outcomes for  
15 conditions like functional GI disorders where  
16 there's no structural or biochemical abnormality  
17 that we're necessarily tracking, input from  
18 patients is really particularly important.

19 Patient-reported outcomes can, for us, represent a  
20 direct measure of treatment benefits. So, if we  
21 can demonstrate that a therapy improves how  
22 patients feel or function in their daily life,



1 which, of course, has to come directly from the  
2 patient, then that's a way that we can assess  
3 whether or not one of these treatments is  
4 providing benefit. These measurements need to be  
5 well understood and evaluated in what we call  
6 adequate and well-controlled trials. So, when  
7 you're comparing against patients who are not on  
8 the same treatment so that we can see how that  
9 would compare. So, really, you know, these  
10 meetings are always very important and it's always  
11 really helpful for us to get insights from  
12 patients and caregivers, but in a disease -- in a  
13 group of disorders, like functional GI disorders  
14 where we're really relying on that input to  
15 determine if drugs are working or not, I think  
16 it's really even more important. So, we very much  
17 appreciate your time and your thoughts today. And  
18 that's it, thank you.

19 DR. EGGERS: So, I'm the last FDA person  
20 to speak for a while and then we'll move to the  
21 patients. I just want to go over the format and  
22 how this works. This meeting is quite different in

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

26

1 format and style than what you might expect from a  
2 public meeting by a government agency. We're  
3 happy to say that. Our intent is really to foster  
4 open dialog on -- about people's personal  
5 experiences living with their conditions. We are  
6 going to be navigating through the spectrum of GI  
7 disorders today. Our goal is not to focus on any  
8 one particular condition, but to identify the  
9 commonalities and perhaps the differences amongst  
10 your experiences and perspectives.

11           We have the two topics. The questions  
12 that are really framing our discussion are found  
13 in the back of your agenda on the second page and  
14 you can see those. And the first topic, again,  
15 focuses on the symptoms that matter most to you,  
16 which ones have the most significant impact on  
17 your life? How do they affect your ability to do  
18 specific activities and how they change over time?

19           What's critical to hear today is the  
20 specific examples of your symptoms. How do you  
21 describe them? What terms do you use? What  
22 activities can you not do? What might surprise

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

27

1 FDA if they knew that you can't do this activity  
2 but you really want to or you're limited in that  
3 activity? And what makes a flare? And what's the  
4 difference between your worst days and your best  
5 days? So, we're going to get into that in just a  
6 few minutes. And then, after the break, we'll  
7 come back and talk about the current approaches to  
8 treating functional GI disorders. And we know  
9 it's a complex treatment regimen. What we are  
10 going to try to tease out is what is the role of  
11 pharmaceutical treatments within that treatment  
12 regimen? How well are they working for you? What  
13 are their downsides? What do you wish they could  
14 do better?

15           For each of those topics, we're going to  
16 first hear from a panel of patients. We have no  
17 caregivers. They're all patients today who will  
18 be coming up. And I'm going to ask those who are  
19 in Topic 1 to start to make your way to the front  
20 and bring your name tags, if you can. You can sit  
21 anywhere up here.

22           The purpose of these panel comments is

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

28

1 really to set a good foundation for our discussion  
2 by hearing brief snapshots of four different sets  
3 of experiences. Each of the panelists has  
4 prepared about four minutes of remarks. After  
5 that, we will move into a facilitated discussion  
6 and we will engage all of the patients,  
7 caregivers, patient advocates in the room to  
8 really build on the discussion. What's similar to  
9 what you heard reflected up here? What's  
10 different? We have -- staff will be coming around  
11 with microphones so you don't need to get up.  
12 We'll come to you. And I ask that you please  
13 state your first name. We don't need your last  
14 name, just your first name, every time you speak  
15 so that we can capture that. And because we have  
16 so many conditions, please state your disorder or  
17 your primary disorder or a few disorders that  
18 you're speaking about. Please try to limit your  
19 responses and keep them focused to the topic  
20 that's being discussed or the question that's  
21 being asked, the symptom that's being talked  
22 about. We hope that we, you know, get to come to

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

29

1 you several times, and so this will just help our  
2 discussion move forward. I'll ask, periodically,  
3 with a show of hands if you agree with what  
4 someone said or if you don't agree. So, that's  
5 another way we can get input.

6           We have also some polling questions,  
7 which just give us a little bit more insight and  
8 aid our discussion, if we can hand out the little  
9 polling clickers. We have these little clickers  
10 that you can push a button. We're going to have  
11 some practice with this in a bit. These are not  
12 at all meant to be scientific questions or a  
13 polling or a survey of any kind. It's just to aid  
14 our discussion. You know, who's in the room, what  
15 kind of experiences you have, and where we can  
16 really move the discussion. We ask that patients  
17 and patient representatives only please.

18           And then, the webcast, I mentioned that  
19 there's a strong showing on the webcast. And you  
20 are playing a very valuable contribution to this  
21 meeting. Sometimes the folks who are on the  
22 webcast are slightly different in terms of

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

30

1 representation than the people in person, and we  
2 hope that you're typing furiously in response to  
3 the questions that we ask, and we're collecting  
4 all this information. We'll be summarizing -- if  
5 we don't read yours out, we'll be summarizing it  
6 periodically through the day and it's being  
7 captured.

8           We're also going to go to the phones  
9 occasionally to give those of you who are  
10 participating remotely and opportunity to  
11 contribute. I ask the same ground rules apply.  
12 Please keep your comments, if you're commenting on  
13 the phone, tailored to the topic that we're on so  
14 that we can gather a few more phone comments.

15           We also want your comments -- comments  
16 from you and others who you know who haven't been  
17 able to attend the meeting. Reach out to your  
18 networks and get your peers and your colleagues  
19 and your -- those of you in your support groups to  
20 also contribute to us by sending comments through  
21 the public docket. If there's something we can't  
22 get to today, we didn't flesh out in detail, you

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

31

1 can also -- we want you to comment as well. And  
2 that's basically a website that you visit. You  
3 click on a comment now button and you can type in  
4 a comment or you can upload a Word document. If  
5 you have any trouble, go to the patient- focused  
6 email address that we provided. Our docket will  
7 be open until July 13th. Again, these comments  
8 will be reviewed by us and summarized -- included  
9 into our summary report.

10           There are some more resources at FDA. I  
11 just want to point out to you we have the FDA  
12 Office of Health and Constituent Affairs. And is  
13 someone from that office here today? Yes, in the  
14 back, we have Andrea Tan. So, that office runs  
15 the patient representative program that Theresa  
16 talked about. So, if you're interested in  
17 furthering your engagement with FDA, go find  
18 Andrea and she can give you more information.  
19 Within our seat of the drug side of FDA, we have a  
20 professional affairs and stakeholder engagement,  
21 and is Chris here? He's floating around. He's  
22 also one -- you can stand up, Chris. He's also

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

32

1 one that if you have questions, particularly if  
2 you're a patient organization and have questions  
3 or comments or want to contribute, continue to  
4 contribute, please identify him and their  
5 information. These -- our web slides will be  
6 posted, so you can contact them directly.

7           There are a few ground rules just to  
8 make sure that our discussion is as most effective  
9 for all of us involved. We really encourage  
10 patients to contribute to the dialog. That's who  
11 we -- that's a perspective we really want to hear.  
12 Caretakers, loved ones, and advocates, we want to  
13 hear your perspectives, too. If you can, what  
14 your role is, is what might others that you know  
15 who have these conditions, what might their  
16 perspectives be, and can you round this out a bit  
17 to build on what we hear from the patients who are  
18 in the room. We are going to try to accommodate  
19 everyone who wants to share today. And again, if  
20 we don't get to everything that you want to share,  
21 that's what the docket's for. Please follow up  
22 with that.



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

33

1           The industry, the others in the room, we  
2 ask that you stay in listening mode. There is an  
3 open public comment, as we mentioned that you can  
4 contribute if you have something you'd like to  
5 share.

6           The FDA is here to listen. We may not  
7 be able to address every question that may be on  
8 your mind about drug development, about FDA. Our  
9 role really is to listen to you. But there will  
10 be evaluation forms, and if you have a specific  
11 question, write it out there with your contact,  
12 your email, and we will try to find the answer to  
13 that question for you.

14           As have been described, our discussion's  
15 really narrowly focused, symptoms, impact, burden,  
16 and then treatment. We know that there are so  
17 many issues that you face regarding diagnosis,  
18 regarding getting the adequate care and support  
19 that you need. We're not going to be able to  
20 delve in as deeply to those topics today. Again,  
21 you can tell us that through the docket, if you  
22 want to explain -- provide more of your thoughts

1 on that.

2           We also will be talking about treatments  
3 throughout the day. And our discussion -- when we  
4 talk about treatments, it's not our intent to come  
5 out at the end of the day and say, "This treatment  
6 works great. This treatment's not great." What  
7 we're looking is, what is it about treatments in  
8 general that you find beneficial? How do you know  
9 they they're beneficial? How do you know that  
10 they're working for you and what are their  
11 downsides in general? That helps generally expand  
12 our context.

13           The opinions expressed here are personal  
14 opinions and demonstrating respect is of paramount  
15 importance. This discussion is going to touch  
16 upon very sensitive topics. And we respect you  
17 and appreciate so much your willingness and  
18 courage to share those. And everyone in the room  
19 is here to support -- we want to hear from you.  
20 We want to learn from you. So, we hope that you  
21 feel comfortable to share your thoughts.

22           Finally, we want your feedback on the

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

35

1 meeting. What we learn here today will help us as  
2 we continue to design and implement further future  
3 Patient-Focused Drug Development meetings. There  
4 are evaluation forms on the desk.

5           With that, okay, I guess we're on to the  
6 polling questions. Does everyone have their  
7 clickers? So, when we ask the question, you can  
8 choose A. I think it's also 1. Or whatever  
9 number corresponds to your -- to the right choice  
10 for you. So, where do you live? Within the  
11 Washington, D.C., metro area, click

12           A. And B, outside of the metro area. And  
13 if you're on the web, you should be seeing these  
14 questions as well, and you just click in the right  
15 choice.

16           Okay, so we can see the results. So,  
17 two thirds of you deal with the Beltway every day  
18 -- one third of you deals with the Beltway every  
19 day and two thirds of you have the pleasure of  
20 only once in a while dealing with the Beltway.  
21 So, thank you very much. And on the web --

22           MR. THOMPSON:   Ninety percent outside

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

36

1 of D.C.

2 DR. EGGERS: And the web does like that.

3 You're from all over, we hope.

4 Are you male, A? B, female?

5 We knew this coming in. We have a big,  
6 robust representation from women, but as Laurie  
7 mentioned, this condition affects everyone. So,  
8 on the web and in the docket, if you can go out  
9 and reach out to people who are men and get them  
10 to share their experiences, we do -- it's very  
11 important that we hear from men as well.

12 Have you or your loved one ever been  
13 diagnosed as having a functional GI disorder?

14 So, for the remainder of the set of  
15 questions, some of you are here with clickers,  
16 you're here as a loved one or as an advocate. For  
17 the purposes of the clickers, we're going to ask  
18 that the remainder of these questions, that it's -  
19 - every clicker is from one person, so if you're  
20 the person living with the condition, you've got  
21 the clicker, or if you're a caretaker and you're  
22 here on behalf of someone who's not here, use the

1 clickers. But otherwise, please keep -- no more  
2 use of the clickers.

3           Which of the following functional GI  
4 disorders do you have? And you know, some of you  
5 here have some things other than functional GI  
6 disorders. We think most of you have some form of  
7 a functional GI disorder. So, you might be an  
8 other. You can choose all that apply. A,  
9 irritable bowel syndrome; B, gastroparesis; C,  
10 chronic persistent symptomatic gastroesophageal  
11 reflux despite standard therapeutic interventions.  
12 I'm going to guess, if they have GERD, is this the  
13 one that they -- close enough? Close enough. If  
14 you have GERD, do C. D, chronic idiopathic  
15 constipation. And E, some other.

16           These numbers indicate, as Laurie said,  
17 many of you have multiple things. And it's great  
18 to see we have reflection of -- across the  
19 spectrum, some more than others.

20           On the web?

21           MR. THOMPSON: Forty-three percent  
22 irritable bowel syndrome, 60 percent

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

38

1 gastroparesis, 27 percent GERD or other, and 29  
2 percent chronic idiopathic, and 24 percent other.

3 DR. EGGERS: Thank you. What is your  
4 age or your loved one's age? A, younger than 18;  
5 B, 18 to 30; C, 31 to 40; D, 41 to 50; E, 51 to  
6 60; F, 61 to 70; or G, 71 or better.

7 So, this means that we have a nice -- we  
8 have a robust range in the middle in person. And  
9 what do we have on the web?

10 MR. THOMPSON: A very similar range.  
11 Four percent under 18; nine percent 18 to 30; 31  
12 percent for both for both 31 to 40 and 41 to 50;  
13 14 percent 51 to 60; and 11 percent 61 to 70.

14 DR. EGGERS: It's going to be very  
15 important if advocates and if others, if you can  
16 help support finding perspectives that can be  
17 shared through the docket on the pediatric and the  
18 older populations, that would be very helpful.  
19 We're going to be staying in this discussion today  
20 toward the middle.

21 And with that, we will move on to the  
22 Topic 1 discussion. We're going to go through and

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

39

1 ask each of you to share your remarks. You're  
2 going to push the red button, and we'll go through  
3 -- there may be some clarifying questions we have  
4 at the -- beyond, but unless it's a real burning  
5 clarifying question, we'll probably just move  
6 right into the next person. So, we will start with  
7 Tanya.

8 MS. TAYLOR: Hi, my name is Tanya  
9 Taylor. I have gastroparesis along with a number  
10 of other of the esophageal, dysmotility, small  
11 intestinal dysmotility, and colonic inertia, which  
12 actually led to removal of my colon. The three  
13 things -- I'm going to read what I wrote. It's, I  
14 think, easier that way. The three things that are  
15 most bothersome for me in this life is the pain,  
16 nausea, and the inability to eat. I very rarely  
17 get a hunger pain, and that started quite some  
18 time ago. There are a number of specific  
19 activities I can't do. I cannot go out with  
20 friends and be able to keep up. And that's been  
21 seven years, I guess, been seven. I've lost most  
22 of my friends because of that. I do not sleep more

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

40

1 than three hours at a time because of pain and  
2 tachycardia and shortness of breath. I've been  
3 unable to take normal showers for a couple of  
4 years because of the weakness and blackout spells  
5 that the water instigates. The routine for me to  
6 get washed up is it takes a one- to three-hour  
7 period for me to get washed up, because I have to  
8 take too many breaks to rest.

9           And once in a blue moon, my husband and  
10 I get to go to a friend's house, but I think it's  
11 been several years since we've done that. We used  
12 to go out and eat. That was one of our favorite  
13 things to do, and we haven't been able to do that  
14 for five-plus years. My granddaughter, I haven't  
15 been able to take her to the park by myself. I  
16 have to have an adult come with me, because I'm  
17 just too weak. I'm 114 pounds now, but I was 94  
18 pounds when I first started back on the IV  
19 nutrition again, and you have a little more  
20 strength being this weight, but I know when I was  
21 94 pounds, I could even do less than I do now. On  
22 my bad days, I'm not able to get dressed. I'm too



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

41

1 weak. I generally am in the bed.

2 I haven't been able to do laundry,  
3 cleaning, cooking, anything like that in I know at  
4 least four years. And I used to love to clean,  
5 cook, and do all of those things. On my best  
6 days, it takes an hour to get washed up and that  
7 includes the rest time. Putting my hair -- using  
8 my muscles, I'm always fatigued and it just kind  
9 of sets me back, so I have to get the energy to  
10 keep up. On the worst days, I could be  
11 hospitalized or throwing up constantly. I had to  
12 have two Botox injections because of that.

13 And during the early stages, when I was  
14 younger, I've had pain and problems the entire  
15 time, constipation, diarrhea, bloody stools, all  
16 of that. And having to deal with that, even in  
17 high school, I ended up having to eat baby food  
18 for one of the years in high school. And when I  
19 was real young, my grandmother would send me out  
20 back to pick mint and she would chew on mint with  
21 me to get that nausea down.

22 And then as I started getting into my

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

42

1 30s -- this didn't become life threatening until  
2 2007, so I am living on IV nutrition, which I have  
3 with me. I stay on that during the day. If I use  
4 it at night, then I have to get up and go to the  
5 bathroom even more so, which interrupts that,  
6 maybe, three-hour sleep I get. So, I have to make  
7 sure I get sleep. And the symptoms are like a  
8 roller coaster ride. They do vary in degrees, and  
9 today, I'm sitting here and talking. I am in a lot  
10 of pain sitting here. The nausea is, like,  
11 dealing with food poisoning. And you just learn  
12 to live with this stuff. Doctors will look at me  
13 and not believe I'm in the degree of pain that I'm  
14 in and pass me over a lot of times because of it.

15           And different things that make this  
16 worse, any type of stress, whether it's positive  
17 or negative, it doesn't matter. Any of it makes  
18 it worse. I can have a great time and try to  
19 laugh. I end up having to hold my belly, because  
20 the pain's too much. When everyone else is  
21 sitting around eating -- most everything in the  
22 country revolves around food. There's, like,

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

43

1 there's nothing that doesn't revolve around food,  
2 so it's a health issue that keeps us out of normal  
3 functioning life. And for me, I was very active.  
4 I had owned my own businesses. I was a single  
5 parent for a long time. I'm remarried, but I have  
6 no life from this stuff. Doesn't seem that most  
7 people understand what's happening. And most  
8 people don't think it's as difficult as it is.  
9 They'll say that you can modify it with diet.  
10 Everybody's different. There's not one person  
11 that's the same. We might have similar issues, but  
12 somebody might be able to eat one thing that  
13 somebody else can't. And it's such an outlandish  
14 type of illness to get a hold of that you can't  
15 base, I guess, how one person is feeling on  
16 another. We're not the same in any respect.

17 DR. EGGERS: Any final remarks, Tanya?  
18 Final points that you want to make sure you get  
19 across?

20 MS. TAYLOR: Thank you. Different types  
21 of foods that if I try to eat something that's a  
22 smoothie that has vegetables in it, the

1 vegetables, even if they're juiced, will turn my  
2 stomach and make it into such pain that I'm on the  
3 floor in a ball or I'm in my bed in a ball. So,  
4 those types of things do increase it and anything  
5 with preservatives and anything like that. And  
6 that's all I remember.

7 DR. EGGERS: Thank you so much, Tanya.

8 And now, we'll have Cynthia.

9 MS. BENS: I'd like to thank FDA for  
10 having this meeting today, and actually, for  
11 inviting me to come and speak about my experience  
12 as a patient with irritable bowel syndrome. My  
13 name is Cynthia Bens and I live locally. I was  
14 diagnosed with IBS approximately a year and a half  
15 ago. And I say I was diagnosed a year and a half  
16 ago, but I feel like this is something I've really  
17 been dealing with since I was a teenager, all  
18 through my 20s and 30s. I have a family that's  
19 made up largely of boys, and not that they were  
20 unsympathetic, but I was just told most of my life  
21 that I had a nervous stomach. And it was mostly  
22 because every time I had any sort of abdominal

1 symptoms, it was around the time that I had  
2 something really stressful going on at school or  
3 some really emotional times in my life, during a  
4 teenager, that really just forced me to accept it  
5 as a part of life.

6           And then I hit my 30s. I think this is  
7 something that's probably going to be a theme. I  
8 see it already. I began experiencing a lot of  
9 cramping, a lot of bloating, and irregularity, and  
10 it was almost a daily occurrence. The cramping  
11 and bloating were so bad and they still are, for  
12 the most part. And they're the two symptoms that  
13 I'd say affect my life the most. At times, they  
14 can be really severe. I'm doubled over in pain.  
15 And on occasion, I have to miss work because the  
16 cramping and bloating are coupled with loose and  
17 unpredictable bowel movements. I will call this  
18 from now on my major flare-ups.

19           I first started talking about my  
20 symptoms with my primary care doctor. Over the  
21 course of a few years, he suggested that I just  
22 try to work out more and relieve stress. I have a

1 pretty stressful job. He also suggested things  
2 like, oh, just take a probiotic. You're probably  
3 having a lot of caffeine, cut bac on the caffeine.  
4 But nothing that I really did made a significant  
5 impact in my life.

6           And I started becoming really  
7 emotionally distressed. I was irritable, because  
8 I had almost daily discomfort. I was really  
9 moody, mostly because of my growing frustration.  
10 That's something from my perspective, most people  
11 didn't have to think about. I'm learning that  
12 that's not the case. It's just a lot of people  
13 don't talk about it. But it was really sort of  
14 driving my life. And there was one day that I was  
15 having a major flare-up that I just sort of hit a  
16 wall and I said, I need to do something about  
17 this. And so, I brought up my computer and I  
18 started researching gastroenterologists that  
19 accept my insurance, and I just closed my eyes and  
20 picked on. Not the best way to do it, but I went  
21 in and I made an appointment that week. I went in  
22 to see my gastroenterologist. And, you know, I

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

47

1 think that most people here realize, this is not  
2 something that's comfortable to talk about. And  
3 so, my doctor, when he walked in, he saw that I  
4 was really stressed out about the whole situation.  
5 And he said, "So, it says in your chart you're  
6 here for a colonoscopy." And of course, I have a  
7 really sick sense of humor, and so I laughed. But  
8 it totally set me at ease and more than I have  
9 with any doctor, I just laid it out on the table  
10 and I said, "Here's what I deal with." And he  
11 said, you know, based on my symptoms, he thought  
12 that I should go for a CT scan to rule out Crohn's  
13 disease. Also I had to have a fecal test, which,  
14 you know, both of those are incredibly unpleasant  
15 experiences. But I was able to avoid the  
16 colonoscopy, because when I went for my follow-up  
17 to find out what my test results were, he just  
18 basically showed me the Rome criteria and said,  
19 "You have irritable bowel syndrome." So, I knew,  
20 at least, what I had. And, you know, like any  
21 good patient I just hoped he would write me a  
22 script for a pill and I'd walk out the door and

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

1 I'd start feeling better. Little did I know, that  
2 was not going to be the case at all. And I  
3 started my long journey. To really sort of  
4 encapsulate what I do, most people will look at me  
5 and they don't think that there's anything wrong  
6 with me. But I struggle on a daily basis. I  
7 don't wake up any day feeling great. I wake up  
8 most days I have cramping and bloating. I have  
9 bloating so bad, I can't even fit into my work  
10 clothes. I just have a range of clothes that I  
11 sort of pick on a daily basis what I feel like  
12 wearing and what I can wear. That's if I'm well  
13 enough to go to work.

14 My doctor did prescribe medication  
15 called hyoscyamine. It's not really the  
16 foundation of my treatment regimen at all, because  
17 I speak for a living. That's what I largely do,  
18 and so having dry mouth to the point of sandpaper  
19 makes my job very difficult, and also it comes  
20 with constipation, for the most part, so then I  
21 have bloating and cramping of a different kind, so  
22 it's just weighing that. But I've learned to do a



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

49

1 lot of different things. I do acupuncture. I do  
2 two different types of yoga. I meditate. But the  
3 most dramatic changes have been to my diet. And  
4 you are right, until you have a functional GI  
5 disorder, you do not realize how much your life  
6 revolves around food. And from that point on,  
7 your life will do nothing but revolve around food  
8 and what you can't have.

9 My doctor gave me a nice stack of papers  
10 when I left his office, and it was mostly, you  
11 know, what foods you should try to remove from  
12 your diet and what you can start reintroducing  
13 back, and a nice big old 30-page sheet of what  
14 sort of limitations I should make to my dietary  
15 intake. And of everything I was told to cut out  
16 of my diet, I can only introduce back a handful of  
17 vegetables. I can only introduce back things like  
18 honey. I'm hypersensitive to artificial  
19 sweeteners, which are in everything. It's in  
20 cough medicine. I mean, I had a cold and I went  
21 and when I found out I could not have artificial  
22 sweeteners, there was one cough medicine that I

1 could take and it was not an oral, it was a pill.

2 It's a real problem.

3           And, let's see, what else? I had to  
4 eliminate high fiber foods, cruciferous  
5 vegetables, no alcoholic beverages. Any one or a  
6 combination of it is going to trigger one of my  
7 major episodes. And so, I feel like I'm that  
8 annoying woman when I go out to a restaurant,  
9 because there's no one plate of food that's on a  
10 menu that I can actually eat. I also do a lot of  
11 luncheons for my job and, you know, I eat in  
12 social situations and I really can't do that  
13 effectively anymore. So, in most cases, I carry a  
14 bagful of snacks that I know are not going to  
15 really trigger anything to the extent that you can  
16 predict that. You really can't predict that. So,  
17 you know, that's really sort of what my daily  
18 life's been like.

19           And at least once a year, I have a major  
20 flare-up, and so, I had to talk to my employers  
21 about the fact that I have this condition, which  
22 is a really uncomfortable conversation to want to

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

51

1 have with any of your employers. And, you know,  
2 on the days that I can't go to work because I feel  
3 so bad, I don't want to eat anything. I don't  
4 want to leave my house. I just basically lay  
5 around and hang out and, you know, get behind on  
6 work. It's not necessarily that it's something I  
7 feel like I'm really managing my life effectively.

8 DR. EGGERS: Any final thoughts?

9 MS. BENS: Yeah. And so, you know, the  
10 one thing that I would say, I know that there are  
11 people here who are developing drugs. I would  
12 say, you know, please don't focus just solely on  
13 certain symptoms. I know that this is something  
14 that I'm managing in various ways. I don't feel  
15 like I'm eating the most nutritious diets. I'm  
16 afraid that I'm leaving myself vulnerable to a lot  
17 of diseases, so please also don't just focus on  
18 the symptoms. Try to get to the bottom of what's  
19 causing it and help us cure it, because it's  
20 something that I'm not the only one suffering  
21 with. There's 48 percent of the people who are  
22 logging on through the web. I'm just the one

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

52

1 that's up here talking about it. So, there's a  
2 real need. Thank you.

3 DR. EGGERS: Thank you, Cynthia.

4 Now we're going to Carrie.

5 MS. REILY: Hi, my name is Carrie Reily.  
6 I actually came down from Syracuse, New York. So,  
7 we drove about -- my family and I drove six hours,  
8 it's how important we deemed this. I was  
9 diagnosed, finally, after years, in July. I have  
10 severe gastroparesis. I did the four-hour gastric  
11 emptying study, which is not fun at all. I had to  
12 glow in the dark. I joked about my kids, I glew  
13 in the dark for days afterwards.

14 The three symptoms that have an impact  
15 on my daily life are the pain and discomfort. And  
16 when I say "pain," to me it's like, my stomach is  
17 trying to work. It's trying to digest that glass  
18 of water I drank or cookie or pretzel I ate,  
19 because I'm so nauseous. I just want something in  
20 my stomach to join the pain medication. Or I'm  
21 hungry and my stomach's saying, oh, it's time to  
22 eat, but you can't eat, but you're hungry and it

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

53

1 hurts because you're hungry. Anybody that's been -  
2 - you're starving is basically what I'm doing.  
3 Discomfort is when I do drink or if I  
4 drink too much or if I ate too much, my stomach  
5 hurts. I mean, it looks like I'm pregnant and I'm  
6 not. It hurts to move. Sometimes, it gets so bad  
7 it hurts to breathe, because it's pushed up on  
8 your lungs and it hurts. It hurts on your rib  
9 cages. It makes you stomach hard. Wearing  
10 clothing is horrible, because you have different  
11 size clothing. I have my yoga pants and I have  
12 four different sizes of them, because I never know  
13 how I'm going to be that day. The pain is  
14 temporary, but the discomfort will last for hours  
15 and hours. Our society revolves around food for  
16 pain, for pleasure, for social activities.  
17 There's not one thing you can do where you don't  
18 have food. Nothing, You can't -- you go weddings,  
19 funerals, it doesn't matter. It's all food  
20 related. It's hard. It's hard to be a part of  
21 anything. My friends, family, they don't  
22 understand this disease. And a lot of them, they

1 don't invite me to things. My family, my kids  
2 don't get invited to that birthday party or that  
3 meeting at school, because they know I can't make  
4 it or I'm not going to be able to eat the food, so  
5 the parents feel weird and don't invite me or my  
6 kids.

7 My biggest problem I have lately is  
8 lethargy. I have two -- my kids are nine and 12.  
9 I can't do the normal mom activities. I can't  
10 take them to dance lessons, baseball games. It's  
11 hard for me to sit through my son's two-, three-  
12 hour baseball game without getting sick. And the  
13 bathrooms are either very far away or it's a port-  
14 a-potty, and nobody wants to be sick in there.  
15 It's just horrible. Even just to come down here,  
16 I gave six hours, I had to plan rest periods. We  
17 had to drive halfway, spend the night, and then  
18 take off some more the next day. It's a matter of  
19 -- it's not even so much that day. It's the days  
20 leading up to it and the days afterwards. I know  
21 that the next two, three days, I'm going to really  
22 have to plan to sleep almost a whole day and make

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

55

1 sure that I have to be -- I can take care of  
2 myself. I can't, to make sure, like, even going  
3 to the grocery store is horribly challenging.  
4 Between the smells of those wonderful free  
5 samples, but even the bakery department, it's a  
6 very hard thing to do and then to know that you  
7 can't eat anything in there that you're even  
8 buying. I still have to take care of the kids and  
9 cook and clean, and it's a very, very hard thing  
10 to do.

11           In the mornings are horrible. I wake up  
12 in the morning, it's really bad to the point that  
13 my husband had to take a different job so he could  
14 be home in the morning to take the kids to school  
15 for me, because I can't do it anymore. I'm very  
16 limited on what I can and can't do. Everyone in  
17 my family feels this. Unfortunately, my kids are  
18 more self-sufficient than they probably should be.  
19 They had to make -- they learned how to make  
20 peanut butter and jelly sandwiches when they were  
21 four, because they had to be able to feed  
22 themselves something if mommy's having a bad day.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

56

1 And it's very hard to see. My daughter couldn't  
2 make it today. She's actually sitting outside and  
3 walking around, because she's nine, and just even  
4 reading my comments, she couldn't get through it  
5 all without crying, because she's scared I'm going  
6 to die. That was very, very hard, because she  
7 wanted to come down and she wanted to be with me  
8 and support me, but they couldn't make it -- they  
9 couldn't deal with the stress of even knowing what  
10 I go through. I try to hide it from them so they  
11 don't know. They don't know how sick I am. You  
12 know, I'm fighting with doctors on a daily basis  
13 not to get that feeding tube so I don't have -- so  
14 they don't have to see that. It's very hard.

15           This morning, it was unfortunate. I had  
16 a cup of tea at breakfast at the hotel, because I  
17 was tired. And I threw that up, and  
18 unfortunately, my kids were in the room with us,  
19 and it was very hard for them. Like, our family  
20 vacations revolve around medical things. From  
21 Syracuse, we go to Pennsylvania and go to  
22 Philadelphia to go see a doctor there, because



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

57

1 there's nobody in New York that can help me. My  
2 date night, that was our date night. We drove to  
3 Philadelphia. It was great, you know, that was  
4 our date. We don't get that kind of thing. A  
5 good day for me isn't a day. It's hours. There's  
6 never a day where I can say, "Oh, this is a great  
7 day." No, it's, "Look, I had a couple of good  
8 hours today, and will I have to pay for them  
9 tomorrow or the next day?"

10           It's, you know, even on the good day  
11 where I'm having those good few hours, I can't --  
12 I still have to stop and rest. It's still not --  
13 I still know I can't push myself. It's very hard.  
14 A good day would be not to throw up all day long,  
15 to have a little bit more energy and not be able -  
16 - just to be able to do something to get out of my  
17 house and see my kid's dance recital or my son  
18 play his baseball game.

19           The bad days do outweigh the good. A  
20 bad day, I can't leave my bedroom. Luckily, my  
21 bathroom's right next door to it. I can't leave  
22 my bathroom, my bedroom. And I'm lucky that I

1 don't end up in the emergency room, which  
2 everybody does, because, of course, you say you're  
3 in pain, they think you're a drug-seeker, which  
4 unfortunately, we get labeled very quickly.  
5 Everybody says, "Oh, I'm in pain," "Oh, wait, you  
6 must mean that you have to -- you have a drug  
7 problem." So, you're pushed to the back of the  
8 line. They don't seem to understand that just  
9 because you say the word "pain," doesn't mean  
10 you're there to get drugs. It's very hard to get  
11 a doctor, especially emergency room or urgent care  
12 center to realize that.

13 DR. EGGERS: Any final thoughts, Carrie?  
14 Final things you want to share?

15 MS. REILY: Every day is a struggle,  
16 whether it's being tired and nausea and just  
17 everything in general is just hard. It's the  
18 pain, it's the nausea, it's having to have the  
19 puke bucket in the car to make sure you get there  
20 on time and you're there for your kids. Thank you  
21 for having us and for doing this. Thank you.

22 DR. EGGERS: Thank you very much,

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

59

1 Carrie.

2 And now we have Bettemarie.

3 MS. BOND: Hi, my name is Bettemarie.

4 Thank you. I want to thank the FDA for doing  
5 this. And I'm honored to be here. I've struggled  
6 so much with my GI condition ever since I was  
7 younger. And just knowing that some of what I  
8 went through might be able to help somebody else  
9 in the future just makes a big difference. I have  
10 a mitochondrial disorder, and I have autonomic  
11 dysfunction, gastroparesis, overall gut  
12 dysmotility through my entire GI tract, esophageal  
13 spasms, intestinal spasms, biliary dyskinesia with  
14 a smooth muscle disorder, pancreatitis, and  
15 chronic constipation. That's just to name a few  
16 things. Hypoglycemia myoclonus on top of all of  
17 that.

18 Due to my GI disorder, I've been on IV  
19 nutrition for 25 years. And I started out  
20 originally on tube feedings, however my gut did  
21 not tolerate that. And so, then it progressed  
22 onto TPN. And at first, I hated it. I wanted no

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

60

1 parts of it. But through family, friends, and a  
2 wonderful organization for patient support called  
3 the Oley Foundation, with that it helped me see  
4 the TPN as an abling device and how it enabled me  
5 to live my life. You know, you go from being a  
6 dog on a leash all the time to actually -- to me,  
7 my TPN and my PCA pump are like wings are to an  
8 eagle. It allows me to be me. It gives me energy  
9 to do the things that I want to do in life.

10           The pain was so severe when I was  
11 younger. Oh, my goodness. And kind of just like  
12 what you mentioned, from having severe pain  
13 continuously, I became very good at hiding it. I  
14 could look totally fine, but yet be in severe  
15 pain. I was very good at joking with -- talking  
16 and telling jokes as a way of distracting myself,  
17 that it was hard for the doctors to really  
18 understand that I was in pain. Also, the first  
19 thing they go to, oh, it's stress. Take time off.  
20 Next thing they go to, oh, you must be anorexic. I  
21 love to eat. Oh, my goodness, if I could, I'd be  
22 eating.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

61

1           So, that's just a little bit of the  
2 struggles just with getting a diagnosis. And then  
3 with a lot of the testing, because it is a  
4 functional GI disorder, a lot of the tests come  
5 back normal until they finally get around to,  
6 okay, well, what are the pressures and what's the  
7 motility like. So, that took years. Like, it's  
8 not something that just happens right away.  
9 Thankfully, my parents took me to specialists all  
10 over the country in order to figure out and to  
11 determine what was going on.

12           As I mentioned, the pain was very  
13 severe. I would go into Children's Hospital and  
14 live in there three to four months at a time,  
15 several times a year. And finally, we did a lot of  
16 trials with different medications and I've had  
17 numerous surgeries, but the pain continued.  
18 Finally, we found one medication. I'm on a PCA  
19 pump, which is -- oh, my goodness, that thing is  
20 wonderful. With that I have IV pain medication.  
21 And I actually use less pain medication with that.  
22 I can just hit a bolus. I get a continuous rate.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

62

1 With that and with managing techniques, I ended up  
2 fighting to improve my life. And I ended up  
3 working for 14 years all while connected to the  
4 PCA pump and getting my TPN at night. My last few  
5 years, I actually worked with my TPN running  
6 during the day right in my backpack. As a side  
7 effect of -- I've done very well with not many  
8 episodes of sepsis, but this last few years, I've  
9 had multiple episodes of sepsis and that was very  
10 challenging, because with that, I've lost a lot of  
11 functional ability. So energy is a big factor,  
12 just being able to take a shower, take care of  
13 myself. I now have a CAN that comes out and helps  
14 me for 42 hours a week just doing ordinary,  
15 everyday things. And as everybody has mentioned,  
16 it's kind of like a give and take with what you  
17 want to do. Okay, well, I want to do this, so now  
18 I need to rest. But then, how is it going to  
19 affect me afterwards?

20 Another big way that this has affected  
21 me and my life is, as everybody's mentioned is  
22 eating. Everything does revolve around food. I'm

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

63

1 just going to take it a little bit in a different  
2 way. Due to my biliary pancreatic issues, I can't  
3 have any fats or oils. A drop will send me into  
4 pancreatitis and the severe pain and stuff. And  
5 I've tried going out buying foods, however, the  
6 labeling is just -- I wish it was a little bit  
7 better. For example, I would buy fat free frozen  
8 yogurt, but yet it would have cookie pieces in it.  
9 I would eat it, I'd get bad. I'd call the  
10 company. Oh, well, the yogurt's fat free, but not  
11 the cookie pieces. And it's tricky. Just like  
12 there's some candy, some gummy candy and Gummy  
13 Bears. There no oil listed in the ingredients,  
14 however, I ate it, I'd get bad. I'd call the  
15 company and they'd say, "Well, oil is used on the  
16 -- to coat the mold. So, it's not really an  
17 ingredient, so we don't have to list it." So,  
18 stuff like that is very challenging, because it's  
19 still used in making the product, but yet for me,  
20 I'm very sensitive and it causes a whole chain of  
21 reactions. Going out to eat can be very  
22 challenging. I love going out to eat. I'm not

1 eating. I'm just sitting their enjoying the meal.  
2 Years ago, it was nice because I could maybe take,  
3 like, a can of soup that I could have and I could  
4 ask them to heat that up. Nowadays, it's harder  
5 to find a place that would actually heat up a can  
6 of soup for me, because you're not allowed to take  
7 prepared items into the restaurants. But I do  
8 enjoy the social interactions. I wish --  
9 sometimes, I can get a waiter or waitress to fix  
10 the soup for me.

11           Some other things, the constipation has  
12 been a huge issue, the bloating, all of the  
13 intestinal symptoms, the spasms. But with the  
14 constipation, oh, my goodness, it's not only with  
15 the motility of things moving slowly, not at all  
16 moving, or even moving backwards, but physically  
17 at times, I'm unable just to kind of push it out  
18 whether it's soft or hard. And then, at times, it  
19 feels like I'm passing razor blades. So,  
20 something as simple as a bowel movement is not  
21 simple at all.

22           And then, your whole GI system is



1 interconnected, so you start getting backed up at  
2 the lower end, well, now that's affecting the  
3 upper end and how much food you can put in and how  
4 much stuff you can drink. So, it's all  
5 interrelated. You kind of have to keep the lower  
6 end moving if you want to try to get the upper end  
7 to move. Medications can help a little.

8 DR. EGGERS: Any final thoughts,  
9 Bettemarie? Any final thoughts?

10 MS. BOND: Yeah, one thing with just --  
11 with the eating, sometimes it's easier -- I feel  
12 so much better if I don't eat at all. Oh, my  
13 goodness. But I would enjoy to eat. Sometimes,  
14 if I do try to take a taste, a bite of food, you  
15 know, the food tastes good. You want to take  
16 another bite. You want to take another bite. But  
17 usually just three bites could fill me up. And  
18 then that fourth bite can just send me right over  
19 the hill. So, sometimes it's just as simple as  
20 that, just a little bite could cause a lot of  
21 pain, but the pain is one of my biggest issues,  
22 and the fatigue.

1           But thank you for trying to come up with  
2 this. Oh, my, when I was younger that's all I  
3 kept -- was like, okay, maybe down the road  
4 there'll be a new medication. Maybe there'll be a  
5 new treatment or something, but it seems like  
6 there's not one thing that really makes a huge  
7 difference, but it's a lot of little pieces that  
8 kind of come together that help the symptoms, and  
9 that just makes the quality of life during that  
10 day a little bit better.

11           DR. EGGERS: Thank you so much. Thank  
12 you, Bettemarie. I'm going to invite -- if you  
13 want to stay up here, you can, or you can return  
14 to your seats wherever you feel most comfortable  
15 with, any of you.

16           I need to go get that microphone over  
17 there, so give me one second.

18           I just want to thank you guys so much  
19 for your courage. It's hard for me to stand up  
20 here and maintain my composure while you're  
21 telling about your difficult struggles you've  
22 lived with for your whole life, maybe not always

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

67

1 as badly as it is now. But can I ask for a round  
2 of applause to --

3 (Applause.)

4 We give them such an unfair assignment, which is  
5 boil everything down to a few minutes. And I know  
6 it's so difficult. We are going to be touching on  
7 many of the things you talk about. Some of it  
8 will be in Topic 2. But to begin the discussion  
9 to just kind of set the stage, can we have a show  
10 of hands to see how many of you heard, at least,  
11 heard your story, your experiences reflected in at  
12 least one of the women up here.

13 Anyone who -- I'm not going to ask you  
14 to say it now. Anyone whose is completely  
15 different?

16 Then you have represented your peers  
17 well. So, thank you very much.

18 We are going to dig into this a little  
19 bit more now. To start us off, we're going to  
20 start with a few polling questions. And this is  
21 only going to get at the tip of the iceberg, I  
22 think, about what the symptoms are and how --

1 throughout your body system. But we have here  
2 focused on symptoms that are related to the upper  
3 GI, the abdomen and up. And what we first want to  
4 note is to see what symptoms we have collectively  
5 reflected here and on the web.

6 Which of the following upper GI symptoms  
7 have you or your loved one experienced in the past  
8 year? You can check all of them that apply. Give  
9 you a few minutes to do that.

10 Unsurprising, many, many of them,  
11 looking like that the most common here are  
12 vomiting and nausea and feeling of fullness,  
13 followed by heartburn and abdominal pain and  
14 discomfort. With those in mind, I'm going to move  
15 to the next question. And on the web, first, is  
16 it roughly the same?

17 MS. GIAMBONE: Yes. We had vomiting or  
18 nausea as the top most experienced symptom, and  
19 then we followed by abdominal pain or discomfort,  
20 and bloating.

21 DR. EGGERS: So, now we want to -- we  
22 knew that not everyone might experience every

1 symptom, but of those symptoms that you experience  
2 now, which -- looking only at these upper GI  
3 symptoms, which one of these -- or which one to  
4 three of these have the most significant impact on  
5 your life? And again, you can choose up to three  
6 of them.

7 All right, so the abdominal pain -- I  
8 don't -- the abdominal pain, most of you who said  
9 that you have it have rated it as one of the top  
10 three. Similarly with vomiting or nausea followed  
11 by bloating.

12 And on the web, can we just get a sense  
13 of what we're getting?

14 MS. GIAMBONE: Yep, similar to in the  
15 meeting room, it's vomiting or nausea followed by  
16 abdominal pain or discomfort, and then followed by  
17 feeling of fullness or inability to eat a full  
18 meal.

19 DR. EGGERS: Thank you very much. Let's  
20 focus on abdominal pain or discomfort. We heard  
21 very eloquently the experiences here. What I'd  
22 like to hear, I'd like to hear someone build upon

1 that, the feelings of the abdominal pain or  
2 discomfort. And as you describe your --  
3 especially if they're slightly different. What  
4 terms do you use, and how do you distinguish  
5 between pain, discomfort, bloating, and all of  
6 those terms? That's very important to us as we  
7 try to tease apart what terms mean to people. So,  
8 would anyone like to volunteer to describe that  
9 symptom first? We have the mikes and they'll come  
10 to you. If you can just say your name first and  
11 what condition or conditions you have. We'll go  
12 here and then we'll go over there. With  
13 Katharine.

14 KATHARINE: Hi, my name's Katharine. I  
15 have gastroparesis. First, can I just say thank  
16 you for coming and talking, and thanks to the FDA  
17 for even having this meeting. But the way I  
18 differentiate pain and discomfort, the best I can  
19 explain is the pain is -- both of them are  
20 crippling, but the pain is so crippling that I can  
21 end up in a ball on the floor and I can't move.  
22 But discomfort, it's like a duller pain. I can do

1 things to kind of ignore it. But it's still  
2 there, it's just not as severe.

3 DR. EGGERS: Is it sharp? Sharp versus -  
4 - the first one's sharper than the second one,  
5 discomfort?

6 KATHARINE: Yes. It's a much sharper  
7 pain and it's continuous. Discomfort, it's  
8 continuous, but it doesn't -- like -- I forgot  
9 your name. Like you said, the discomfort lasts a  
10 very long time, but the pain can come and go.

11 DR. EGGERS: I'm seeing some head nods.  
12 Those of you that said abdominal pain, you want to  
13 raise your hands, if that -- if you, if this is  
14 your experience and perspective, well, it  
15 resonates with you. Anyone have a different --  
16 oh, we'll come here.

17 MS. WOLFSON: Hi, my name is Lynn  
18 Wolfson, and I have gastroparesis and  
19 Hirschsprung's disease and dysmotility of my  
20 entire digestive tract. I find that after I try  
21 to eat -- I'm on a feeding tube. But after I try  
22 to eat even a very small amount, I get stomach

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

72

1 pains, but if I lay down for an hour or two after  
2 I get the stomach pains, I'm able to handle them  
3 and they could dissipate. But if they continue on  
4 further than that, within the two hours that I  
5 laid down, and generally when I lay down -- I have  
6 an ostomy, my bag will fill up with gas and also  
7 with fecal matter. I generally feel better.  
8 However, many times I can -- many times I have  
9 episodes where I just continue and the pain just  
10 doesn't get any better. And there's nothing that I  
11 can do. I just feel totally crippled by the pain,  
12 can't do anything. There's so many times I find  
13 that when I go to an ER when the pain just  
14 continues for two, three days a week. And they'll  
15 ask me about my discomfort. And I feel so  
16 insulted when they ask me about my discomfort.  
17 There's something wrong with that word.  
18 Discomfort to me is a pebble in your shoe or a  
19 wedgie with your underwear. It is not what's  
20 happening with my abdomen. And it makes me very  
21 angry for them to think that I want to spend the  
22 afternoon or the evening or the night in the ER



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

73

1 because I have discomfort.

2 DR. EGGERS: Thank you very much, Lynn.

3 You got a lot of head nods to that.

4 We'll take another one right here.

5 MS. SARRIS: I just wanted to elaborate  
6 a little bit on what you were saying and what all  
7 the ladies were saying. My name is Elizabeth  
8 Sarris. I, too, have gastroparesis. I also have  
9 GERD. I also have irritable bowel syndrome and  
10 several other health issues we're not going to  
11 talk about today. But anyway, I think discomfort  
12 is chronic for those of us who have the diagnosis.  
13 And I think for the FDA, that's good information.  
14 I'm also in the health profession. So, my  
15 language may be a little stronger. I think  
16 abdominal -- when I hear abdominal pain, I think,  
17 like this young lady -- I'm sorry, I forgot your  
18 name -- said, can be incapacitating. The  
19 discomfort is something we live with on a daily  
20 basis. Now, whether the discomfort is horrible  
21 that day or I can pull through the day with it,  
22 that's variable. But abdominal pain defines true

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

74

1 pain that is, on some level, incapacitating,  
2 whether it involves vomiting, ceasing activity,  
3 not being able to take a shower, those are all, I  
4 think, just to embellish.

5           And then, the abdominal thing pain with  
6 the hospital, I recently had a hospitalization,  
7 and many times what they'll do, the nurses have a  
8 pain scale, right. And so, I was just going to  
9 speak to the pain scale. And, I guess, there  
10 hasn't been another way of identifying that.

11           DR. EGGERS: I'm going to ask if there  
12 are any follow-up questions from you on pain.  
13 Yes, go ahead, Donna.

14           DR. GRIEBEL: So, I'd like to follow up  
15 on what you just said about the pain scale. It  
16 sounds like you're frustrated with the pain scale,  
17 or did I misinterpret that?

18           MS. SARRIS: I think, as health  
19 professionals and as the FDA, I think we all have  
20 to be good listeners. And I think we really need  
21 to be tuned in to the patient, not just on a pain  
22 scale basis. I think in many situations, the pain

1 scale is adequate and even more so identifying how  
2 severe it is, if they can administer pain meds or  
3 whatever it is they have to do. It's  
4 significantly great with children. But I also  
5 think that identification of what that  
6 interpretation is, and perhaps part of the problem  
7 is, I'm not sure how educated our medical people  
8 are regarding this kind of disorder, regarding any  
9 of these disorders. And so, you know, perhaps  
10 there's a misunderstanding in that regard.

11 DR. EGGERS: We have -- taking, maybe  
12 Tanya.

13 MS. TAYLOR: I wanted to add on to that  
14 pain scale. One of the reasons I wasn't quite  
15 ready today is because of this pain thing. And  
16 so, I left out a lot of things because of that.  
17 This pain scale, when you go in to these ERs and  
18 these people have this pain scale, our pain is not  
19 on that scale. Our pain is somewhere way out  
20 here. So, when we can't get that across to people  
21 who don't experience this, and to be in a buckled  
22 over -- you are, you're in a ball. You cannot

1 move. And then have people call you drug- seekers  
2 or instigate your pain to where then it's even  
3 rising further because they want you in this pain  
4 scale, and I truly believe it's because of the  
5 lack of education. I truly believe that this --  
6 oh, well, you have constipation pain. You don't  
7 understand constipation pain if you've got this  
8 kind of a health issue. So, I just -- for us, I  
9 think that needs to be adjusted or people need to  
10 understand.

11 DR. EGGERS: Carrie and Bettemarie, are  
12 your perspectives similar, generally similar,  
13 something different?

14 MS. BOND: One of the problems is, is  
15 when you have the pain, you can hide it, is you  
16 don't look like the faces on there -- on the pain  
17 scale. So, I could be, like I would be bent over,  
18 but yet be smiling. And so, that's where some  
19 trouble can fall in with others understanding.

20 But one thing that I wanted to mention  
21 that was a little different is the doctors were so  
22 focused on my most severe pain with the biliary

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

77

1 and the pancreatic and that the other stuff was  
2 kind of overlooked, and it wasn't until 10-12  
3 years later when I saw a different GI and he said,  
4 "Well, you know, it's okay. You can have  
5 different types of GI pain." You know, this may  
6 hurt the most, but you can have the bloating pain.  
7 You can have the pain from the stuff backing up  
8 and intestinal spasms and so it was just so  
9 refreshing to hear a doctor admit that there are  
10 different types of abdominal pain as well, but  
11 usually they focus in on just the one.

12 DR. EGGERS: Thank you so much. I want  
13 to make sure that we get to some of the other  
14 symptoms, but it sounds like -- I'm going to ask  
15 for folks on the web to write in on this, too.

16 Graham, are we getting anything from the  
17 web on pain?

18 MR. THOMPSON: We're getting a lot of  
19 similar-type comments, people talking about sharp  
20 pain, sharp abdominal pain, or general aches in  
21 the lower abdomen. A few people talking about how  
22 pain is generally the sharper, and discomfort is

1 kind of more of the ache or the more manageable  
2 version of pain. One person said her seven-year-  
3 old describes her pain as a cramp in her belly and  
4 her back. And a lot of comments like that.

5 DR. EGGERS: Okay, thank you.

6 So, please elaborate on this. If  
7 there's something in the docket, this is a topic  
8 of much interest. Yes, go ahead.

9 DR. GRIEBEL: Just one follow-up  
10 question. So, when we're talking to companies  
11 about the clinical trial and what it's going to  
12 look like and how will we measure how the drug is  
13 affecting symptoms, pain is a common symptom. And  
14 I'm hearing pain and discomfort. If you were  
15 having a day where you were not doubled over in  
16 pain and you had a pain scale and you had to say,  
17 what's my worst pain that I had today, but you had  
18 discomfort, would you fill out that pain scale  
19 based on your discomfort, or would you consider  
20 the discomfort something else that you should have  
21 been measuring on a different scale?

22 DR. EGGERS: Carrie, yes.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

79

1 MS. REILY: It's two separate issues,  
2 because on a daily basis there's discomfort. But  
3 you could flare up and you're -- be in pain. And  
4 pain, unfortunately -- if you're in chronic  
5 discomfort, that pain is worse, because in a pain  
6 scale, you're at that five. You're at 105.  
7 You're not at five. Your discomfort is five on a  
8 regular basis, and that's what they don't  
9 understand is we live at that constant state of  
10 five. So, when you say pain, our discomfort is  
11 always at a five. You need to take into  
12 consideration -- you need almost like two separate  
13 scales, almost like -- people in constant chronic  
14 pain versus the people who just stubbed their toe  
15 and are in pain. It's two totally different  
16 things. I can tell you -- my kids joke with me,  
17 like, "Mommy, oh, look, I hurt my toe." I'm like,  
18 "I don't want to hear about it." Like, I  
19 understand, but you don't know what real pain is.  
20 I live in a constant state of five, because that's  
21 my discomfort level. If was going to the ER,  
22 though, I wouldn't be much higher. If I'm actually

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

80

1 at a state where I have to go somewhere, I'm much  
2 higher, and they don't take it seriously, because  
3 you're not.

4 DR. EGGERS: Well, we have one more  
5 comment here from Ceciél.

6 CECIEL: I think that question, Donna,  
7 is very relative to what's going on or what has  
8 happened. So, I had a severe episode of functional  
9 abdominal pain last Thursday. Just happened to  
10 have a full day of meetings and conference calls  
11 that day. And if you had asked me on Wednesday  
12 what my general severe pain was, I would have put  
13 it higher than I would have on Friday when the  
14 episode wasn't as bad because in my memory was the  
15 day before. So, I think that if you ask the  
16 patient to look at the scale and say generally  
17 speaking where are you at, if I had just had a  
18 severe episode yesterday, then I'm going to tell  
19 you, oh, I'm great today, because this isn't  
20 yesterday. So, I think that that's relative and  
21 it's really hard in dysfunctional GI, because you  
22 get away from a severe episode and so some of us -



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

81

1 - I'm so sorry for your pain all the time. I  
2 don't have it all the time. But when I have an  
3 episode, it's bad. And in my -- in the work that  
4 I do, there are certain times when I have lots of  
5 meetings and a lot of things going on that I can't  
6 afford to have an episode. Generally, that's when  
7 it happens, right? But because this is a roller  
8 coaster ride, you can ask me the same set of  
9 questions today, ask me again next Monday, and ask  
10 me again the next Monday, and I'm going to answer  
11 it differently every time.

12 DR. EGGERS: There one question from  
13 Laura.

14 DR. MULDOWNNEY: So, frequently, when we  
15 do clinical trials, we ask people to fill out  
16 these scales every day. So, because we understand  
17 that it can be very variable from day to day. And  
18 a lot of times, our question is, what was your  
19 more severe pain in the last 24 hours? But my  
20 question is to you is, do we need to be evaluating  
21 pain differently? Do we need to be asking  
22 different kinds of pain? Are there different

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

82

1 kinds of pains you have that need different  
2 questions? Should it just be one question, how  
3 severe was your pain? Or do we need more focused  
4 questions?

5 DR. EGGERS: Then we'll go here and then  
6 we'll come to the striped sweater.

7 DEBBIE: Hi, my name's Debbie. I have a  
8 diagnosis of gastroparesis and several other GI  
9 issues, but I do think, for me, what I experience  
10 most often is, like a diffuse low burning and a  
11 sort of sour acidic feeling in my stomach. And I  
12 think what I'm hearing is that, you know, some  
13 people have really severe pain that's very  
14 disabling to where you're doubled over, but a lot  
15 of us with functional GI problems have chronic,  
16 ongoing severe discomfort that lasts for a lot of  
17 -- you know, like our waking hours, and is very  
18 debilitating in terms of doing things like  
19 socializing and being able to concentrate at work.  
20 But, like, I would never rate my pain, like, as  
21 eight or nine or ten. So, it does seem like it  
22 would be really helpful when drugs are being

1 evaluated to not just get at the most severe pain  
2 that you've had that day, but how much it's  
3 relieving the sort of background, ongoing chronic  
4 discomfort that a lot of these disorders cause.

5 MARY: My name is Mary and to address  
6 that question, I would think rather than just  
7 using, like, the Baker-Wong Pain Scale, that there  
8 needs to be more descriptive terms as well. I  
9 mean, yes, it is sharp and writhing at times.  
10 Like, for me, on an average day, I live with a  
11 discomfort level between a one and a two. But on  
12 my really bad flare-ups, I have gastroparesis,  
13 IBS, and GERD. I'm at an -- so I would think that  
14 for evaluation of drugs that there needs to be  
15 more descriptive terminology for people to be  
16 able, okay, is it sharp, is it burning, is it  
17 achy, is it -- you know, those kind of things need  
18 to be in there as well, rather than just the  
19 regular one to ten scale.

20 DR. DIMICK: So, maybe we need to ask  
21 descriptive terms and we need to ask things like  
22 not just how severe it was, but how disabling it

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

84

1 was, how many hours during the day it lasted?

2 MARY: Exactly.

3 DR. DIMICK: All these more pointed  
4 questions.

5 MARY: Exactly.

6 DR. DIMICK: Because it's different day  
7 and night. How much did it interfere with your  
8 sleep?

9 MARY: We heard from the audience  
10 daytime and nighttime.

11 DR. DIMICK: Yeah, so, like, how much  
12 does it -- did it interfere with your sleep last  
13 night?

14 DR. EGGERS: We'll take one more and  
15 then I'll -- if there's no more questions, it  
16 looks like, so we'll take one more here.

17 JILLIAN: I'm Jillian. I have  
18 gastroparesis. I have lived with these symptoms  
19 for all of my life. And I think, to some extent,  
20 I have to be coached as to what pain is. I have  
21 severe GERD and if you asked me if it was painful,  
22 I would never say yes, because I've always lived

1 with it. I mean, to me, that's not pain. So,  
2 when you have something you're dealing with for  
3 such a long period, it may be painful to most  
4 people, but to someone who's living with it, it's  
5 just there. Not to erode the discomfort or pain  
6 levels that anybody's feeling, but I just know I  
7 don't consider it pain anymore after such a long  
8 period of time.

9 DR. EGGERS: Andrew, did you have a  
10 question?

11 DR. MULBERG: For the last string of  
12 comments regarding pain and how to measure it, can  
13 people comment on functioning? And are there any  
14 common themes of not being able to function that  
15 we can understand? It seems the numbers don't  
16 correlate with people's perceptions of their pain.

17 UNIDENTIFIED VOICE: We're saying that  
18 it should go with the numbers because somebody  
19 could not be able to function at, say, ten, where  
20 some people have pain all the time. They --  
21 somebody that has pain all the time can function  
22 at a ten, where somebody with the same pain

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

86

1 occasionally can't function when at a number two.

2 DR. EGGERS: Are there specific types of  
3 functioning that -- when you say functioning --

4 UNIDENTIFIED VOICE: When you get the  
5 pain constantly, you can function and tolerate  
6 more amounts of pain, and that could be a ten for  
7 somebody. And they may rate it as a two, because  
8 they're able to function. Where somebody else  
9 could have that exact pain would rate it as a ten  
10 and not (indiscernible).

11 DR. EGGERS: So, it sounds like you're  
12 saying at least it has to go hand in hand.

13 UNIDENTIFIED VOICE: Yes.

14 DR. EGGERS: We have one there and then  
15 --

16 DEBBIE: Yeah, I was just going to say  
17 that I think there are so many areas that the  
18 discomfort can cross that it would be pretty easy  
19 to ask people to rate to what extent it affected  
20 their ability to fall asleep, their ability to  
21 concentrate at work, their socializing with  
22 friends, their ability to eat meals. I think you

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

87

1 could easily come up with five or ten activities  
2 of daily life that participants in clinical trials  
3 could be asked to rate the extent to which they  
4 suffered, you know, inability to do those things  
5 or their symptoms were relieved.

6 DR. EGGERS: I'm going to -- unless  
7 there's any burning questions from here about  
8 pain, I think we should move on just for the sake  
9 of time. I'm never really quite the most popular,  
10 because I'm always saying we have to move on, but  
11 there is the docket and on the web, and so,  
12 continue to write this in. It sounds like we  
13 could have spent all day on just this issue.

14 I do want to touch upon the vomiting and  
15 nausea. We did hear some of it up here. Does  
16 anyone have an experience with vomiting and  
17 nausea? Again, think about how we talked about  
18 pain. What terms do you use to describe that  
19 feeling that you'd want to share? We're going to  
20 go right here. We haven't heard from you yet.

21 MS. PASINKOFF: Hi, my name is Carol  
22 Pasinkoff. I have severe gastroparesis, and I

1 suffer from unrelenting nausea all day. I take  
2 any medicine, anti-nausea medicine that's out  
3 there, and it doesn't even come close to helping  
4 me with my nausea. I mean, I always explain it to  
5 people, like, think about when you have a stomach  
6 flu, and it's like, you're throwing up and you're  
7 so nauseous and you can't move and you don't want  
8 to get out of bed. Well, this is what I live  
9 with. It's like being seasick all time. It's  
10 like being -- having a stomach virus all the time.  
11 It just doesn't want to go away. It's brutal.  
12 You know, in the beginning, I was vomiting a lot.  
13 We managed to get a handle on my vomiting, but the  
14 nausea, nobody has been able to come up for  
15 anything for me for nausea. It's terrible.

16 DR. EGGERS: We have -- we'll go to  
17 Katharine.

18 KATHARINE: I, too, have nausea on a  
19 daily basis. It goes up and down from the moment  
20 I wake up in the morning to the time I go to bed.  
21 I'm woken up in the middle of the night because  
22 I'm nauseous, and sometimes I have to puke. My



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

89

1 vomiting has been under control since I first got  
2 gastroparesis. But, yeah, you can't go out  
3 anywhere. You can't do anything for the fear that  
4 you're going to just end up vomiting right in  
5 front of everyone, or you can't concentrate. You  
6 can't focus because that nausea, too, is just so  
7 debilitating. I can't focus on classwork. I  
8 can't enjoy conversations, because that nausea is  
9 just, like she said, it's there all the time.  
10 It's like being sick all the time.

11 DR. EGGERS: We'll go back here.

12 DEBBIE: This is again about  
13 gastroparesis. I suffered from nausea from my  
14 other GI issues, but about five years ago, I  
15 started having incredible, unrelenting severe  
16 nausea. The only time I felt good during the day  
17 was the first hour that I was awake when my  
18 stomach had been empty for about 12 hours. I  
19 would take my Zegerid, which I take for gastritis  
20 and GERD, and in about an hour when I had  
21 breakfast, within a half an hour to an hour, I  
22 started feeling nauseous. With each subsequent

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

90

1 meal that I ate, it got more severe to the point  
2 that by the early afternoon, I just really felt  
3 horrible. It is so debilitating, and I didn't  
4 really, at first, realize that it was associated  
5 with eating. Once I did, I had a gastric emptying  
6 study done, and I was immediately put on  
7 domperidone, and I have to say I'm so thankful,  
8 because I got immediate and 100 percent relief  
9 from the nausea. As long as I take a capsule  
10 before I have my lunch and dinner, I have not  
11 experienced any nausea in the last four and a half  
12 years since I've been taking it. So, I just want  
13 people to know about that for those who are  
14 suffering with nausea, it really is so miserable.  
15 And you don't look like you're in misery, and  
16 especially, I didn't have any vomiting, so I  
17 didn't really look like somebody who was  
18 suffering, but it really is miserable and it did  
19 impact so much of my life. And to be put on that  
20 drug and to have such relief with no side effects  
21 has really been so helpful to me.

22 DR. EGGERS: We'll be talking about the

1 treatments in the second half of the course. I'm  
2 going to take one more on nausea with Meredith.

3           MEREDITH: I have gastroparesis and  
4 chronic unexplained nausea and vomiting. To the  
5 nausea, my first gastroenterologist told me early  
6 on that he thought chronic nausea was one of the  
7 most demoralizing physical sensations a human  
8 being could experience. And I really felt that as  
9 to be very true. I equate chronic nausea as very  
10 similar to chronic pain. It interferes with your  
11 functional activities. My nausea, until I had  
12 relatively successful treatment, was so bad and  
13 vomiting upwards of 20 to 30 times a day. I kept  
14 little Zip-loc baggies on my person all the time  
15 so I could lean over and puke into a Zip-loc bag  
16 and zip it up and throw it into the nearest trash  
17 can.

18           A couple of other points about vomiting  
19 and nausea, the closest I've ever come to dying  
20 from my gastroparesis was actually -- I inhaled at  
21 the same time I was vomiting. I almost choked on  
22 my own vomit. That's a very scary thing.

1           And the last point about vomiting and  
2   nausea, one of the long-term consequences of  
3   vomiting 20 to 30 times a day for several years in  
4   a row is, we were talking about this at the table,  
5   is I've experienced significant dental decay. I  
6   am 38 and I'm moving towards full prosthetic teeth  
7   in the next couple of years. So, there are long-  
8   term consequences as well.

9           DR. EGGERS: We want to move on. I just  
10   want to see, does this resonate -- the experiences  
11   about nausea have resonated. If you have more,  
12   please, again, write about it in the docket.

13           On the web, are we having any comments  
14   on nausea, vomiting?

15           MR. THOMPSON: A lot of similar comments  
16   that people have -- either their in constant  
17   states of nausea. They don't think of nausea as  
18   pain. They associate often with vomiting. One  
19   person talking about her child said that she  
20   describes her nausea just as feeling sick. And if  
21   it progresses to a low moan, it means that she's  
22   about to vomit. And a lot of similar comments.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

93

1 DR. EGGERS: Thank you. I'm going to  
2 ask the panel if there's any questions on any of  
3 these symptoms that you'd like to know more about  
4 or why people raised them. Yes?

5 DR. KOVACS: Meredith, you mentioned  
6 that you vomit 20 to 30 times a day, and I just  
7 had a question. Are you counting the number of  
8 times that you physically, let's say, go to a  
9 toilet to vomit, or the number of times something  
10 comes out in that one episode at the toilet?

11 MEREDITH: It would include maybe what  
12 would be described as regurgitation, so any time  
13 something came from my stomach into my mouth. And  
14 I stopped going to the toilet, because it was  
15 exhausting to go 20 or 30 -- that's why I carried  
16 around the Zip-loc bags.

17 DR. EGGERS: Another question? Lara?

18 DR. DIMICK: It sounds to me like we  
19 obviously need to evaluate nausea with several  
20 questions by itself, you know, duration, is it  
21 constant, is it intermittent, you know, how  
22 (indiscernible) is it, how much does it interfere

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

94

1 with you functioning in social -- socially and  
2 (indiscernible) vomiting, also not only number of  
3 episodes, but amount. Although, that might be  
4 very difficult to quantify, but I mean, it seems  
5 like -- because some people have mostly nausea and  
6 some people have mostly vomiting that maybe you  
7 could help us on the web to think about the  
8 questions that would be helpful for you to be able  
9 to explain it.

10 DR. EGGERS: I really encourage you to  
11 do this homework assignment. Write down the  
12 questions. You can send multiple comments to the  
13 web. We don't care how often you hit that comment  
14 now button. Just jot them down to answer this  
15 question. I think it's really important. Lara --  
16 Laurie.

17 DR. MULDOWNNEY: And this is actually not  
18 on this slide, but it's not on the next one  
19 either, I don't believe. But I heard a theme  
20 about just overwhelming fatigue. And I was just  
21 curious. I think I heard that from a lot of the  
22 patients suffering from gastroparesis, if that is

1 something that everybody is experiencing,  
2 particularly those of you who may not have  
3 gastroparesis as well. I'm interested if that  
4 sort of covers everybody.

5 DR. EGGERS: Is the fatigue -- can I ask  
6 a follow-up question to that? Is the fatigue  
7 because of -- primarily because of some of your  
8 other symptoms that just expend your energy and  
9 cause your fatigue, or is it something even when  
10 you don't have the symptom, even you are -- have a  
11 more average day, not maybe in an intense flare-  
12 up, is the fatigue still present?

13 UNIDENTIFIED VOICE: (Indiscernible).

14 UNIDENTIFIED VOICE: But even on the bad  
15 -- the good days, you still are fighting some form  
16 of fatigue. All of us with chronic illnesses know  
17 about the spoon theory. You have to save your  
18 spoons and count which spoons you're going to use  
19 for what -- you know, if I do this, then tomorrow,  
20 am I going to be able to do that? No, maybe not,  
21 you know. So you have to make judgment calls.  
22 And sometimes that means missing things you really

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

96

1 want to do, but it is what it is.

2 DR. EGGERS: Down here.

3 MEREDITH: I have lots to say about  
4 this. I just wonder if a lot of -- some of the  
5 fatigue that we experience with functional GI-  
6 related disorders is related to nutritional  
7 deficiencies that we develop, like anemia. It's  
8 exhausting if undiagnosed and untreated.

9 DR. EGGERS: We'll go to Katharine and  
10 then we're going to go to Carrie, and then I think  
11 we'll move on.

12 KATHARINE: I was just going to expand  
13 on the malnutrition. I've lost about 20-some  
14 pounds since this started, and I was only 117 at  
15 first. So, the fatigue, even on good days, it's -  
16 - like you said, even on good days, there is  
17 fatigue, a lot of it. It's hard being able to  
18 exercise, which everyone suggests to do to help  
19 with the symptoms. You know, with class again,  
20 I'm tired in class all the time. It's hard to  
21 focus because of the fatigue, but I think it's a  
22 lot of the malnutrition, not being able to eat.



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

97

1 DR. EGGERS: Thank you, Katharine.

2 We'll go to Carrie.

3 CARRIE: With the fatigue, whether we  
4 have the vomiting or the nausea, you can't eat.  
5 So, even if you feel like you're going to throw  
6 up, you're not going to want to eat anything. So,  
7 you're not getting those necessary vitamins. And  
8 it isn't just like a one-time thing. The vitamins  
9 built up in your system, so you may not eat for a  
10 couple days. Well, those vitamins, you depleted  
11 your supply, so it's a -- it will take you two  
12 weeks just to build back up to where you're  
13 supposed to be. So, whether you're having a good  
14 day or a bad day, you're still depleting that  
15 little supply you already have and it's really  
16 hard to keep that balance. I suffer from all the  
17 time, my doctors are constantly, like, oh, you can  
18 use this vitamin, you need this vitamin. And the  
19 thing is, those vitamins, they're not easy to  
20 digest either themselves. I mean, they're  
21 horrible to take and taste horrible, which makes  
22 you want to throw them up. I mean, I, myself, have

1 switched to liquid vitamins, chewable vitamins.  
2 And it's just trying to find ones that I can  
3 actually keep down and keep my levels up without  
4 having to get the IV fluids or the liquid  
5 nutrition. It's even -- it's just really hard to  
6 keep the levels up and sustain them, because they  
7 get -- that's why we're constantly tired, because  
8 you don't keep your vitamin levels high enough.  
9 And they say the best source of Vitamin D is the  
10 sun. Well, I can't go outside in the sun. Just  
11 to walk outside and you get outside to be in the  
12 sun is exhausting. It is a constant battle to see  
13 and keep where you're supposed to be because of  
14 this pain. You can't eat because you're in pain.  
15 You can't eat because you're nauseous. It's just  
16 a combination of everything that we face on a  
17 daily basis, you can't keep that nutrition where  
18 it's supposed to be.

19 DR. EGGERS: I want to be fair -- one  
20 more. Is it a different perspective? Okay, we'll  
21 take one more and then we're going to move on to  
22 the lower GI symptoms.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

99

1           LYNN: My name is Lynn, again. I find  
2 that I have to take a minimum of a two-hour nap  
3 every afternoon. Generally, by two o'clock, I'm  
4 done. I have to rest from 2:00 to 4:00. I do  
5 find there are certain things that, if I need to  
6 get through the day, like today, that I do. For  
7 instance, I went swimming this morning. So, I do  
8 swim 16 laps in an Olympic pool or I go to  
9 aquasize class. I also go to acupuncture and  
10 massage once a week. And I find on those days  
11 when I have acupuncture and massage and/or that I  
12 swim, I find I can go a little further, and eat  
13 very little on those days as well.

14           DR. EGGERS: We'll be following up on  
15 these non-pharmaceutical treatments after a bit.

16           It is at the time when the agenda says  
17 we would be taking a break, but if you all give us  
18 permission, we're going to go until three o'clock  
19 and then we'll take a break, but please feel free  
20 to get up if you need to, whenever. I do want to  
21 make sure we get to the other symptoms and then  
22 talk about a wrap-up on this topic.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

100

1           So, can we go to the next slide. And if  
2 you're on the phone, we're going to be teeing up  
3 the phone. And since we're so limited on time  
4 with the phone, if you were looking for comments,  
5 we would welcome your comments on symptoms and  
6 ways that you experience the symptom that has not  
7 been mentioned yet. We're teeing that up. We'll  
8 come at the end of this brief discussion here on  
9 the lower GI-related symptoms.

10           First, we just want to know what is  
11 experienced in the room. So, we're going to ask  
12 to choose all that apply. Which of the following  
13 lower GI-related symptoms have you or your loved  
14 one experienced in the past year?

15           So, many of you experienced many things,  
16 the most frequent being the gas or flatulence.  
17 And on the web, what are we getting?

18           MR. THOMPSON: Similar results.

19           DR. EGGERS: You've really tested my  
20 abilities there. So, let's now go on to the next  
21 one. So, given what you experienced, which have  
22 the most -- of these, of these symptoms, which has

1 the most significant impact on your life? Choose  
2 up to three symptoms.

3           So, the gas or flatulence comes out as  
4 the number one -- the most frequently mentioned  
5 here, followed by hard or dry stools and sense of  
6 urgency. Okay, so you -- we won't be able to cover  
7 all of this in the next few minutes, but we'll do  
8 as best we can. And on the phone, what are -- on  
9 the web, what are we getting?

10           MR. THOMPSON: A little bit different,  
11 about 40 percent for the frequent, loose watery  
12 stools, hard or dry stools, or rectal pain.  
13 Sixty-six percent gas or flatulence and about 20  
14 percent for the other three.

15           DR. EGGERS: So, I think -- I'm going to  
16 turn to my colleagues. Is there a symptom that  
17 you would really like to know more about why they  
18 -- how they conceptualize it and why they picked  
19 it? Should I go with the gas or the flatulence?  
20 I don't think we heard about it as much up here,  
21 so let's hear -- can someone explain how they did  
22 it? Let's come here first.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

102

1 JILLIAN: So, as insignificant as it  
2 sounds, gas is extraordinarily painful if it's  
3 stuck and if you have gastroparesis, it does not  
4 move. And it doesn't -- it's just like having  
5 food in your gut. That's the reason for the  
6 bloating and the abdominal pain.

7 DR. EGGERS: So, it's contributing to  
8 the symptoms that we talked about in the first  
9 part of the session?

10 JILLIAN: Correct.

11 DR. EGGERS: I'm getting a lot of head  
12 nods.

13 JILLIAN: Because then you get backed  
14 up. You get nauseous. It's a vicious cycle, and  
15 so, I don't perceive in my situation personally, I  
16 don't perceive gas any less threatening than food.  
17 I still feel the discomfort we talked about that's  
18 chronic. I still can have abdominal pain from it.  
19 It's not moving. We have a paralysis of sorts.  
20 So, you know, that's --

21 DR. EGGERS: Thank you very much. Any  
22 different experiences or different

1 conceptualizations of the gas or flatulence?

2 We'll go with Meredith.

3           MEREDITH: I just am wondering how much

4 research needs to be done on gas and flatulence.

5 Is it really just a small bowel bacterial

6 overgrowth that seems to be a fairly constant

7 thing amongst those with lower GI dysmotility or

8 even upper GI dysmotility.

9           DR. EGGERS: Okay. Did we get any

10 comments on the web regarding this?

11           MR. THOMPSON: We had a few people say

12 that gas and flatulence can be very painful. It

13 can cause severe bloating, that it's embarrassing

14 and makes it difficult to go out in social

15 situations and things like that.

16           DR. EGGERS: Okay. Then I'm going to

17 suggest we -- oh, go ahead, Bettemarie, you go

18 ahead while I'm formulating the question to ask.

19           MS. BOND: Just on a different note, not

20 about the gas or flatulence, but this may sound a

21 little strange, but when things don't move at all

22 and it gets so backed up, I did a prep for the

1 colonoscopy, and I had to do a two-day because I'm  
2 so backed up and I didn't even go with that stuff.  
3 Over- the-counter medications just cause a lot of  
4 spasms and just increase the pain drastically.  
5 Not many medications really help, but I would  
6 actually have to -- I wouldn't go unless I had  
7 enemas. And then eventually, they were working  
8 less and less, but I actually had to plan when I  
9 was going to get an enema. Like, it sounds kind of  
10 strange, but you just get so uncomfortable. And  
11 then, as I mentioned before, the one just kind of  
12 then triggers other problems and other issues.  
13 It's just a different take on it.

14 DR. EGGERS: Can anyone explain -- we  
15 haven't heard sense of urgency described in as  
16 much -- we heard a little bit up there, but I want  
17 to make sure, are there any different  
18 conceptualizations other than what was described  
19 on the panel for how you think about that and why  
20 it got rated?

21 KATHARINE: You were talking about sense  
22 of urgency?



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

105

1 DR. EGGERS: Yes.

2 KATHARINE: Okay. With a sense of  
3 urgency, just for me, is that if it hits, I got to  
4 go, because if I wait, it causes so much more pain  
5 and then I can't go later. I can't go at all.  
6 So, you need to go when you need to go. And then,  
7 working retail or working anywhere, you can't just  
8 get up and go to the bathroom when you need to.

9 DR. EGGERS: Tanya.

10 MS. TAYLOR: I had that written, but I  
11 didn't touch on that. That sense of urgency, and  
12 as for most of the -- I know I have fecal  
13 incontinence. If I cannot get to the bathroom,  
14 I'll just -- there are times that I don't even  
15 know I'm going and I'm going. And this -- when  
16 you get to severe stages of this, the colon acts  
17 like a plug. And not one -- so, when they took  
18 that colon out, this is not -- this information  
19 needs to be discussed and it's not being  
20 discussed. There was not one cell in the colon  
21 that was functioning. They weren't dead. They  
22 were just in a state of paralysis. So, the organ

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

106

1 itself looked perfectly healthy. So, to the naked  
2 eye, to a colonoscopy and a laparoscopy, you could  
3 never tell that the colon was not functioning.  
4 So, when they had to -- I had that removed after  
5 the perforation, for at least 10, maybe 15 years,  
6 I had to move the food through my colon when I was  
7 able to eat. And unfortunately, my small  
8 intestine is slowing like the colon did, but if  
9 these cells aren't functioning and we're losing  
10 organs and it's acting like a plug, and so, you  
11 said, I mean, you can't get cleaned out. You  
12 can't go to the bathroom. I guess that what gets  
13 these cells started again, is there something that  
14 maybe can be a drug or something that can be  
15 looked at to get the cells to begin to function  
16 again to get the organ to function again?

17 DR. EGGERS: Thank you very much, Tanya.

18 So, I want to make sure we get to the  
19 phone. Are there any phone -- okay, we have no  
20 phone. Okay.

21 I'm going to give -- if anyone on the  
22 FDA has a final question before we move into the

1 break.

2 MS. BREZOCZKY: Hi, my name is Kelly  
3 Brezoczky, and I do clinical research in this  
4 particular area. And I would just encourage the  
5 FDA, as you look at lower GI-related symptoms that  
6 you also explore language here. You know, these  
7 are very difficult topics for people to describe.  
8 And I think we had a very rich, robust discussion  
9 about pain and discomfort and different ways that  
10 people feel that. When it comes to the particular  
11 symptoms of the lower GI tract, incontinence is  
12 not a word that's patient- friendly. And even if  
13 you look at the NIH studies that have been done to  
14 understand what's happening with leakage in the  
15 lower GI tract, the question in the Haynes  
16 research is, have you experienced any accidental  
17 leakage of liquid or solid stool? And so,  
18 incontinence is a big word that people tend to  
19 correlate with heavy bowel movements or loss of  
20 full bowel control. And often the symptom isn't  
21 necessarily that. It can be accidental-type  
22 leakage of smaller volumes, not necessarily larger

1 volumes. And so, I would encourage you to really  
2 look at some of the research that's been done in  
3 this area as you're looking at that particular  
4 symptom, because I think incontinence is a really  
5 big word that, unfortunately, many people do not  
6 relate to. But yet, if you turn around and ask,  
7 well, do you experience any accidental leakage of  
8 liquid or solid stool, everybody will raise their  
9 hand.

10           And I really commend -- I think it's  
11 Tanya, for actually raising this, because I think  
12 this is one of the symptoms that nobody likes to  
13 talk about. Nobody likes to say or hear the word  
14 fecal incontinence. And I've done a lot of  
15 research in this area that I'll speak later about.  
16 But I just think this is a really important  
17 symptom that we get the language right as we work  
18 to improve outcomes for this population.

19           DR. EGGERS: Thank you very much. And  
20 what was your name, again?

21           MS. BREZOCZKY: Kelly Brezoczky.

22           DR. EGGERS: Kelly, thank you very much.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

109

1           We're going to move into the break, but  
2 what I want to -- if I can say, from our  
3 perspective, the planning team, we get so much out  
4 of the summaries that get sent to us to help  
5 identify who's going to be on the panel, because  
6 you use the terms that you want to use that  
7 connect with you. So, as you -- there are so many  
8 symptoms we didn't get to talk about. As you  
9 describe them, if you write to the docket or as  
10 you're putting on the web, use the terms that make  
11 sense to you and we'll figure out what you mean,  
12 rather than feeling like you have to use technical  
13 terms, because it's more important, to your point,  
14 that we know how you are conceptualizing and how  
15 you are feeling and how you are speaking about  
16 this with others and with your doctors.

17           So, with that, we'll take a 15-minute  
18 break and start again at 3:15. Thank you.

19           (Break from 2:57 p.m. until 3:07 p.m.)

20           DR. EGGERS: -- the Topic 2 panelists to  
21 work their way to the front.

22           All right. We have a lot more ground to

1 cover, so I'm going to ask that we get started.  
2 The format of the afternoon is just like the  
3 format of the -- I mean, the format now is just  
4 like the format earlier. I do want to mention one  
5 thing that we got from the web. I just want to  
6 point out that we had an overwhelming response to  
7 the question about fatigue. And so, it sounds like  
8 we could have had a lot -- well, we could have had  
9 a lot more discussion on any topic. But on that  
10 one, too, so, if those on the web, and you hear  
11 fatigue is one thing really to discuss further in  
12 the docket.

13           We have five panelists to kick off our  
14 discussion of Topic 2 on the treatment approaches.  
15 And so, what we're looking here, and again, the  
16 questions that were guiding our discussion on the  
17 second half of your agenda is what you're  
18 currently doing to treat your condition and  
19 symptoms and what specific aspects of your  
20 condition that that addresses, and how well does  
21 it do so? And the downsides to those treatments.  
22 And then, an ideal treatment.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

111

1           We are going to be covering a wide range  
2 of treatments, pharmaceutical, surgical, devices,  
3 et cetera. As we go through, we'll try to pull  
4 out as much as we can, the role of pharmaceutical  
5 treatments in that. But we have five great panel  
6 comments to get us started, and we have someone  
7 who is participating on the phone, and so, I'm  
8 going to start with her. Her name is Anne. Anne,  
9 are you on the phone?

10           MS. SIROTA: Yes, I am.

11           DR. EGGERS: Again, we've asked them  
12 each to prepare a few minutes of comments, so,  
13 Anne, we would love for you to kick us off. Thank  
14 you.

15           MS. SIROTA: Thank you. Thank you for  
16 having me speak. I was diagnosed with diarrhea  
17 predominant IBS 26 years ago after a month-long  
18 bout of diarrhea. Today, I continue to have  
19 frequent, at times, daily diarrhea, urgency,  
20 abdominal pain, heartburn, bloating, and  
21 incontinence. Over the 26 years that I've had  
22 this, I have alternated conventional medicine

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

112

1 treatments and complementary medicine approaches.  
2 I have tried different dietary protocols, taken  
3 prescription and over-the-counter meds, tried  
4 acupuncture, homeopathy, chiropractic, Chinese  
5 herbal remedies, supplemental vitamins and  
6 minerals. I get temporary relief, but none of the  
7 treatments have been permanent or even last very  
8 long.

9           In the first few years, I first tried a  
10 restricted diet, and I took Xanax, Lomotil,  
11 Imodium, anti-spasmodic, and some fiber products.  
12 When those didn't work, I tried complementary  
13 medicine approaches. The Chinese herbs were the  
14 most effective, but they were very difficult to  
15 take, and I wasn't sure they were safe. And then  
16 I couldn't take them because of insurance issues  
17 and I had to stop.

18           Over the 26 years, I also took part in  
19 several studies that included support groups,  
20 hypnosis, and therapy sessions specifically for  
21 IBS, which included reading information, breathing  
22 techniques, and meditation practice. Some were



1 more effective than others, at least temporarily.

2 I also tried anti-depressants.

3 Desipramine, which has scary side effects, so I

4 didn't take it. Lexapro, Cymbalta, Wellbutrin.

5 They didn't really help.

6 In between each alternative treatment, I

7 would go back on the Imodium. So, in some ways

8 it's the most reliable for short-term relief. It

9 also has the rebound effect and I developed a

10 tolerance to it, so I have to keep taking more and

11 more.

12 A few years ago, I was taking Verapamil

13 for palpitations and found it to be very effective

14 in controlling the diarrhea and the pain. This

15 was probably the longest lasting relief I ever

16 had, but the Verapamil has some dangerous side

17 effects and I had to stop. And then the diarrhea

18 came back worse than ever. Again, I tried

19 acupuncture, hypnosis, Chinese herbs. And then I

20 went back on Imodium. Again, it didn't work

21 completely and I was getting a rebound effect.

22 Over the past three or four years, the IBS has

1 become progressively worse. I've had multiple  
2 episodes of diarrhea, urgency, some incontinence,  
3 abdominal pain, gas, bloating, heartburn, a little  
4 bit of nausea.

5           Two years ago, I was taking up to eight  
6 Imodium caplets a day, though they did not always  
7 work. I still had diarrhea almost every day,  
8 sometimes more than once. Two years ago, in the  
9 fall of 2013, I consulted with a naturopath. She  
10 prescribed several supplements such as probiotics  
11 and vitamin support and some minerals. Two of the  
12 supplements, glutamine and activated charcoal  
13 seemed to have the most immediate relief. The  
14 naturopath believes that taking Imodium, as much  
15 as I do or as much as anyone does, may make it  
16 harder for the GI system to heal properly.

17           The naturopath also put me on a low  
18 FODMAP diet. FODMAPs are basically carbohydrates.  
19 They're sugars that are osmotic, means that  
20 pulling the water from the digestive track and  
21 they don't digest or absorb well and could become  
22 fermented aggravating the IBS. The combination of

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

115

1 the FODMAP diet and the supplements seemed to work  
2 better than most other treatments. I was  
3 definitely better for a while. However, a low  
4 FODMAP diet is very restrictive and hard to  
5 maintain even over the initial six weeks. It's an  
6 elimination diet where you reintroduce foods a  
7 little -- one at a time.

8           After about 15 months of relative well-  
9 being, the diarrhea urges and stomach pains now  
10 continue on and off. The symptoms can occur at  
11 any time, any place. Bad days cause a great deal  
12 of anxiety and depression and I have a hard time  
13 concentrating, focusing on other tasks. I use  
14 motivation. I become obsessed about my symptoms.

15           Certain foods can make it worse, but  
16 sometimes it's just dairy -- just eating that  
17 triggers an episode. Currently, then, to address  
18 the IBS, I'm taking Bentyl, which is an anti-  
19 spasmodic, a probiotic, Vitamin D, digestive  
20 enzymes, fish oil, glutamine, and other herbal  
21 combinations, plus, if I need it, Imodium and  
22 deactivated charcoal. I feel that the IBS is

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

116

1 barely managed. Over the years, I've seen six or  
2 seven different gastroenterologists. None of the  
3 treatments have been totally successful. I feel  
4 like conventional medicine has not really taken  
5 into consideration the debilitating effect of the  
6 symptoms or the effect on my daily life. I  
7 sometimes wonder whether other diagnostic tools  
8 may lead to better treatment. I think I have had  
9 more positive and encouraging results from  
10 complementary medicine, though even there, nothing  
11 has been permanent. Complementary medicine has  
12 provided other diagnostic tools and other  
13 treatments that are not available in conventional  
14 medicine. Obviously, I would like to find a cure  
15 for the IBS, but if anything, something to treat  
16 the symptoms, diarrhea, urgency, incontinence and  
17 the pain. We needs meds or other treatments that  
18 will prevent the symptoms of poor digestion and  
19 poor absorption and would reduce the inflammation  
20 that actually caused the diarrhea.

21 IBS seems to be more of a confluence of  
22 symptoms. So, a gentle med or supplement without

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

117

1 a possibility of serious side effects, without the  
2 rebound effect, one that would not lead to  
3 tolerance would be a tremendous relief. On an  
4 immediate basis, I would like to have a medicine  
5 or supplement that would have a very immediate  
6 result, so if I feel an episode coming on, I'd be  
7 able to avoid it and gain some security wherever I  
8 am.

9 Thank you for allowing me to speak.

10 DR. EGGERS: Thank you very much, Anne.  
11 And you can't see us in the room as well, but you  
12 have been speaking to a group that understands and  
13 has been nodding their heads to what you're  
14 saying, so we thank you very much for that.

15 MS. SIROTA: Thank you.

16 DR. EGGERS: Now, we will go on to have  
17 Lynn.

18 MS. WOLFSON: Good afternoon. My name  
19 is Lynn Wolfson, and I'm here from Fort  
20 Lauderdale, Florida. I am honored to be here. I  
21 came to speak about my rare genetic disorder,  
22 Hirschsprung's disease. I was born with this

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

118

1 disease and have had it all 56 years of my life.  
2 Consequently, the intestines, which do not have  
3 ganglion cells or have ganglion cells which are  
4 formed but not functioning, do not have rhythmic  
5 peristalsis. This results in severe constipation,  
6 vomiting, obstructions, distention, intestinal  
7 ruptures, and lots of pain. There is no cure for  
8 Hirschsprung's disease. I spent the first four  
9 years of my life taking milk of magnesia, getting  
10 enemas and suppositories regularly, and eating  
11 very little. I was very much underweight,  
12 constipated, projectile vomiting, and frequently  
13 in pain. I began my surgeries in 1963 at the age  
14 of four. I had a full rectal thickness biopsy, an  
15 intestinal resection, an intestinal rupture, a  
16 colostomy, and a colostomy closure by the time I  
17 was eight years old. By the time I became an  
18 adult, I had very bad reflux. I was still very  
19 much underweight. I was five foot four and a half  
20 inches, and 103 pounds when I got married at age  
21 27.

22 I tried many medications for GERD, such

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

119

1 as Reglan, Zantac, Prevacid, Prilosec, Tagamet,  
2 and Protonix. Nothing seemed to work. During the  
3 delivery of my first child, I was vomiting bile  
4 and then blood. In addition, I would get severe  
5 intestinal infections while pregnant. After my  
6 second child was born, I had a laparoscopic Nissen  
7 fundoplication. The vomiting finally stopped,  
8 however, my abdomen grew very large. I had severe  
9 abdominal pains and multiple intestinal  
10 infections. My lungs started to become affected  
11 from the pressure from my abdomen. I developed  
12 asthma as an adult. My pain started to worsen. I  
13 was in a lot of pain after eating. My distention  
14 grew until I looked six months pregnant. I was  
15 severely constipated. I was physically unable to  
16 defecate. I had another full rectal thickness  
17 biopsy to check for ganglion cells like when I was  
18 four years old.

19           In 2002, the colorectal surgeon was  
20 shocked to find that I was still positive for  
21 Hirschsprung's disease. There were no ganglion  
22 cells present on any of the biopsies. The surgeon

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

120

1 repeated the surgery I had when I was a child.  
2 Five days later, another intestinal rupture and my  
3 second colostomy. In 2003, I had more surgery.  
4 During this surgery, my colostomy was closed down,  
5 my rectum was removed. I had a colo- anal  
6 connection and and ileostomy was formed.  
7 Unfortunately, I also lost 15 units of blood and  
8 ended up on life support in trauma/intensive care  
9 for five days. During this surgery, several  
10 nerves were inadvertently slashed causing me to  
11 have a neurogenic bladder and neuropathy in my  
12 legs. The ileostomy was closed a few months  
13 later. The constipation, nausea, and pain  
14 continued. My gall bladder was removed. My  
15 constipation issues got worse. I was taking  
16 prescription laxatives multiple times a day, lost  
17 total fecal control, was in pain, and still had  
18 fecal impactions. I was still very thin.

19 In April 2006, it was found that 90  
20 percent of my colon was non-functioning. In  
21 addition, my fifth cervical disc had herniated and  
22 ruptured as a result of malnutrition. In August



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

121

1 2006, I had the surgery to remove my entire colon,  
2 rectum, and anus, and to get a permanent  
3 ileostomy. I started to do better. I finally  
4 started to gain some weight. My ileostomy is the  
5 best thing to happen to me. No more laxatives,  
6 enemas, suppositories, sitting on the toilet,  
7 constipation, or rectal exams. In 2008, more  
8 surgery with a new ileostomy. In 2011, I had  
9 another intestinal obstruction, more surgery,  
10 another ileostomy. In September 2012, I got  
11 sepsis and then ten days later, sepsis again. I  
12 tried going off of TPN in December 2012. It  
13 lasted until April 2013, when I could not tolerate  
14 the pains from eating. I start J-tube feedings in  
15 May. I had another obstruction in June 2013.  
16 More surgery in August 2013 with a seventh ostomy  
17 and a G-J-tube. I'm happy to say that my last  
18 hospitalization was in July 2014. I am now going  
19 to Mayo Clinic in Minnesota who has been able to  
20 manage my condition so I can have quality of life.  
21 I eat very minimally, wear my J-tube feeding, and  
22 hook up my gastric bag when I feel nauseated or

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

122

1 bloated. Bottom line is, I am the happiest bag  
2 lady.

3 I do find the area around the J-tube to  
4 develop skin tabs and to be very sore. I have  
5 tried silver nitrate and stomahesive powder.  
6 Nothing seems to work. I just keep the area clean  
7 and the plate of my tube within an quarter inch of  
8 my abdomen. My J- tube is 750 cc's of Peptamen  
9 1.5 daily. I have found this formula works much  
10 better for me than when I was on Vivonex Plus with  
11 Pro-Stat, baby rice cereal, and glutamine. I also  
12 take Align to minimize my bloating symptoms. I  
13 have Hyoscyamine to take prior to eating, but find  
14 that it makes me too tired. I prefer to lay down  
15 after I eat for one to two hours for the pain to  
16 dissipate. It is very important to me to have a  
17 clear head and to be in control. In addition, I  
18 also take Vitamin C and Methenamine Hippurate to  
19 make my urine more acidic, to reduce the quantity  
20 of urine infections from catheterizing. For my  
21 intestinal absorption issues, I take sodium  
22 bicarbonate and magnesium gluconate. I find that

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

123

1 the most difficult part of the day is the pain I  
2 get about an hour after eating which lasts up to  
3 two hours. I have not found a medication which I  
4 could take which does not make me tired or make my  
5 head foggy. I also find that the formula does not  
6 give me enough strength to make it through the day  
7 without taking a two-hour nap. I have periods of  
8 time where the pain does not dissipate after two  
9 hours and continues for days to weeks. I believe  
10 this is when I get pseudo-obstructions or  
11 intestinal infections. Unfortunately, there is  
12 nothing to be done during those times. This  
13 occurs every four to six months. I have a  
14 wonderful nurse with me eight hours a day and my  
15 service animal, Zev. He helps me up and down steps  
16 and curves, carries my handbag, let's me know when  
17 my ostomy bag is leaking, and can carry things in  
18 his mouth for me.

19 I am very grateful to have been given  
20 the gift of life. I am married for 29 years and  
21 have two beautiful daughters who are both  
22 biomedical engineers and in medical school. I am

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

124

1 very active within my community. I swim, I tutor  
2 students in math, knit hats for cancer patients,  
3 run a book club, lobby for more money to be  
4 appropriated by Congress for research in digestive  
5 diseases, and I travel the world with my family.  
6 My goal is to inspire others to live life to their  
7 fullest despite their intestinal illnesses. I do  
8 this by sharing my story with professionals such  
9 as you who can make changes to improve the life of  
10 others with digestive diseases. I dream of the  
11 day when no one will be born with Hirschsprung's  
12 disease.

13 (Applause.)

14 DR. EGGERS: Thank you very much, Lynn.

15 MS. CHILSON: Hi, my name is Julian  
16 Chilson and I'm from Richmond, Virginia. I have  
17 had gastroparesis symptoms for as long as I can  
18 remember. Constant nausea, stomach pain, inability  
19 to exercise, weight gain, ongoing breathing  
20 issues, and lung pain. I have pushed myself to  
21 live a normal life, because doctors told me  
22 nothing was wrong. In October of 2009, my body

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

125

1 collapsed. From then on, my lungs stayed full, I  
2 threw up every meal, my heart rate stayed  
3 elevated, my blood pressure high, and I was unable  
4 to breath or move without difficulty. My weight  
5 went up to 240 pounds, although I could not keep a  
6 single meal down. I often was unable to stand up  
7 or walk on my own.

8           For the next four years, I went from  
9 specialist to specialist to get answers. I kept  
10 hearing there was no reason for me to be so sick.  
11 I asked several doctors to be referred to a GI.  
12 None would, because I was too sick. At the end of  
13 four years, I was told there was nothing else that  
14 could be done for me. In desperation, I  
15 researched local acupuncturists, made an  
16 appointment. Within minutes, she told me my  
17 digestive tract was not able to digest food  
18 properly. She instructed me to eat only chicken  
19 broth and crock pot chicken until I felt stronger.  
20 She gave me an acupuncture treatment from which I  
21 immediately felt improvement for the first time in  
22 four years.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

126

1           For the next eight months, my doctors  
2 were amazed by my sudden improvement, but doubted  
3 I had gastroparesis. I asked to be referred to a  
4 GI again. They refused. After eight months, I had  
5 a really bad flare. The one doctor finally agreed  
6 to send me to a GI for the purpose of proving to  
7 me I did not have gastroparesis. That GI ended up  
8 diagnosing me with severe gastroparesis and  
9 inertia of the small intestine. Immediately, I  
10 was prescribed Zofran and banned from eating all  
11 vegetables. Soon after, he put me on Reglan,  
12 because I was having severe fatigue issues. I was  
13 able to start eating regularly, suffered less  
14 nausea and dizziness, but still suffered from  
15 severe fatigue. With Reglan, I was able to reduce  
16 Zofran used by quite a bit, but not completely.

17           This past February, I had a Botox  
18 injected into my pylorus. I feel like a different  
19 person. I can now drink water and expand what I  
20 eat. Because my insurance does not like covering  
21 Botox, I am scheduled for a pyloroplasty later  
22 this summer. But even after the Botox, I was

1 having severe fatigue issues and excessively high  
2 heart rate. A cardiologist determined that my  
3 metabolism was off kilter from being sick for so  
4 long and was acting like I was still in the middle  
5 of that -- where I was a few years ago. Three  
6 weeks ago, I started Diltiazem, a medicine that  
7 was not a beta blocker, because of the aspiration  
8 issues. It is steadily increasing my energy  
9 without excessive heart rate.

10 As a result of severe aspiration, I have  
11 an extreme sensitivity to smoke, chemicals, and  
12 their residues, leading to multiple ER visits.  
13 Recently a dietician contacted me to try Vitamin E  
14 due to studies that it helps build allergic  
15 responses in the respiratory system. The full  
16 effect kicks in after 16 weeks. After six weeks,  
17 I am seeing improvement. I can now handle some  
18 exposures with little effect if I take my rescue  
19 inhaler as soon as possible. Gummy vitamins,  
20 Vitamin D, and probiotics help my system function.  
21 I am continuing with acupuncture with great  
22 success, and yoga has helped me in getting my

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

128

1 bowels to move regularly. Nutrition drinks are  
2 not an option for me, since I am soy and dairy  
3 intolerant, unable to handle dairy or dairy  
4 substitutes and corn sweeteners.

5           A change I would like to see made for  
6 gastroparesis symptoms is to include weight gain  
7 in addition to weight loss as a critical symptom  
8 of gastroparesis. GES testing should be included  
9 for those who are suffering ongoing, unidentified  
10 GI issues as part of the standard testing regime.  
11 Thank you and thank you so much for having this  
12 meeting for us. We really appreciate it.

13           DR. EGGERS: Thank you, Julian.

14           Meredith.

15           MS. HOLT: Hi, I'm Meredith Holt. I  
16 live in Washington, D.C. I have a diagnosis right  
17 now of chronic unexplained nausea and vomiting,  
18 but I say that with some trepidation, because I've  
19 also had a diagnosis of gastroparesis, so  
20 basically, I sometimes pass and sometimes fail the  
21 gastric emptying studies.

22           Treatment for me, since 2010, has



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

129

1 included for my terrible debilitating nausea and  
2 vomiting, domperidone. I've also had multiple  
3 Botox injections to the pyloric valve, various  
4 PPIs, Phenergan, Zofran, Marinol, dietary  
5 modifications, Reglan. I eventually ended up on  
6 TPN and then on feeding tubes. And then, in  
7 August of 2013, following a two-and-a-half month  
8 inpatient hospitalization, the result -- because I  
9 could no longer even take in tepid water, my GI  
10 doctor started me on a trial of Zyprexa, which is  
11 currently on the market as an atypical anti-  
12 psychotic medication to treat my nausea, because  
13 there was one small study that showed that Zyprexa  
14 might be efficient in treating nausea. And within  
15 literally 30 days, I had a complete turnaround in  
16 my symptoms. Zyprexa I take now daily. I still  
17 have Marinol and Zofran as PRNs to take when my  
18 nausea flares. Right now, I'm very fortunate to  
19 be able to eat relatively normally. I still have  
20 to avoid high fiber foods. So, like I still dream  
21 of eating a green salad. I can't drink thick  
22 liquids. Fatty foods tend to trigger abdominal

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

130

1 pain, nausea and vomiting. But the Zofran is very  
2 effective at treating the nausea and the vomiting.  
3 So, I also had a really drastic surgery  
4 in 2012 called a median arcuate ligament release  
5 that was meant to alleviate some of the pain and  
6 bloating that I had with my gastroparesis. It was  
7 also unsuccessful. So, I'm very grateful that  
8 Zyprexa has worked for me. It has been a complete  
9 game changer. It keeps me out of the hospital. I  
10 haven't been in the hospital for gastroparesis  
11 since August of 2013. I don't -- and I was able to  
12 have my feeding tube removed after two or three  
13 months of starting with Zyprexa. I don't think  
14 the Zyprexa does anything to cure my GI  
15 dysmotility, but it does keep the major symptoms  
16 at bay. So, for that, I am grateful. And I'm  
17 able to work full-time. I still struggle, like  
18 many of you, at a lot of social events, because  
19 many social events are centered around food, and  
20 often fatty foods, which is very tricky. And I  
21 feel, again, super grateful that Zyprexa has  
22 really changed the quality of my life over the

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

131

1 last couple of years.

2 DR. EGGERS: Thank you very much,  
3 Meredith.

4 MS. PASINKOFF: Good afternoon. I'd  
5 like to thank the FDA for giving me this  
6 opportunity to share the devastating effects of  
7 digestive disorders. My name is Carol Pasinkoff.  
8 I have GERD, chronic constipation, and idiopathic  
9 gastroparesis. I cannot eat more than a few bites  
10 of food, and I am tube fed. Every single day I  
11 suffer from unrelenting nausea, abdominal  
12 swelling, pain, regurgitation, burping that  
13 sometimes is constant, and constipation. Some  
14 days are worse than others, and on my really bad  
15 days, I am bedridden. I never know what to expect  
16 day to day, and sometimes hour to hour. Due to  
17 the unpredictability of my symptoms, I cannot  
18 work, I have difficulty performing everyday tasks  
19 and chores, and have become isolated from my  
20 friends and social activities. Through the years,  
21 I have tried everything that is available,  
22 including Botox injections into the pylorus

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

132

1 muscle, erythromycin, Reglan, which has a black  
2 box warning from the FDA, Marinol, Cytotec,  
3 Mestinon, Carafate, herbal and holistic remedies,  
4 and many different proton pump inhibitors. None  
5 of these helped. Every day, I take over ten  
6 different medications to treat my symptoms,  
7 including four medications specifically for  
8 nausea, and which some days they don't help at  
9 all. The nausea is brutal. I cannot function at  
10 all when they don't help. Some anti-nausea drugs,  
11 like promethazine and Compazine causes too many  
12 side effects for me. Some drugs that can possibly  
13 help against nausea, such as Mend, my insurance  
14 will not cover, because they are specifically for  
15 people who are undergoing chemotherapy. These  
16 drugs are extremely expensive. I was prescribed  
17 domperidone, which is not FDA approved, and it  
18 gives me minimal relief, even taking the maximum  
19 dosage. I was on Zelnorm, which helped my severe  
20 constipation, but it was pulled from the market.  
21 I was put on Amitiza, which helped with the  
22 constipation, but caused me to faint. My chronic

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

133

1 constipation became so severe that I had to have  
2 90 percent of my colon removed. I still have  
3 constipation and need to take Linzess every day,  
4 as well as over-the-counter products to help me  
5 have a bowel movement. Prior to being approved  
6 for the gastric electric stimulator, I was  
7 vomiting everything I ate and drank and was  
8 severely malnourished and dehydrated. I was  
9 placed on TPN for two years, but after becoming  
10 septic twice, TPN was stopped. A G-tube was  
11 placed in my stomach for decompression, which  
12 helps empty my stomach of bile through the day.  
13 And a J-tube was placed in the small intestine for  
14 feeding. I have been tube fed through the J-tube  
15 for the last nine years. As per my doctor's  
16 advice, every day, I try to eat a few bites of  
17 food. No matter what I eat, and sometimes when I  
18 haven't even eaten, I burp, regurgitate, and my  
19 abdomen becomes very distended to the point where  
20 I look like I'm seven months pregnant. A heating  
21 pad or an ice pack and a Tramadol do little to  
22 alleviate my pain. My doctors will not prescribe

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

1 any stronger pain med, as any opiate causes  
2 constipation. At the moment, being tube fed and  
3 taking the numerous supplements and drugs keeps me  
4 alive and nourished, but there is no cure for  
5 gastroparesis. Doctors try to treat all the  
6 symptoms. Some days my symptoms are tolerable, but  
7 most days I have no relief. My doctors say they  
8 have tried everything that is available to treat  
9 my symptoms, and although they now believe that  
10 the motility of my small intestine and esophagus  
11 are slowing down, there is still no further  
12 treatment options that can be recommended. This  
13 is very depressing and I hold on to the hope that  
14 something will be developed to specifically treat  
15 the symptoms of gastroparesis.

16           There are clinical trials going on in  
17 the United States to treat people who have  
18 gastroparesis caused by diabetes, but many of us  
19 who have gastroparesis do not have diabetes. An  
20 ideal treatment for my condition would be a drug  
21 that is developed that can help alleviate the  
22 extreme nausea from gastroparesis. Also, a drug

1 to increase motility in the stomach that can  
2 diminish the bloating and pain after a few bites  
3 of food and enable me to eat like a normal person.  
4 Although I have the gastric electric stimulator,  
5 also known as the pacer, it does not actually pace  
6 the stomach. It sends signals to the stomach to  
7 help reduce nausea and vomiting. Perhaps a device  
8 can be developed that actually assists the stomach  
9 in contracting. Thank you for this opportunity  
10 for speaking to the FDA today.

11 DR. EGGERS: Thank you very much, Carol.  
12 Again, you can stay up here or you can head back  
13 to your chairs, whatever you feel more comfortable  
14 doing.

15 I'm just going to head over -- it takes  
16 a couple seconds, and I never know that, so  
17 usually everyone misses the first word I say, but  
18 I've learned to wait. Again -- the puppy needed  
19 some air.

20 (Laughter.)

21 Again, please another round of applause to these  
22 women and to Anne.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

136

1 (Applause.)

2 And to Zev, thank you, Zev. I think you're the  
3 first of our four-legged friends to have joined us  
4 in one of these meetings.

5 There was a lot that we heard in these  
6 panel comments today. We heard about -- I'll call  
7 it multi- motile, for lack of anything better. It  
8 doesn't even get close to what you're dealing  
9 with. But the combination, the complexity of the  
10 surgeries, the devices, the treatments, the  
11 treatments that you've had to try over and over.  
12 For some of you, it's managed things better, and  
13 for others, you still are struggling as much as  
14 you have been. Does this resonate with you? Do  
15 you hear your experiences in here even if the  
16 details aren't the same? And we think, again,  
17 that you have represented the patients in the room  
18 well.

19 We have as much of a challenge to get  
20 through Topic 2 as we had through Topic 1, and we  
21 will take it as we go. I want to first ask a  
22 question about pharmaceutical treatments that



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

137

1 you're on, and we have a polling question for you  
2 in the room and on the web, if you can get your  
3 clickers. Does anyone need one? Raise your hand,  
4 if you need one. Everyone's got one, okay. This  
5 is where it gets to be a real test for me, because  
6 I can't always pronounce the drug names, so if I  
7 stumble, please help me out here, FDA.

8           Have you ever used any of the following  
9 prescription or investigational drug therapies to  
10 help reduce the symptoms of your GI disorder?

11 Amitiza, Linzess/Linaclotide, B. Maybe -- if  
12 anyone needs me to read them out, I will,  
13 otherwise, I'll just let you read them here.

14           The largest is other. We will try to  
15 tease that out a little bit more. And proton pump  
16 inhibitors. But it looks like there's several of  
17 you taking a number of other things except  
18 Lotronex we don't have on here.

19           On the web, do we have experiences?

20           MR. THOMPSON: So, 53 percent say other,  
21 66 percent say Prilosec or proton pump inhibitor,  
22 and then the other ones are very similar.

1 DR. EGGERS: Now, remember, this is not  
2 all survey. This is not research here. It's just  
3 to get a sense of what you're collectively trying  
4 in the room. We heard descriptions about the  
5 products that have worked really well or have not  
6 worked really well. Let's find -- if anyone wants  
7 to build on what we heard, especially from  
8 Meredith, again, it's not so much exactly what  
9 treatment it is, but how you knew what you valued  
10 out of a treatment when you think it really worked  
11 for you, what you noticed in the improvement, what  
12 you -- how long it took, et cetera. Those are the  
13 type of things we'd like to hear about. So, can we  
14 start -- we'll start here with Bettemarie and then  
15 we'll go on. A pharmaceutical treatment that has  
16 worked for you well.

17 MS. BOND: Recently, well, a little over  
18 a year and a half ago, I started on Mestinon, the  
19 autonomic neurologist started me on that. But  
20 what's great is I'm actually able to start eating  
21 again. I'm eating tiny bits of food, and so,  
22 that's huge. But it's also helped my skeletal

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

139

1 muscles. And one thing that showed improvement  
2 was she bumped the dose up and my niece came over,  
3 spent the night. I actually sat up with her,  
4 watched a movie. And then, the next morning, I  
5 put this headband on her and I helped wrap her  
6 hair around it. We dried her hair. And I can't  
7 even do my own hair. Like, I have my CNA help me  
8 with mine. And so that, being able to spend time  
9 with her and helping her do her hair that day was  
10 a huge sign of improvement. So, sometimes, like,  
11 little things that just improve the quality of  
12 life, like spending time with family, with  
13 friends, little things like that can really make  
14 the biggest difference in life.

15 DR. EGGERS: Can you just repeat what  
16 the name of the product was.

17 MS. BOND: Mestinon.

18 DR. EGGERS: Anyone else have an  
19 experience they would like to share? If you're on  
20 the web, please do so. We have back here.

21 ELLEN: I'm sorry for the panelists who  
22 have not had luck with domperidone. I have had

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

140

1 tremendous luck with domperidone. Domperidone  
2 makes it possible for me to eat.

3 DR. EGGERS: One more here.

4 DEBBIE: I just want to second that. As  
5 I said before, when I was diagnosed with  
6 gastroparesis and I had tried other things like  
7 dietary change and small meals, nothing had any  
8 effect. And when I started on domperidone, I had  
9 immediate, complete, reliable relief, which I've  
10 had for the past four and a half years. I mean,  
11 that drug has been a godsend. And I have had  
12 absolutely no adverse effects. If I miss a dose,  
13 I'm immediately nauseous, so needless to say, that  
14 does not happen often, but it has worked  
15 wonderfully for me with absolutely no problems.

16 DR. EGGERS: Right here, we'll go with  
17 Elizabeth.

18 ELIZABETH: Thanks. I was looking that  
19 way. Not to be boring, but I advocate the  
20 domperidone treatment. I was in a bad, very dark  
21 place. It saved my life, literally. I've been on  
22 it for about seven years with great success. I

1 have a quality of life. I feel very blessed.  
2 There is, however, a great deal of frustration,  
3 because it is not an FDA-approved drug. And there  
4 are many challenges that go along with that. So,  
5 you know, that's a whole other discussion.

6 DR. EGGERS: Is this about this drug or  
7 a different drug? You can go ahead. We will  
8 transition to a negative.

9 KATHARINE: With the domperidone, I hear  
10 that it's really helping a lot of people, and I  
11 know it's different for each case of  
12 gastroparesis, but what's really frustrating is, I  
13 can't get a doctor to prescribe that to me no  
14 matter what I tell them, no matter how many times  
15 I've gone crying to them that I need something.  
16 I've taken Zofran, Phenergan, promethazine, PPIs,  
17 everything. Everything that you guys have taken.  
18 And it's really unconventional, but the only thing  
19 that helps me be able to get through the day is  
20 marijuana. And I can't even get Marinol, even  
21 though it actually does help. I can go to school,  
22 I can eat. I have an appetite. I don't get

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

142

1   nauseous if I smoke before I eat as well, but it's  
2   illegal. And I don't want to be smoking it,  
3   because it has adverse effects. My biggest  
4   problem is, there's these treatments out there,  
5   and yet they make it seem so difficult and  
6   there's, like, all this red tape and all of this  
7   things that you have to go through just to get  
8   help. I'm not even seeing a GI doctor until July  
9   7th to even discuss domperidone. That's two months  
10   away and that's just, you know, really  
11   disheartening.

12                   DR. EGGERS: We have heard in many of  
13   the comments that were sent in to help us prepare  
14   the difficulty in getting the care and the  
15   treatment and getting the treatments you want.  
16   So, that point is very well taken. So, thank you.  
17   It was a perfect point to make, so thank you very  
18   much.

19                   Can we -- on the web, are we getting  
20   anything about treatments that have worked well  
21   and what's made them work?

22                   MS. GIAMBONE: Let's see, we have

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

143

1 received a few treatments that did not work too  
2 well.

3 DR. EGGERS: Go ahead and say those.

4 MS. GIAMBONE: Okay, similar to what was  
5 said in the room. Reglan did not work. Side  
6 effects were too bad. Xifaxan caused  
7 lightheadedness and stomach pain. Some people  
8 said that they've tried Zofran, Amitiza, and  
9 neither worked. Linzess didn't work and it caused  
10 intense pain. We did have a few that said that  
11 they also tried to domperidone -- I apologize for  
12 saying that wrong. A few people said that it did  
13 not work for them. Some said they were too scared  
14 to use it, while another did say it worked well  
15 and it gave some feeling of hunger.

16 DR. EGGERS: To the FDA panel, we do  
17 have some time if you want to explore any on this  
18 list, any that surprised you that you wanted to  
19 hear more about or anything before we move on.  
20 Donna.

21 DR. GRIEBEL: Just a quick follow-up  
22 question. So, the Marinol, the reason why you

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

144

1 can't get that is just because it's not covered by  
2 your insurance, because of the indication or --

3 CATHERINE: My doctor just told me to go  
4 to Colorado and try getting it there. That was  
5 his actual words, because it's illegal.

6 MS. KORVICK: I was curious about the  
7 people that said that domperidone worked for them.  
8 I was just wondering, in light of our previous  
9 conversation, what particular symptoms did it  
10 relieve for the people that it worked for?

11 ELLEN: So, I have gastroparesis and the  
12 way I describe my sensation is that it is  
13 nauseating, but it's nauseating because I have a  
14 chronic condition of sewer mouth. It's like,  
15 gases coming back up from my GI system exiting in  
16 the wrong direction. Domperidone is a magic  
17 bullet for me in a very small dose, ten milligrams  
18 twice a day taken before breakfast and dinner.  
19 And I can't eat without having that experience,  
20 and -- unless I take the domperidone.

21 DEBBIE: And just as a quick follow-up  
22 for me, it immediately relieved the nausea, which



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

145

1 I had, which just nothing else did anything to  
2 relieve at all, but it was instantaneous.

3 DR. EGGERS: I think we had one -- oh,  
4 we have lots of experience.

5 MS. TAYLOR: I actually am going back  
6 one to the Marinol, I guess I didn't get my hand  
7 raised. The Marinol, we've all through the  
8 country talked about this with the marijuana.  
9 There are so many people that are finding so much  
10 relief from the marijuana through the country who  
11 are -- some doctors have even put some of the  
12 medications down and have them just using the  
13 marijuana, which is actually stimulating appetite,  
14 decreasing pain, so I'm not sure -- and decreasing  
15 the nausea as well. The Marinol, there were some  
16 that that helped. Most people that took that said  
17 it didn't help them where the marijuana did. But I  
18 do want to acknowledge on that, because we have so  
19 much discussion on a daily basis that goes on  
20 about that product helping.

21 DR. EGGERS: Thank you very much, Tanya.

22 Okay, we'll take one more and then we'll

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

146

1 go to -- take two more.

2           MARY: I was just going to comment on  
3 the domperidone. I had a hard time obtaining it  
4 even though I had an IND licensed prescriber at  
5 Johns Hopkins. I was told I had to get it from  
6 Canada while I was hospitalized at Hopkins. But I  
7 knew my own research and I knew there were certain  
8 compounding pharmacies that were FDA-, as far as  
9 the powder itself, approved. So, I -- while I was  
10 admitted, I found a local pharmacy who, you know,  
11 my mom was nice enough to drive there and pick it  
12 up, and then they started giving it to me while I  
13 was in the hospital. At the time, I was on TPN,  
14 and it took a while. I was doing 10 milligrams  
15 four times a day. After a week, I still wasn't  
16 seeing any improvement, so they bumped me up to 20  
17 milligrams four times a day.

18           I was discharged with an NJ tube,  
19 because I still wasn't getting anything, and I  
20 didn't want to do a bunch of other factors in the  
21 mix, because I wanted to know, as far as variables  
22 what was working and what wasn't. So, I was

1 discharged. I was still on the 20 milligrams four  
2 times a day. After two weeks of being home, my NJ  
3 tube got clogged, so we pulled it out, but we  
4 didn't put another one in. Rather, I went to baby  
5 food and liquids. And after another week, I was  
6 starting to be able to eat again. So, for me,  
7 yes, domperidone has worked, but it hasn't been  
8 complete success, because after the 20 milligrams,  
9 I started with the prolactin elevations, so I had  
10 to go back down to 10 milligrams and, I mean, and  
11 I know that at times, I have to stop completely  
12 off of it, because I became a (indiscernible) to  
13 Reglan, because it just stopped working. And I'm  
14 afraid that if I continue to use domperidone  
15 continuously, I'm going to get the same reaction.  
16 So, I -- during -- I peak for a while and use it,  
17 and then I come off of it, then I use it, and then  
18 I come off of it. But just to give you an  
19 experience.

20 DR. EGGERS: Thank you very much, Mary.

21 We'll have Lynn.

22 MS. WOLFSON: Hi. There was one thing

1 that we hadn't discussed. I find, even though I'm  
2 on it, and I haven't heard anyone else mention it.  
3 When I was on TPN and also on J-tube feeding, I  
4 find the hardest part is dealing with the hunger  
5 that I still get. And if I eat, then I'm in pain.  
6 So, it's dealing with that hunger. And I was  
7 wondering if there's a medication -- I don't know  
8 if anyone else is having that problem with still  
9 feeling hunger, if there's a medication that could  
10 take that hunger away so we wouldn't have to  
11 determine whether or not we want the pain of  
12 hunger or the pain from eating.

13 DR. EGGERS: Anyone have an experience  
14 that can address Lynn? Something that has  
15 addressed that? And on the web, invite you to send  
16 in a comment, if you do.

17 MS. TAYLOR: I understand what you mean  
18 about that pain whether your stomach's empty or  
19 not, because either way, it is a lot of pain. I  
20 started eating ice a couple of years ago when I  
21 wasn't able to tolerate anything at all. I very  
22 rarely get hungry. It just doesn't happen, but

1 when there's rare occasions that I do get hungry,  
2 I start eating the crushed ice, and that is the  
3 only thing that I've been able to do to help  
4 subside that pain that you're talking about.

5 DR. EGGERS: Let's go into other types  
6 of downsides of treatments that you're on. Again,  
7 we don't necessarily care exactly what treatment  
8 it is, but what downsides bother you most of the  
9 pharmaceutical treatments that you've tried? So,  
10 we'll start here with Katharine.

11 KATHARINE: I just think it's a huge  
12 problem that you'll be prescribed something to  
13 help a symptom, but the side effects are that  
14 symptom. The anti-depressants that are supposed  
15 to help slow down gastric symptoms -- gastric  
16 emptying. And that really worries me. I'm taking  
17 a drug that actually could be counter productive.

18 DR. EGGERS: Any other -- okay, we'll go  
19 over there with Meredith.

20 MEREDITH: Less anybody think that I'm  
21 saying that Zyprexa is like a magic bullet drug, I  
22 want to add that the side effects that I have from

1 that are hyperglycemia, so I'm now pre-diabetic  
2 and I actually have to take a diabetes drug to  
3 lower my blood sugars, since the Zyprexa is  
4 increasing. I also gained a ton of weight really  
5 fast, and also now have some cholesterol issues,  
6 not related to food, but related to the Zyprexa.  
7 And then secondly, the surgical intervention that  
8 I had, the median arcuate ligament release, which  
9 is, albeit a rare treatment, for whatever reason,  
10 during the surgery, my -- I developed -- I'm  
11 drawing a blank as to the words -- I developed  
12 Addison's disease. My adrenal glands infarcted  
13 during the surgery, so now I have Addison's as  
14 another sort of diagnosis. So, I feel like  
15 there's certainly no magic bullet on the market.  
16 We all have side effects from the drugs that are  
17 meant to treat our symptoms.

18 DR. EGGERS: Thank you. Any other  
19 downsides? Bettemarie?

20 MS. BOND: Just a few points. Years  
21 ago, I tried so many different medications, and  
22 you just feel like a lab rat trying them. And

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

151

1 then also, you start, like, "Did that help? Did  
2 it not help?" And it almost gets to be a mind  
3 game at times. So, you just kind of have to go  
4 with it and just not even think about it and  
5 there's something -- if you notice a difference,  
6 that's great. Also, I'm on many different  
7 medications and the cost just adds up.  
8 Thankfully, I have good health insurance. As I  
9 mentioned earlier, I worked for 14 years and I  
10 officially retired due to medical reasons. It  
11 sounds so much nicer than disabled or on  
12 disability. But any event, insurance is a huge  
13 issue for covering the therapies. The TPN itself  
14 is really expensive, and looking into some of the  
15 different types of healthcare plans through the  
16 Health Market, they didn't cover everything. The  
17 Medicaid didn't cover the different doctors that I  
18 could see. Right now, I'm paying my COBRA, and  
19 that's \$750 a month just to have the good  
20 insurance, but now I will transition into  
21 Medicare. And I've heard some horror stories with  
22 going into Medicare. So, that's just -- I can go

1 on forever about that, but there are just some  
2 major issues that people face. Now, as a young  
3 adult when I was trying to gain my independence, I  
4 was on my parents' plan, then I was on Medicaid  
5 and Medicare, actually, back then. But trying to  
6 become independent and trying to get a job was  
7 another issue, all while on IV nutrition and  
8 covering all of my therapies. But where there's a  
9 will, there can be a way at times.

10 DR. EGGERS: Thank you very much.

11 Are we getting anything on the web?

12 MS. GIAMBONE: So, we've also heard a  
13 few people say that they're using gastric  
14 pacemakers, an Enterra device to control nausea.  
15 We've also gotten more feedback on domperidone  
16 saying that it's worked and it's relieved nausea  
17 and pain. One person tried Desipramine and said  
18 they had tachycardia issues. Several also  
19 mentioned erythromycin and a few said it didn't  
20 work, it caused more pain. And also Reglan, a few  
21 others mentioned that it's had some neurological  
22 side effects.



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

153

1 DR. EGGERS: Before going off of the --

2 MS. BOND: With the insurance, what's  
3 really frustrating is when you find something that  
4 helps and then the insurance is denying it. For  
5 the first time in years, I tried the -- I was  
6 switched to Nexium and I wasn't having all that  
7 regurgitation in my mouth, but now, the insurance  
8 is saying, oh, I have to go back and try these  
9 other medications. Well, I've done that, like,  
10 it's been 25 years. So, it's really frustrating.  
11 And that's just one little example of the  
12 insurance denying stuff.

13 DR. EGGERS: So, with thinking of these  
14 downsides, I want to have one question before we  
15 move on that's going to focus in on side effects.  
16 Has anyone in the room or on the web stopped a  
17 medication that was working for you to a degree  
18 that you can say, "Yes, I can tell this works for  
19 me," but you stopped it because of some side  
20 effect or some adverse reaction that you were  
21 having? We have Carol and then we have Meredith.

22 MS. PASINKOFF: Promethazine actually is

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

154

1 the one medicine that does help me with my nausea,  
2 but it causes me to have restless leg syndrome.  
3 And if I take more than one Promethazine, I will  
4 be up for days, like pacing the house, rubbing my  
5 legs, putting heating pads on them. I mean, I  
6 can't take it. It's just --

7 DR. EGGERS: But you still take it when  
8 -- you've just cut back on it. You still take it  
9 sometime.

10 MS. PASINKOFF: If I'm very desperate  
11 and I'm miserable and rolled up in bed, yes, I  
12 will take it, but I do suffer the side effects for  
13 it.

14 DR. EGGERS: Okay, thank you.

15 Meredith and then someone back here.

16 MEREDITH: Reglan was showing promise  
17 for me years ago when I started taking it, but I  
18 quickly started developing some early Tardive  
19 dyskinesia-type symptoms.

20 DR. EGGERS: Okay, and so you stopped.

21 And one more back here?

22 UNIDENTIFIED VOICE: Kind of along the

1 same lines of -- I can't take any of the drugs,  
2 Reglan, Compazine, Phenergan, anything that  
3 crosses the brain/gut barrier. I have some  
4 neurological issues. They all cause me to be  
5 really restless and jittery and anxious. And they  
6 had to stop them, because they were afraid of  
7 permanent, like, neurological damage, which I do  
8 end up having neurological damage, they were  
9 afraid -- they had to stop it early because of  
10 that fear.

11 DR. EGGERS: So, we could tee up the  
12 phone if anyone on the -- who's remotely  
13 participating wants to address one of those two  
14 questions, either one that you -- a product that  
15 you're taking that we haven't talked about that  
16 has worked wonders for you, or a product that was  
17 working pretty well or had some benefit, but you  
18 had to stop taking it because of a side effect.  
19 And again, we don't really care about what those  
20 treatments are, but what those side effects were  
21 and what that benefit was.

22 And while we do that, then I'm going to

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

156

1 move on to our next polling question. As we know,  
2 that it's not just pharmaceutical treatments. You  
3 have reiterated that. But besides those drug  
4 therapies that we've been talking about, what else  
5 are you doing to help reduce your symptoms or  
6 manage your functional GI disorder? You can  
7 choose all that apply. And I'll just let you read  
8 through those.

9 UNIDENTIFIED VOICE: (Indiscernible).

10 DR. EGGERS: I think -- yes, it doesn't  
11 -- we'll just explain what you mean, because over-  
12 the- counter is a hard one. Lots of stuff is  
13 over-the- counter. We don't define that very  
14 well, but if that's what you included, that's good  
15 to know.

16 So, dietary management is the most  
17 frequent in the room. And on the web, what do we  
18 have as the top most frequent ones?

19 MR. THOMPSON: Dietary management at 82  
20 percent and over-the-counter at 59, and nothing  
21 else above 45.

22 DR. EGGERS: So, I don't think we need

1 to get too much more into dietary management. I  
2 think we heard it very nicely so far. So, we can  
3 delve into a few of these. We did hear about --  
4 well, let's talk about the over-the-counter ones  
5 and just briefly, what did you include in that  
6 when you were talking about those? What type of  
7 medicines? Was it the medicines to treat mainly  
8 gastrointestinal symptoms or were there some other  
9 symptoms that you're trying to address with an  
10 over-the-counter?

11           So, I think we probably have a sense of  
12 what the over-the-counters are. And I think we  
13 have a sense of what the medical devices or the  
14 surgical treatments -- I'm going to guess that the  
15 gastroparesis patients in here are a large part of  
16 that. Are there any other devices or surgical  
17 treatments that have not yet been described that  
18 have worked really -- that have been very  
19 important to you. Then we'll come here.

20           UNIDENTIFIED VOICE: This is, perhaps,  
21 the first patient advocate. I'm the mother of a  
22 deceased gastroparesis patient. And he did have a

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

158

1 gastric -- someone else did mention an implant or  
2 a pacemaker as they called it. So, that was -- in its  
3 initial stage, that was about eight years ago, it  
4 was quite effective and they considered, at that  
5 time -- this was done at Temple University, which  
6 was one of the locations that was a special place  
7 that you could get medications that hadn't been  
8 approved, whether they came from Canada or not.  
9 And we did, in fact, use a compounding pharmacy  
10 for some of the medications, which had the effect  
11 -- some were very effective for a time. I think  
12 it's important to mention this pacemaker, because it  
13 can be very effective for people. And when it was  
14 initially introduced, it was considered that it  
15 would be effective if it did anything. Not that  
16 it made you totally better, if it did anything.  
17 So, to that extent, it was effective for my son,  
18 and initially, the first five -- four and a half  
19 years, I think, it did fairly well, but you have  
20 to -- I don't know if there are newer versions,  
21 but the version he had had to have the battery  
22 replaced, which is kind of funny when you think

1 about it. And so, things got worse and worse, and  
2 I found that we were going to the emergency room,  
3 like, every other week. And it finally dawned on  
4 us that maybe the darn thing wasn't working. So,  
5 when the battery was replaced, it did perk up a  
6 little bit, but never -- it never really did -- it  
7 never solved the problem, but I say it's very  
8 worth investigating for those people who are  
9 having a terrible time, because any relief can be  
10 better than nothing.

11 DR. EGGERS: Thank you very much. And  
12 we'll come here.

13 AMY: Hi, my name is Amy. I've had  
14 gastroparesis for three years. I've went through  
15 Botox. It did help. But then, my insurance said  
16 no more, because they said it's cosmetic surgery,  
17 even though it was helping. In January, I had a  
18 tube put into my colon and I was very sick from  
19 it. I had three infections within a six-week  
20 period. And then, in March, they took the tube  
21 out and I actually have a trap door now and a  
22 hook. I put a hook into that every night and hook

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

160

1 to a bag, and I run Johnson & Johnson baby shampoo  
2 through my body. Now, that makes me very sick  
3 every day of my life now. And it's taken between  
4 an hour to two and a half hours to run this bag  
5 through my body. But I am still getting sick  
6 every day from it. But my stomach is still  
7 compacted yet, but not as much, and the vomiting  
8 has gotten less now, but it is working somewhat.

9 DR. EGGERS: Thank you very much. I'm  
10 going to go back there.

11 MARY: I just want to talk about  
12 Enterra. I do have the gastric neuro stimulator.  
13 And it was kind of a big lifesaver for me, but I  
14 will tell you some downsides as well. As we were  
15 increasing my rate, I started getting shocks. And  
16 so, then speaking with the Medtronic  
17 representatives and my GI docs and whatnot, we  
18 decided that I needed a covering over the leads.  
19 So, we went back in laparoscopically. She put a  
20 layer of omentum over the leads and that helped  
21 the shocking temporarily, because I had, as my --  
22 it's a progressive disorder, so at some point, it



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

161

1 wasn't doing what it should, so we increased the  
2 rate even more, and then I started the shocking  
3 again. So, we had to decrease the rate. So, now,  
4 I'm at a catch-22. Yes, it helps, but not like it  
5 was.

6 DR. EGGERS: Thank you very much, Mary.

7 Do we have anyone on the phone? None on  
8 the phone?

9 Do we have any web comments on devices  
10 or surgeries?

11 MS. GIAMBONE: Yes. We also got some  
12 comments -- one person had a gastro neuro  
13 stimulator. Another one had a tube in the cecum to  
14 give retrograde enemas.

15 DR. EGGERS: Thank you.

16 MR. THOMPSON: Actually, I think Anne  
17 would like to say something. Anne, are you there?

18 MS. SIROTA: Yes, it's more than about  
19 the devices, so it's okay. (Indiscernible).

20 DR. EGGERS: Okay, we'll come back to  
21 you.

22 So, for -- about a device?

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

162

1 KATHARINE: I've never -- I haven't had  
2 this done and I haven't heard any stories about  
3 it. And it was only done at Johns Hopkins, but it  
4 was called a stent that gets put into your  
5 pylorus. Has anyone -- that's my question.

6 DR. EGGERS: Is that what you're getting  
7 -- are you getting this summer? No, you had --

8 UNIDENTIFIED VOICE: Me? No, I had a  
9 stent put in. It comes out after a while. It's  
10 not a permanent solution. It's the same as the  
11 Botox, right? It just opens the pylorus out  
12 temporarily.

13 MARY: Dr. John Clark is my physician  
14 and he is he one that had been running that trial.  
15 And he had had good success with it, and he even  
16 asked me to do it. But because it was a clinical  
17 trial and I live in Richmond, Virginia, it just,  
18 you know, logistics, because I was, like, "Well,  
19 what if it malfunctions? Can I get it done, taken  
20 out down there?" Because my GI felt comfortable  
21 doing that, but he's, like, "No, you can't. You'd  
22 have to come back up here." So, but as far as it

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

163

1 helping, he has seen improvement in the population  
2 that he has done it in. And he said it's kind of  
3 like a segue between trying to figure out if --  
4 not really a permanent solution, but a segue to  
5 see if pyloroplasty would be of benefit. So --

6 DR. EGGERS: Thank you. So, if you  
7 notice the agenda, we are at a time when we would  
8 stop, I think. But I think we can cut a little  
9 bit into the open public comment, so we can go for  
10 another ten minutes or so with this discussion.  
11 I'm getting -- these are the people who give me  
12 permission.

13 MR. THOMPSON: I think we have about 12  
14 people signed up for open public comment.

15 DR. EGGERS: Then good. I just want a  
16 show of hands on the acupuncture, needling, herbal  
17 remedies, those more complementary things. Just a  
18 show of hands, how many of you agree with -- and I  
19 don't remember who said it, one of you -- Julian,  
20 that it is a very, very important part of your  
21 overall management? So, we have several hands.  
22 We won't be able to get into this, but in the

1 docket, please feel free to explain how those are  
2 and build on what we heard.

3 I do want to make sure that we talk  
4 about what an ideal treatment would be, so if  
5 there's any more questions from -- any questions  
6 on any of these treatments from FDA? We've got a  
7 lot of rich stuff.

8 Well, I was going to move on from these  
9 and ask a specific question. Is there one that  
10 we've talked about --

11 MS. TAYLOR: Dry needling is something  
12 that I'd like to share about. Dry needling is not  
13 in every state. And I was in the process of being  
14 worked up for a small intestine transplant, hadn't  
15 eaten for a year and a half, only ice chips. And  
16 I was walking hunched over. I didn't even know I  
17 couldn't stand up straight. So, the first time I  
18 had this dry needling, five trigger points were  
19 released in my stomach. I didn't realize it, but  
20 I started to stand up straight that day. My  
21 stomach growled. I got a real live hunger pain  
22 and I ate that day. Then I had dry needling again

1 three days later. All told, there was four  
2 sessions and 48 trigger points released in my  
3 stomach and a lot more to go. Now, when these  
4 trigger points release, it feels like a snake  
5 moving and then a balloon deflating when it  
6 actually is released, and it takes these muscles  
7 that are just strangling the intestines, and had I  
8 not done this, I would have no idea this would  
9 ever work. I started actually eating. I started  
10 eating solid food, and I have not eaten solid food  
11 in a year and a half or more at that time. But I  
12 can eat again, because you can feel the muscles  
13 contract back. And they snap back into a knot,  
14 which is just as painful as releasing the knot,  
15 but I'm really wondering if, like, a managed  
16 therapy of that type of looking even in that type  
17 of direction might help, because had I not known  
18 that it would release trigger points, I really  
19 thought I was going to have to get that small  
20 intestine transplant. So, I'm not looking in that  
21 direction anymore. Thank you.

22 DR. EGGERS: Thank you.

1 I'm going to ask a show of hands  
2 question. And it can be a show of hands on the  
3 web, too, so if you want to chime in. How many of  
4 you, given today, where you're at today, where  
5 you've been in the past, share the experience and  
6 the fortune of Meredith who find that you're in a  
7 better place than you were and you feel that  
8 you're pretty well managed?

9 We're not going to delve into your  
10 experiences right now. I want to know a show of  
11 hands of the people who are not that fortunate and  
12 do not experience that. You're still struggling  
13 as much as you ever have been.

14 Okay. For those of you who are raising  
15 your hands, what's the one -- absent a complete  
16 cure that's probably outside the scope of our  
17 abilities to discuss today, but what would you  
18 say, yes, I would feel -- this would be something  
19 that is beneficial to me. What aspect would you  
20 like to see improved -- what symptom or some sort  
21 of aspect of your condition?

22 UNIDENTIFIED VOICE: So, I'm one of the

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

167

1 very minorities in the room in that I have IBS and  
2 functional dyspepsia and we have a lot of  
3 gastroparesis people in the room. I think it's  
4 different on the web. But for me, I just wish I  
5 had more options of things that I can do. And I  
6 know in the last couple years, we've gotten two  
7 new drugs for constipation, which is fabulous, but  
8 it's, like -- it seems like the process must be  
9 really difficult to get these drugs through  
10 because it's, like, I kind of do some research and  
11 there's things out there that might be coming, but  
12 then there's nothing coming. And there's just not  
13 a lot of options that I think are safe, because I  
14 have a belief in research, so I'm not going to go  
15 and buy the herbals and things that haven't been  
16 strictly tested. And so, I think if I just had  
17 more options, I would be happier.

18 DR. EGGERS: Anything else? Any other  
19 aspect that you're really looking for? Katharine,  
20 then we'll go with Tanya.

21 KATHARINE: Mine's not really a symptom.  
22 It's really the doctors and the medical field

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

168

1 themselves. I do have a caring doctor, but -- and  
2 I know they can only do so much, but when it takes  
3 months, weeks, you know, even a year to get the  
4 treatments that we need, it's ridiculous. And  
5 then you go in and your doctor doesn't take you  
6 seriously at all. You have to be practically  
7 dying in front of them to see how severe it is.  
8 So, just listening better and actually seeming  
9 like they care. I've had a lot of doctors just  
10 write me off. And it's sad.

11 DR. EGGERS: We had Tanya and then --  
12 and on the phone, if you want to contribute, as  
13 well.

14 MS. TAYLOR: When it comes to the  
15 symptoms, pain and nausea are my two top. If pain  
16 and nausea could be controlled, I could feel human  
17 again. I was in the hospital one time where -- I  
18 can only take them raw. I am a poor metabolizer  
19 when it comes to most types of drugs. So, when I  
20 was in the hospital and the pain was managed on IV  
21 medication, my mouth is how I take it, which  
22 barely works, but when it was managed on an IV



Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

169

1 medication and the nausea was managed, I was  
2 laughing. I was having a good time. I mean, I  
3 forgot what it was like to be human. I really  
4 forgot what it was like to be a human being again.  
5 So, those two tops, sometimes I think, if we could  
6 have more options with that.

7 DR. EGGERS: We'll go here and then --  
8 did you still have something Elizabeth? No? Then  
9 we'll go to Julian.

10 JULIAN: For me, doctor education is  
11 just huge, because diagnosis is usually the  
12 hardest stuff. I mean, I was 45 years old before I  
13 got diagnosed. And actually, I was talking to a  
14 doctor who is just fresh out of her residency, and  
15 basically, she said everything that she saw about  
16 my gastroparesis case contradicted everything she  
17 learned in medical school. And that actually kind  
18 of scares me, especially when it's a doctor that  
19 people go to as the first step.

20 DR. EGGERS: Thank you very much,  
21 Julian. We had Anne on the phone. Anne, I didn't  
22 quite catch what Anne wanted to be talking about.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

170

1           MS. SIROTA: I was talking about -- when  
2 you were talking about the drugs that had side  
3 effects, that worked, but then had side effects.  
4 I was going to mention Verapamil, the calcium  
5 channel blocker, which is good for -- I mean, I  
6 have palpitations, PAC. And I was taking that for  
7 that. But what it did, it created another  
8 problem. It was a heart block. I had a very slow  
9 heartbeat. And so, I had to take -- get off of  
10 it. So, that was a side effect of a drug that's  
11 not even given for IBS, for diarrhea, IBS.

12           But the other thing I was going to say  
13 was that I think that one of the issues is that  
14 there isn't enough research being done on  
15 alternative medicines. And I realize that for a  
16 lot of people, the scientific proof is what's  
17 needed, and that may be true for all of us, but I  
18 have found more success with some of these over-  
19 the-counter supplements, but I don't really know  
20 if they're safe, because there is no research  
21 being done.

22           DR. EGGERS: Thank you very much, Anne.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

171

1           Is there anyone else on the phone? We  
2 could take one more comment.

3           We have two more minutes, if I can see  
4 that far, my alarm clock. I'm going to ask, are  
5 there any final questions from the panel to ask?

6           (No response.)

7 Then is there someone who maybe focused on  
8 pharmaceutical treatments or your symptoms or your  
9 experience with you condition that you've had this  
10 perspective or this thought and it has not yet  
11 been shared.

12           ELIZABETH: I was just going to say, as  
13 a patient and a healthcare professional that the  
14 realistic life we are in right now is to ask  
15 questions, own your illness, own your symptom, be  
16 forthright about it, and never hesitate to get a  
17 second or even a third opinion. And pray that you  
18 find a physician or a healthcare provider that  
19 will listen. And that is key.

20           DR. EGGERS: Thank you very much,  
21 Elizabeth.

22           We'll take one more and then we will

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

172

1 wrap up. Bettemarie.  
2 MS. BOND: Sometimes a big part of the  
3 treatment is advocating for yourself and being  
4 aware of what's out there and what's going on, not  
5 only treatment-wise, but two things that really  
6 have impacted my treatment and care, I was reading  
7 articles and I actually took the article in to my  
8 doctor and said, you know, "This helped that  
9 person. I wonder if that could help me." And  
10 they sent me out to Pittsburgh and Pittsburgh did  
11 this radical surgery and helped take away some of  
12 the worst part of the pain. And then, there was  
13 another one that I read of a medication that was  
14 in trial and they ended up connecting me with the  
15 doctor. I couldn't use it, because it was still  
16 in animal trials, but out of that came a meeting -  
17 - a wonderful doctor who then really provided a  
18 lot of help and support, so sometimes the  
19 physicians may not be aware of things, but it's  
20 actually doing your own research and care in  
21 trying to find out about new trials and  
22 medications and treatments and surgeries and

1 stuff. And it's not -- you know, sometimes it can  
2 take years to get a diagnosis. And it's not that  
3 you want something to be wrong with you, but you  
4 start wondering, oh, my goodness, I'm having this  
5 and all these tests are coming out normal, am I  
6 imagining it? And you know you're not, because  
7 stuff's not right going on in your body. But when  
8 they actually say, we finally figured out this is  
9 what's going on, it's just you want the validation  
10 that, yes, something is going on in your body, and  
11 it's not that you're looking for something to be  
12 wrong, it's just that you're looking for answers  
13 to try to improve your life.

14 DR. EGGERS: Thank you so much. And I  
15 think that is a great comment upon which to end  
16 our discussion. This has been a truly remarkable  
17 day and a thank you from all of us to you, to our  
18 four-legged friends who have provided input, so,  
19 please, a round of applause to all of you.

20 (Applause.)

21 We're going to move into open public comment,  
22 because our discussion here is ended and Pujita's

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

174

1 going to come and do that, and I'll just put a  
2 plug in to be as concise as possible, because we  
3 did dip into the open public comment time. But I  
4 think it was worth it. I think you'll all agree  
5 with me. So, thank you very much.

6 MS. VAIDYA: Hello, everyone. I'd like  
7 to thank you all for coming today. We're now  
8 moving into the open public comment session, and  
9 for those of you who are not aware, the purpose of  
10 this session is to allow an opportunity for those  
11 who have not had a chance to speak on issues that  
12 are not related to our two main discussion topics  
13 today. This is an opportunity for folks who are  
14 not a patient or a patient representative to come  
15 up and comment. Please keep in mind that we will  
16 not be responding to your comments, but they will  
17 be transcribed and be part of the public record.  
18 Since we would like this to be a transparent  
19 process, we encourage you to note any financial  
20 interest that you may have that are related to  
21 your comment. If you do not have any such  
22 interest, you may state that for the record as

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

175

1 well.

2           So, we have collected sign-up before the  
3 meeting and then during the break. We have 12  
4 people signed up and about 20 minutes or so for  
5 the session, so please be respectful of your other  
6 colleagues here and other patients, and try to  
7 stick to the two-minute limit. I have a timer  
8 here, so if you start approaching the two-minute  
9 mark, I will kind of try to nudge you along.

10           So, I'll run through the order of  
11 speakers, and I apologize if I mispronounce your  
12 name. So, we have Tegan Gaekano, Marilyn Geller,  
13 Ellen Komichers, Carissa Haston, Amy Foore, Nancy  
14 Ginter, Kelly Brezoczky, Ritu Verma, Mary Berger,  
15 Bruce Zagnit, Debbie Fisher, and then Raymond  
16 Panus. So, first, could I get Tegan to the mike,  
17 please.

18           MS. GAEKANO: I'd like to start by  
19 thanking all of the patients and family members  
20 for bringing your stories, your courageous stories  
21 here today. So, my name is Tegan Gaekano. I work  
22 for a patient advocacy organization, the

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

176

1 International Foundation for Functional  
2 Gastrointestinal Disorders, or IFFGD. And I do  
3 appreciate this opportunity to present our  
4 comments with you here today. I do have a few  
5 prepared comments.

6           So, for almost 25 years, IFFGD has been  
7 working on behalf of patients affected by the  
8 functional GI disorders. We have conducted  
9 research to learn about this population, sharing  
10 our findings with the public, the healthcare  
11 community, and with regulators such as FDA in  
12 order to advance understanding of the burden of  
13 illness and unmet needs of all of those affected.

14           As we have heard here today, the  
15 functional GI disorders cause a tremendous  
16 individual and societal burden both in term of  
17 economic and personal costs. Disorders such as  
18 IBS, chronic constipation, refractory GERD, and  
19 gastroparesis can be debilitating, taking away a  
20 person's ability to participate in daily life, in  
21 family, social, educational, and employment  
22 activities. In the case of gastroparesis, the



1 condition may sometimes be life threatening.  
2           Although dozens of conditions have been  
3 characterized as functional GI disorders affecting  
4 the different segments of the GI tract, these  
5 conditions share many common features. Among them  
6 they are chronic. Effective treatments are few.  
7 And most are characterized by combinations of  
8 multiple symptoms that can greatly diminish  
9 quality of life. Although research into the  
10 functional GI disorders has long lagged behind the  
11 study of structural disorders, we have seen  
12 increasing interest over the past two decades in  
13 these disorders. What we have found is that there  
14 are too few effective treatments for these  
15 disorders and that among patients, there is a high  
16 level of dissatisfaction with the treatments that  
17 are available. Treatments that work for simple  
18 acute constipation, diarrhea, heartburn, stomach  
19 pain, or nausea just to name a few are not  
20 adequate for the chronic symptoms that accompany  
21 the functional GI disorders.

22           MS. VAIDYA: Thank you, Tegan. Sorry,

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

178

1 two minutes is up.

2 Next, could I get Marilyn Geller?

3 MS. GELLER: Thank you. I'm Marilyn  
4 Geller from Celiac Disease Foundation. And I was  
5 invited to speak because the symptoms of the  
6 celiac disease population really are the same  
7 symptoms as those with functional GI. The issue  
8 is, for me, both personal and public. Celiac  
9 Disease Foundation represents the three million  
10 Americans with celiac disease, about two and a  
11 half million undiagnosed who don't realize that  
12 they have it. It's personal that I have a son  
13 who's 22, and his father, who's now in his mid-  
14 50s, both were not diagnosed for a large number of  
15 years. Our son was diagnosed first at 15 with  
16 lifelong symptoms. He suffered horrifically. His  
17 father did the same and was not diagnosed until he  
18 was 45. We spent years and thousands and  
19 thousands of dollars dealing with functional GI  
20 diagnoses. And the data that we've collected with  
21 Celiac Disease Foundation is it's quite similar.  
22 The vast majority of patients with celiac disease

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

179

1 are diagnosed first or misdiagnosed first with  
2 functional GI disorders. And with the billions of  
3 dollars spent in the testing and the treatments  
4 for misdiagnoses, it becomes imperative that as we  
5 look at the functional GI population in the  
6 screening that we include celiac disease testing  
7 as a standard of care. Thank you.

8 MS. VAIDYA: Thank you, Marilyn.

9 Next we have Ellen.

10 MS. KOMICHERS: Thank you so much for  
11 holding this panel this afternoon. As I've said  
12 earlier, I'm a patient with severe, but managed,  
13 gastroparesis. Domperidone is my magic bullet.  
14 With it, I can eat, without it, I cannot. My  
15 gastroenterologist has informed me that there is  
16 no safe alternative to domperidone for treating my  
17 gastroparesis and that the special permission  
18 process allowed by the FDA is opaque and  
19 overwhelming. I need domperidone to stay healthy.  
20 I am urging the FDA to put domperidone on its  
21 positive list for compounding pharmacies so that I  
22 may locally obtain safely- compounded, domestic

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

180

1 domperidone or failing that, that the FDA not  
2 enforce the fact that domperidone is not on the  
3 positive list. Thank you.

4 MS. VAIDYA: Thank you, Ellen.

5 Next we have Carissa Haston.

6 MS. HASTON: I am Carissa Haston and I  
7 am the president and founder of G-PACT or the  
8 Gastroparesis Patient Association for Cares and  
9 Treatments. And I just want to thank the FDA for  
10 working with us on this. We've been working for  
11 15 years trying to get something like this going.  
12 And I could say that, you know, we deal with tens  
13 of thousand patients every single day and they  
14 have been so hopeless. And finally, a lot of  
15 those hopeless people are starting to feel a  
16 little bit more hope like there might be some  
17 progress towards this that we're finally getting  
18 the attention that we need for these conditions  
19 and there's a real focus on it. So, I just want  
20 to thank you for working with us, and I also want  
21 to thank the patients who went and filled out the  
22 survey on our website to help get prepared for

(866) 448 - DEPO

www.CapitalReportingCompany.com © 2015

1 this. And I encourage people to keep doing that,  
2 because that's a big part of understanding -- you  
3 know, helping them understand.

4           A little bit about my story. I was  
5 diagnosed with gastroparesis in 1994 at the age of  
6 16. And basically, there was, like, I tried  
7 Propulsid and erythromycin and I went into cardiac  
8 arrest. I almost died. And so, they had to stop  
9 those drugs. And by the year 2000, I developed  
10 chronic intestinal pseudo- obstruction. They were  
11 not able to feed me by a feeding tube, so I was  
12 started on TPN. And because my gut was so slow, I  
13 kept developing so many infections that were  
14 backing up into my bloodstream from my gut, and  
15 also because of the TPN. And I lost all my venous  
16 access. I lost down to 68 pounds. They were not  
17 able to feed me anymore. Basically, sent me home  
18 from the hospital to die. And finally, they said,  
19 okay, you can go to the University of Pittsburgh  
20 for a five- organ transplant. And so, in 2006, I  
21 had a five-organ transplant, and they did my small  
22 bowel, stomach, pancreas, duodenum, and they had

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

182

1 to do my liver, because my liver had failed on  
2 TPN. It was twice its normal size and full of  
3 fatty deposits. They did not think -- when I got  
4 there, I was the sickest patient that they had  
5 ever seen. And they did not think I would even  
6 make it to the transplant, and they were fortunate  
7 to be able to find enough veins in me in  
8 Pittsburgh. Hershey had blacklisted me for  
9 central lines. Pittsburgh was able to find enough  
10 veins to get me through transplant for TPN for 13  
11 months. I had a 13-month wait, which is longer  
12 than most people. They did not think that I was  
13 going to make it to the transplant. And when I  
14 had it done, by the time I had it done, I was so  
15 sick, I had literally days, if not just hours to  
16 live when my organs arrived.

17 MS. VAIDYA: Thank you, Carissa. Sorry.  
18 Please submit your comments to the docket. We  
19 really encourage you to do that.

20 MS. HASTON: All right.

21 MS. VAIDYA: Next, could I please have  
22 Amy Foore.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

183

1 MS. FOORE: (Indiscernible).

2 MS. VAIDYA: Okay, that's fine. Go  
3 ahead.

4 MS. HASTON: I'll try to finish up here.  
5 So, anyway, then I -- my gastroparesis ended up  
6 coming back. I did really well for four years.  
7 It ended up coming back. But I had to go back on  
8 TPN and my liver started to fail again, so they  
9 had to eventually stop that. I finally -- my  
10 colon shut down and I had my colon completely  
11 detached a couple years ago, and now I'm on an  
12 ileostomy for life, and I'm on feeding tube now as  
13 well. And so, there's not any, like, treatment  
14 options. But I face a future of kidney failure  
15 from the transplant medications, the anti-  
16 rejection meds. I have severe osteoporosis from  
17 the steroids that they're using to treat the  
18 transplant as well. And I was legally blind for  
19 two years and they don't know why, but they think  
20 possibly some of the IV antibiotics that I was on,  
21 and some of the infections made me go legally  
22 blind. And it's starting to come back, but I'm

1 still quite low vision. So, anyway, there are  
2 just a lot of issues that come with this that --  
3 and I'm loosing (indiscernible) in my brain. I  
4 have dysautonomia and I also have mitochondrial  
5 disease along with some other things. So, there's  
6 a lot of issues that need to be addressed when  
7 dealing with treatment options, because it's not  
8 just the gut. There's other things going on as  
9 well, so --

10 MS. VAIDYA: Thank you, Carissa.

11 Next, could I get Nancy Ginter, please.

12 MS. GINTER: Well, thank you all very  
13 much again. By now, you know that I'm the mother  
14 of a son who had gastroparesis. And as you all  
15 also know now, it is a disastrous situation. So,  
16 I want to just speak for a moment about that.  
17 Some of the points that were brought up, one  
18 that's most important, I think, and that is that  
19 you are so delightfully and importantly embracing  
20 the voice of the patient. And I think that many  
21 of the folks here have talked about that in their  
22 own experience that if the people they were



1 dealing with in the medical profession had  
2 listened more carefully to the voice of the  
3 patient, they would have taken that voice more  
4 seriously. And so, I'm all for taking it  
5 seriously and I -- someone made a wonderful  
6 suggestion about improving the language that we  
7 use so that people will be truly understood and  
8 can bring the language that's being asked for to  
9 the patient's language and not the medical  
10 language. And it's not, perhaps the standard that  
11 we use today. So, that's my thought about the  
12 functional GI disorders.

13 I happen also to work for the National  
14 Foundation for Celiac Awareness. And like Marilyn  
15 with the Celiac Disease Foundation, we're very  
16 concerned about the diagnosis of those two and a  
17 half million Americans who do have celiac disease  
18 and don't know it. Many, many of them have been  
19 told that they have irritable bowel. So, like  
20 Marilyn, I hope that when that topic comes up and  
21 a doctor says, "You have irritable bowel," they  
22 might just think, maybe, just maybe this patient

1 has celiac disease. We would like -- our mission  
2 is to get these folks diagnosed and to live life  
3 to the fullest. And it can't happen until they  
4 have -- until they, too, are taken seriously and  
5 celiac disease is considered a serious, serious  
6 illness that can have dramatic effects, just as  
7 these functional GI disorders do. So, we're all  
8 for taking it seriously.

9           And one of the other points that I'd  
10 like to make, and I've spoken to a couple of folks  
11 today. When the nominations -- I call it  
12 nominations for serious diseases to be part of  
13 this program or considered, we did submit celiac  
14 disease as one of those. We did not win the  
15 Academy Award. And so, I'm asking again if  
16 there's another round of consideration or if  
17 there's some time that we can submit that, and we  
18 will put it on the docket that it be considered as  
19 part of this program as well, so it will get the  
20 attention. And again, as we have a new campaign,  
21 we say, seriously, celiac disease.

22           MS. VAIDYA: Thank you, Nancy.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

187

1           Next we have Kelly Brezoczky.

2           MS. BREZOCZKY: You did a nice job on my  
3 name, by the way. Most people don't get that one.  
4 So, I am Kelly Lewis Brezoczky. I am the founder  
5 of the non-profit Healthy Mature Living  
6 Foundation. Our first educational initiative is  
7 ablinfo.org, and we developed that in  
8 collaboration with Dr. Heidi Brown at the  
9 University of Wisconsin-Madison. Dr. Brown and I  
10 have also published in the International Journal  
11 of Clinical Practice on the quality of impacts of  
12 accidental bowel leakage as a symptom associated  
13 with many common conditions, including the  
14 functional gastrointestinal disorders discussed  
15 today.

16           I will also separately state for the  
17 record that I am the founder of Butterfly Health,  
18 which has developed a new absorbent protection  
19 product called butterfly, which some of you may  
20 have heard of. I am not your ordinary industry.  
21 I am the mother of three girls who, like all of  
22 you today, felt compelled to make a difference. I

1 have spent too many years working with people who  
2 experience accidental bowel leakage not to be here  
3 today.

4           A comment I would like to make and leave  
5 you with is that today I think you are listening  
6 and talking about symptoms. But failing to focus  
7 enough attention on the root cause and mechanism  
8 that cause these conditions, especially in the  
9 enteric nervous system. All of you here today  
10 reflect the experience of many years of living  
11 with a functional gastrointestinal disorder. Yet  
12 many more millions suffer in silence wondering  
13 slowly what is happening to them, wondering who to  
14 turn to, especially when their physician tells  
15 them that test after test comes back normal. The  
16 thought I would like you to think about is how do  
17 we get at the mechanism so that we can help people  
18 sooner. Everybody that's in this room today is  
19 reflecting and representing nearly a lifetime of  
20 experience of something that has progressed. We  
21 need to better understand the mechanism of action  
22 if we are to get better treatments and better

1 physician care, because all of you are right.  
2 Today, doctor education is one of the biggest  
3 opportunities that we face. The pharmaceutical  
4 companies will investigate mechanism when it is  
5 only financially attractive to do so. This is not  
6 happening sufficiently with the population here  
7 today.

8           The FDA this morning spoke of the  
9 enteric nervous system at the start of this panel.  
10 If you look at any of the other neurological  
11 diseases, you will see that they share a common  
12 characteristic. They progress. Research on panic  
13 and anxiety would show that it gets worse, not  
14 better, if it's left untreated. If you look at  
15 diseases like MS and Parkinson's, they will show  
16 that the sooner you help the pathways, the  
17 understanding of the pathways, the better.  
18 Interestingly, with panic disorder specifically,  
19 the literature is very clear that behavior  
20 treatment is more likely to reduce relapse.

21           MS. VAIDYA: Thank you, Kelly.

22           MS. BREZOCZKY: Today we have listened

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

190

1 to stories of progression. I'd just like to ask  
2 the FDA, I hope that you can follow up this  
3 wonderful session with a nationally representative  
4 survey so that you can get national sampling on  
5 this topic, because I think it's far more  
6 prevalent than people realize. Thank you.

7 MS. VAIDYA: Thank you, Kelly.

8 Next we have Ritu Verma.

9 DR. VERMA: Thank you. I'm a pediatric  
10 gastroenterologist at Children's Hospital in  
11 Philadelphia and I'm here to represent the kids.  
12 I do have children, but I'm here to represent the  
13 children with functional GI disorders. We have a  
14 wonderful center, by the name of the Lustgarten  
15 Motility Center, that has contributed money so  
16 that we can actually study children who have these  
17 conditions.

18 I think the FDA has taken on a huge,  
19 huge task. I wonder how you go from here. So,  
20 first of all, I think, from a children's  
21 standpoint, there's not just the child, but  
22 there's the child and the parent, and then there's

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

191

1 the child and the school, and child and the  
2 friends. So, all of those things affect the  
3 children. We've learned that this is not just a  
4 medicine, but here we have more to do with the  
5 function part of it. The child goes to school,  
6 has abdominal pain, the teacher does not believe  
7 the child. The child comes home, is upset, and  
8 does not want to go back to school. So,  
9 immediately, it's thought of that this child has  
10 school phobia. It really is not school phobia.  
11 The child is in pain and in discomfort. So, we  
12 need to educate the children. We need to educate  
13 the parents, and we need to educate the schools.  
14 So, education has to be on many levels for the FDA  
15 to see that this is going to be a success.

16 Partnership has to happen with parents.  
17 We have to agree that our children should be part  
18 of studies so that we can actually get more drugs.  
19 Partnership has to be with industries.  
20 Partnership has to be with insurance companies  
21 that do not allow the children to have these  
22 conditions -- to have these medications.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

192

1           I also think what we have not talked  
2 about here is non-invasive tests. No one talked  
3 about breath tests that are available for  
4 gastroparesis. So, I think sharing knowledge is  
5 going to become important. So, from my  
6 standpoint, knowledge has to be part of wherever  
7 we go with these functional GI disorders and  
8 knowledge at many levels. There's so much work  
9 here to be done and I really commend the FDA that  
10 you actually set up this forum. And I really am  
11 quite interested to see what happens next. Not  
12 going to be an easy task. Thank you.

13           MS. VAIDYA: Thank you, Ritu.

14           Next we have Mary Berger.

15           MS. BERGER: I'm going to talk about  
16 some novel ways for drug companies to pursue other  
17 options to help with functional GI illnesses. In  
18 2013, there was a trial done to look at IV hemin  
19 for GP at Mayo Clinic. They told wherein humans  
20 and animal models of idiopathic GP, there was a  
21 loss of the ICC cells. And that was needed for  
22 sufficient stomach emptying. And it was shown by



1 another researcher, (indiscernible) that heme  
2 oxygenase 1 is a target for gastrointestinal  
3 disease. So, Dr. Farrugia at Mayo said a critical  
4 role is oxidative stress, so why not look into  
5 other areas and avenues of fighting free radical  
6 formation, antioxidants at higher levels.  
7 Because, for example, I started taking NAC, and  
8 Alpha Lipoic Acid, to increase the glutathione  
9 peroxidase in the mitochondria. And that started  
10 helping me. So, more research into oxidative  
11 stress.

12 Another thing is celiac disease. Half  
13 of the patients with celiac disease do have  
14 gastrointestinal motor abnormalities. Most of  
15 them have some form of functional dyspepsia that  
16 goes undiagnosed. So, it would be good if we  
17 could find a better way to develop testing methods  
18 for those with celiac disease, and use the ones we  
19 have in a more efficient manner. It doesn't even  
20 touch on the segment of the population that has  
21 non-celiac gluten sensitivity, which probably have  
22 some form of motor impairment as well.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

194

1           But the key, I believe, to a cure, lies  
2 in an article by Holter et al. in Neuropeptides  
3 from 2012. What do NPY, PYY, and pancreatic  
4 polypeptide do in the gut/brain axis? Just look  
5 at figures 1 and 2. It's not a one-drug cure, but  
6 rather it's going to take multiple drugs. NPY in  
7 the brain has an effect on food intake, anxiety,  
8 mood, energy balance, and cognition. If this is  
9 out of whack, what happens? With NPY an Y1 --

10           MS. VAIDYA: Excuse me, Mary. Sorry,  
11 your two minutes is up. Please submit your  
12 comments to the docket.

13           Next we have Bruce Zagnit.

14           MR. ZAGNIT: Thank you very much. I'm a  
15 compounding pharmacist. And first of all, I'd  
16 like to thank the FDA for allowing us to come in  
17 and speak about these topics. I'd like to thank  
18 the people who relayed their stories to us. It  
19 must be on one hand, very difficult to relay those  
20 stories, and the other hand, it must be very  
21 comforting to know that you're speaking to a group  
22 of people who really care.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

195

1           As your survey shows, 60 percent of the  
2 people who are taking domperidone currently or  
3 taking domperidone in conjunction with other  
4 drugs. Domperidone is a highly effective safe  
5 treatment or adjunct for gastroparesis and emesis  
6 with very limited side effects. The people who  
7 are getting those prescriptions are either getting  
8 them -- most of them are probably not getting them  
9 through the FDA IND program, but rather are  
10 getting them from outside the country from Canada  
11 or Australia or from compounding pharmacies  
12 throughout the country who are doing it without  
13 the better wishes of the FDA. What I'm asking the  
14 FDA is to change the regulations, put domperidone  
15 on the positive list, and allow me and other  
16 compounding pharmacies throughout the country to  
17 provide this very vital, lifesaving drug to our  
18 patients in hopes that it will make it more  
19 accessible to them and there will be a lot more  
20 benefit. That's it, thank you.

21           MS. VAIDYA: Thank you, Bruce.

22           And next we have Debbie Fisher. Debbie,

1 where are you?

2 MS. FISHER: I just want to say that I  
3 know that there is no treatment that is going to  
4 work for everybody, but for those of us who have  
5 had good results with domperidone, it's really  
6 frustrating and disheartening to know that there  
7 are such efforts going on to restrict it from  
8 patients. There are drugs that are FDA approved,  
9 like Reglan and Compro that have severe  
10 neurological effects that are irreversible and  
11 they can only be used for a short period of time.  
12 People become -- develop a tolerance to  
13 erythromycin. There are few alternatives, and the  
14 studies that have been done on domperidone for the  
15 most part that have shown any negative effects  
16 have been done on lactating women and people with  
17 pre-existing cardiac risk factors.

18 So, I just -- and finally, I just want  
19 to note that for the clinical guidance from the  
20 Journal of the American Association of  
21 Gastroenterologists notes that domperidone is  
22 generally as effective as Metoclopramide with a

1 lower adverse risk profile. And I just really  
2 hope that people will understand how important it  
3 is for patients who are suffering with this  
4 problem to be able to get hold of this medication  
5 that can be used safely, and to please put your  
6 efforts into maybe developing clinical guidance  
7 for doctors and compounding pharmacies and  
8 patients rather than making this drug not  
9 available.

10 MS. VAIDYA: Thank you, Debbie.

11 And last, finally, we have Raymond  
12 Panus.

13 DR. PANUS: Hello. I'm Dr. Raymond  
14 Panus, and I'm an employee of Enterra Health,  
15 which is a medical foods company. And first, I'd  
16 like to thank the FDA for putting this meeting  
17 together. And I'd also like to thank all the  
18 patients who provided their story for this  
19 afternoon.

20 I would like to note that these meetings  
21 often discuss a variety of drugs, both  
22 prescription and over-the-counter products. They

1 discuss devices, dietary modification, and various  
2 other therapies, such as supplements, herbals,  
3 acupuncture, and other types of therapies. But  
4 often these meetings do not discuss FDA-regulated  
5 medical foods which are usually not part of these  
6 discussions. And so, I was curious what the FDA  
7 is doing to help support the study of medical  
8 foods and FDA-regulated medical foods for the  
9 management of GI disorders. And additionally, I  
10 would also like to see that the FDA include FDA-  
11 regulated medical foods in future discussions such  
12 as these as well. Thank you.

13 MS. VAIDYA: Thank you, so much.

14 So, now, before we get started with our  
15 last agenda item, I'd like to ask everyone to  
16 leave your clickers at the table and we'll have  
17 staff pick it up. And also, we have evaluation  
18 forms. If you haven't gotten a chance to fill  
19 those out, yet, please do. We definitely do read  
20 them.

21 And so now, finally, I'd like to call  
22 Dr. Andrew Mulberg to the stand for the closing.

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

199

1           DR. MULBERG: Thank you, Pujita. So,  
2 within the spirit of staying within two minutes,  
3 I'll do my best so I won't be thrown off the  
4 stage. First of all, I want to thank Sara Eggers  
5 and the Office of Strategic Programs and all of  
6 the staff that was involved in producing what by  
7 far for me here has been an amazingly empowering  
8 powerful experience.

9           I also wish to thank all of the  
10 panelists and the public speakers who shared a  
11 tremendously honest and transparent communication  
12 regarding their signs and symptoms in a public  
13 forum. I find that, as a physician, not only  
14 heartwarming, but truly educational, and I truly  
15 appreciate it.

16           I think I'll just summarize this  
17 wonderful afternoon by saying I've identified at  
18 least three issues that I know will be added to by  
19 all of us as we download from such a wonderful  
20 meeting. There's a need for additional  
21 pharmacotherapies and additional therapies to be  
22 developed for the unmet need that has clearly been

Capital Reporting Company  
Functional GI Disorder Patient Focused Drug Development 05-11-2015

200

1 discussed today.

2 I was struck by the profound repeated  
3 communication that there's really a significant  
4 ignorance in the medical community. Both -- since  
5 I'm a pediatric gastroenterologist, I know Dr.  
6 Verma, there is no ignorance there. But for the  
7 adult community, there seems to be a need for  
8 education.

9 Lastly, there is a tremendously  
10 justified unmet medical need that you've  
11 communicated to us today. And as has been  
12 communicated by everyone here, the partnerships  
13 amongst all of us with the device and pharma  
14 companies, with you as a patient community, and  
15 with us, with the academic physicians and us in  
16 regulatory agencies, we really do value this kind  
17 of input, and we look forward to sharing,  
18 hopefully, new therapy and therapeutic advances  
19 over the next few years, if not sooner. So, thank  
20 you very much. Have a great evening.

21 (Whereupon, the above entitled matter  
22 concluded)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

CERTIFICATE OF NOTARY PUBLIC

I, MICHAEL FARKAS, the officer before whom the foregoing proceeding was taken, do hereby certify that the proceedings were recorded by me and thereafter reduced to typewriting under my direction; that said proceedings are a true and accurate record to the best of my knowledge, skills, and ability; that I am neither counsel for, related to, nor employed by any of the parties to the action in which this was taken; and, further, that I am not a relative or employee of any counsel or attorney employed by the parties hereto, nor financially or otherwise interested in the outcome of this action.



\_\_\_\_\_  
MICHAEL FARKAS  
Notary Public in and for the  
Commonwealth of Virginia



1 CERTIFICATE OF TRANSCRIPTION

2

3

4 I, WENDY C. CUTTING, hereby certify that I am not  
5 the Court Reporter who reported the following  
6 proceeding and that I have typed the transcript of  
7 this proceeding using the Court Reporter's notes  
8 and recordings. The foregoing/attached transcript  
9 is a true, correct, and complete transcription of  
10 said proceeding.

11

12

13

14

  
WENDY C. CUTTING  
Transcriptionist

15

16

17

18

19

20

21

22

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 1

<u>          </u> \$	17 2:5	2009 124:22	38 92:6
\$750 151:19	175 2:16	2010 128:22	39 2:7
<u>          </u> 1	178 2:17	2011 121:8	<u>          </u> 4
1 27:19 35:8 38:22	179 2:18	2012 14:14	4:00 99:4
136:20 193:2	18 38:4,5,11	121:10,12 130:4	40 38:5,12 101:11
194:5	180 2:19	194:3	41 38:5,12
1.5 122:9	184 2:20	2013 14:13 114:9	42 62:14
10 106:5 146:14	187 2:21	121:13,15,16	44 2:8
147:10	190 3:2	129:7 130:11	45 19:1 156:21
100 90:8	192 3:3,4	192:18	169:12 178:18
10-12 77:2	196 3:5	2014 121:18	48 51:21 165:2
103 118:20	1963 118:13	2015 1:7	<u>          </u> 5
105 79:6	197 3:6	2017 14:13	5 2:3
10903 1:11	199 3:7	20993 1:12	50 38:5,12
11 1:7 2:4 38:13	1994 181:5	20s 44:18	50s 178:14
111 2:11	<u>          </u> 2	20-some 96:13	51 38:5,13
114 40:17	2 67:8 109:20	22 178:13	52 2:9
117 2:12 96:14	110:14 136:20	24 38:2 81:19	53 137:20
12 54:8 89:18	194:5	240 125:5	56 118:1
163:13 175:3	2:00 99:4	25 2:6 59:19	59 2:10 156:20
124 2:13	2:45 7:15,16	153:10 176:6	<u>          </u> 6
128 2:14	2:57 109:19	26 111:17,21	60 37:22 38:6,13
13 14:15 182:10	20 14:10 22:17	112:18	195:1
131 2:15	91:13 92:3	27 38:1 118:21	61 38:6,13
13-month 182:11	93:6,15 101:13	29 38:1 123:20	66 137:21
13th 31:7	146:16 147:1,8	<u>          </u> 3	68 181:16
14 38:13 62:3	175:4	3:07 109:19	<u>          </u> 7
151:9	2000 181:9	3:15 109:18	70 38:6,13
15 106:5 115:8	2002 119:19	30 38:5,11 91:13	71 38:6
120:7 178:15	2003 120:3	92:3 93:6,15	750 122:8
180:11	2006 120:19 121:1	129:15	7th 142:9
15-minute 7:15	181:20	30-page 49:13	
109:17	2007 42:2	30s 42:1 44:18	
16 14:17 99:8	2008 121:7	45:6	
127:16 181:6		31 38:5,11,12	

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 2

<hr/> <p style="text-align: center;">8</p> <hr/> <p><b>82</b> 156:19</p> <hr/> <p style="text-align: center;">9</p> <hr/> <p><b>90</b> 120:19 133:2  <b>94</b> 40:17,21</p> <hr/> <p style="text-align: center;">A</p> <hr/> <p><b>abdomen</b> 68:3      72:20 77:21      119:8,11 122:8      133:19</p> <p><b>abdominal</b> 19:13      21:13 44:22      68:13,19      69:7,8,16,20      70:1 71:12      73:16,22 74:5      77:10,20 80:9      102:6,18 111:20      114:3 119:9      129:22 131:11      191:6</p> <p><b>abilities</b> 100:20      166:17</p> <p><b>ability</b> 26:17 62:11      86:20,22 176:20      201:8</p> <p><b>able</b> 30:17 33:7,19      39:20      40:13,15,22 41:2      43:12 47:15 54:4      55:21 57:15,16      59:8 62:12 72:2      74:3 82:19 83:16      85:14,19 86:8      88:14 94:8 95:20      96:17,22 101:6      106:7 117:7      121:19 125:17      126:13,15</p>	<p>129:19      130:11,17      138:20 139:8      141:19 147:6      148:21 149:3      163:22      181:11,17      182:7,9 197:4</p> <p><b>ablinf.org</b> 187:7</p> <p><b>abling</b> 60:4</p> <p><b>abnormal</b> 9:5      18:17,18      20:11,12,15 21:1</p> <p><b>abnormalities</b>      18:21 193:14</p> <p><b>abnormality</b> 18:8      24:16</p> <p><b>absent</b> 166:15</p> <p><b>absolutely</b>      140:12,15</p> <p><b>absorb</b> 114:21</p> <p><b>absorbent</b> 187:18</p> <p><b>absorption</b> 116:19      122:21</p> <p><b>academia</b> 11:4</p> <p><b>academic</b> 200:15</p> <p><b>Academy</b> 186:15</p> <p><b>accept</b> 45:4 46:19</p> <p><b>access</b> 181:16      194:4</p> <p><b>accessed</b> 24:8</p> <p><b>accessible</b> 195:19</p> <p><b>accidental</b> 107:16      108:7 187:12      188:2</p> <p><b>accidental-type</b>      107:21</p> <p><b>accommodate</b></p>	<p>32:18</p> <p><b>accompany</b>      177:20</p> <p><b>accurate</b> 201:7</p> <p><b>ache</b> 78:1</p> <p><b>aches</b> 77:20</p> <p><b>achy</b> 83:17</p> <p><b>Acid</b> 193:8</p> <p><b>acidic</b> 82:11      122:19</p> <p><b>acknowledge</b>      145:18</p> <p><b>across</b> 19:22 20:1      37:18 43:19      75:20</p> <p><b>acting</b> 106:10      127:4</p> <p><b>action</b> 188:21      201:10,14</p> <p><b>activated</b> 114:12</p> <p><b>active</b> 43:3 124:1</p> <p><b>actively</b> 16:2</p> <p><b>activities</b> 20:17      26:18,22 39:19      53:16 54:9 87:1      91:11 131:20      176:22</p> <p><b>activity</b> 27:1,3      74:2</p> <p><b>acts</b> 105:16</p> <p><b>actual</b> 144:5</p> <p><b>actually</b> 10:10      17:2,5 22:20      23:22 39:12      44:10 50:10 52:6      56:2 60:6 61:21      62:5 64:5 79:22      91:20 94:17 98:3</p>	<p>104:6,8 108:11      116:20 135:5,8      138:20 139:3      141:21 145:5,13      149:17 150:2      152:5 153:22      159:21 161:16      165:6,9 168:8      169:13,17      172:7,20 173:8      190:16 191:18      192:10</p> <p><b>acupuncture</b> 49:1      99:9,11 112:4      113:19 125:20      127:21 163:16      198:3</p> <p><b>acupuncturists</b>      125:15</p> <p><b>acute</b> 177:18</p> <p><b>add</b> 75:13 149:22</p> <p><b>added</b> 199:18</p> <p><b>Addison's</b>      150:12,13</p> <p><b>addition</b> 22:19      119:4 120:21      122:17 128:7</p> <p><b>additional</b>      199:20,21</p> <p><b>additionally</b> 198:9</p> <p><b>address</b> 31:6 33:7      83:5 115:17      148:14 155:13      157:9</p> <p><b>addressed</b> 148:15      184:6</p> <p><b>addresses</b> 110:20</p> <p><b>adds</b> 151:7</p> <p><b>adequate</b> 25:6      33:18 75:1</p>
---	--	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 3

<p>177:20  <b>adjunct</b> 195:5  <b>adjusted</b> 76:9  <b>administer</b> 75:2  <b>Administration</b>          1:9  <b>admit</b> 77:9  <b>admitted</b> 146:10  <b>adrenal</b> 150:12  <b>adult</b> 40:16 118:18          119:12 152:3          200:7  <b>advance</b> 176:12  <b>advances</b> 200:18  <b>adverse</b> 140:12          142:3 153:20          197:1  <b>advice</b> 133:16  <b>advocacy</b> 16:1          175:22  <b>advocate</b> 36:16          140:19 157:21  <b>advocates</b> 8:16          28:7 32:12 38:15  <b>advocating</b> 172:3  <b>affairs</b> 31:12,20  <b>affect</b> 10:3 18:8          26:17 45:13          62:19 191:2  <b>affected</b> 19:21          62:20 86:19          119:10 176:7,13  <b>affecting</b> 65:2          78:13 177:3  <b>affects</b> 36:7  <b>afford</b> 81:6  <b>afraid</b> 51:16</p>	<p>147:14 155:6,9  <b>afternoon</b> 5:7          6:8,21 8:7 11:14          72:22 90:2 99:3          110:2 117:18          131:4 179:11          197:19 199:17  <b>afterwards</b> 52:13          54:20 62:19  <b>against</b> 25:7          132:13  <b>age</b> 20:1 38:4          118:13,20 181:5  <b>agencies</b> 200:16  <b>agency</b> 5:2 26:2  <b>agency's</b> 4:16  <b>agenda</b> 6:8 7:16          26:13 99:16          110:17 163:7          198:15  <b>agents</b> 23:8  <b>aggravating</b>          114:22  <b>ago</b> 39:18          44:15,16 64:2          89:14 111:17          113:12 114:5,8          127:5,6 138:18          148:20 150:21          154:17 158:3          183:11  <b>agreed</b> 126:5  <b>ahead</b> 16:3 74:13          78:8 103:17,18          141:7 143:3          183:3  <b>aid</b> 29:8,13  <b>air</b> 135:19  <b>al</b> 194:2</p>	<p><b>alarm</b> 171:4  <b>albeit</b> 150:9  <b>alcoholic</b> 50:5  <b>Align</b> 122:12  <b>alive</b> 134:4  <b>allergic</b> 127:14  <b>alleviate</b> 130:5          133:22 134:21  <b>allotment</b> 7:9  <b>allow</b> 174:10          191:21 195:15  <b>allowed</b> 64:6          179:18  <b>allowing</b> 117:9          194:16  <b>allows</b> 60:8  <b>alosetron</b> 23:20  <b>Alpha</b> 193:8  <b>already</b> 7:6 8:10          12:8 16:19 17:4          45:8 97:15  <b>alternated</b> 111:22  <b>alternative</b> 113:6          170:15 179:16  <b>alternatives</b>          196:13  <b>am</b> 4:6 41:1 42:2,9          56:11 92:6 95:20          103:3 111:10          117:8,20 121:18          122:1          123:19,20,22          126:21          127:17,21 128:2          130:16          131:10,15 145:5          160:5 168:18          173:5 179:20</p>	<p>180:6,7          187:4,17,20,21          192:10 201:8,11          202:4  <b>amazed</b> 126:2  <b>amazingly</b> 199:7  <b>American</b> 196:20  <b>Americans</b> 178:10          185:17  <b>Amitiza</b> 132:21          137:11 143:8  <b>among</b> 177:5,15  <b>amongst</b> 26:9          103:7 200:13  <b>amount</b> 71:22          94:3  <b>amounts</b> 86:6  <b>Amy</b> 159:13          175:13 182:22  <b>anal</b> 120:5  <b>anatomic</b> 18:7  <b>and/or</b> 99:11  <b>Andrea</b> 31:14,18  <b>Andrew</b> 3:7 5:7          85:9 198:22  <b>anemia</b> 96:7  <b>angry</b> 72:21  <b>animal</b> 11:1          123:15 172:16          192:20  <b>Anne</b> 2:11          111:8,13 117:10          135:22          161:16,17          169:21,22          170:22  <b>annoying</b> 50:8</p>
---	--	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 4

<p><b>anorexic</b> 60:20</p> <p><b>answer</b> 33:12 81:10 94:14</p> <p><b>answers</b> 15:18 125:9 173:12</p> <p><b>anti</b> 115:18 129:11 149:14 183:15</p> <p><b>antibiotics</b> 183:20</p> <p><b>antidepressants</b> 24:4</p> <p><b>anti-depressants</b> 113:2</p> <p><b>Antidiarrheals</b> 23:7</p> <p><b>anti-nausea</b> 88:2 132:10</p> <p><b>antioxidants</b> 193:6</p> <p><b>anti-spasmodic</b> 112:11</p> <p><b>anus</b> 121:2</p> <p><b>anxiety</b> 115:12 189:13 194:7</p> <p><b>anxious</b> 155:5</p> <p><b>anybody</b> 53:1 149:20</p> <p><b>anybody's</b> 85:6</p> <p><b>anymore</b> 50:13 55:15 85:7 165:21 181:17</p> <p><b>anyone</b> 7:2,4 67:13,14 70:8 71:15 87:16 104:14 106:21 114:15 137:3,12 138:6 139:18 148:2,8,13 153:16 155:12 161:7 162:5</p>	<p>171:1</p> <p><b>anything</b> 8:2 41:3 44:4,5 48:5 50:15 51:3 53:21 55:7 72:12 77:16 88:15 89:3 97:6 116:15 130:14 136:7 142:20 143:19 145:1 146:19 148:21 152:11 155:2 158:15,16 167:18</p> <p><b>anyway</b> 73:11 183:5 184:1</p> <p><b>anywhere</b> 18:9 27:21 89:3 105:7</p> <p><b>apart</b> 70:7</p> <p><b>apologize</b> 143:11 175:11</p> <p><b>a-potty</b> 54:14</p> <p><b>APPEARANCES</b> 3:1</p> <p><b>appetite</b> 21:16 141:22 145:13</p> <p><b>applause</b> 67:2,3 124:13 135:21 136:1 173:19,20</p> <p><b>application</b> 10:21 11:20 12:2 14:9</p> <p><b>applications</b> 10:13 13:8 14:3 16:22</p> <p><b>apply</b> 30:11 37:8 68:8 100:12 156:7</p> <p><b>appointment</b> 46:21 125:16</p> <p><b>appreciate</b> 25:17 34:17 128:12</p>	<p>176:3 199:15</p> <p><b>approaches</b> 6:19 27:7 110:14 112:1,13</p> <p><b>approaching</b> 175:8</p> <p><b>appropriated</b> 124:4</p> <p><b>approval</b> 10:21</p> <p><b>approved</b> 24:7 132:17 133:5 146:9 158:8 196:8</p> <p><b>approximately</b> 19:1 44:14</p> <p><b>April</b> 120:19 121:13</p> <p><b>aquasize</b> 99:9</p> <p><b>archived</b> 8:4</p> <p><b>arcuate</b> 130:4 150:8</p> <p><b>area</b> 14:11 35:11,12 107:4 108:3,15 122:3,6</p> <p><b>areas</b> 86:17 193:5</p> <p><b>aren't</b> 106:9 136:16</p> <p><b>array</b> 23:2</p> <p><b>arrest</b> 181:8</p> <p><b>arrived</b> 182:16</p> <p><b>article</b> 172:7 194:2</p> <p><b>articles</b> 172:7</p> <p><b>artificial</b> 49:18,21</p> <p><b>aside</b> 6:21</p> <p><b>asleep</b> 86:20</p> <p><b>aspect</b> 166:19,21 167:19</p>	<p><b>aspects</b> 12:21 15:15,21 110:19</p> <p><b>aspiration</b> 127:7,10</p> <p><b>assess</b> 11:19 25:2</p> <p><b>assignment</b> 67:4 94:11</p> <p><b>assists</b> 135:8</p> <p><b>associate</b> 92:18</p> <p><b>associated</b> 15:22 17:1 23:9 90:4 187:12</p> <p><b>Association</b> 180:8 196:20</p> <p><b>asthma</b> 119:12</p> <p><b>astounding</b> 22:16</p> <p><b>ate</b> 52:18 53:4 63:14 90:1 133:7 164:22</p> <p><b>attend</b> 30:17</p> <p><b>attention</b> 180:18 186:20 188:7</p> <p><b>attorney</b> 201:12</p> <p><b>attractive</b> 189:5</p> <p><b>atypical</b> 129:11</p> <p><b>audience</b> 8:18 84:9</p> <p><b>August</b> 120:22 121:16 129:7 130:11</p> <p><b>Australia</b> 195:11</p> <p><b>autonomic</b> 59:10 138:19</p> <p><b>available</b> 12:8 13:1 23:13 116:13 131:21 134:8 177:17</p>
---	---	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 5

<p>192:3 197:9  <b>Avenue</b> 1:11  <b>avenues</b> 193:5  <b>average</b> 83:10          95:11  <b>avoid</b> 47:15 117:7          129:20  <b>awake</b> 89:17  <b>Award</b> 186:15  <b>aware</b> 172:4,19          174:9  <b>Awareness</b> 185:14  <b>away</b> 54:13 61:8          80:22 88:11          142:10 148:10          172:11 176:19</p> <hr/> <p style="text-align: center;"><b>B</b></p> <p><b>baby</b> 41:17 122:11          147:4 160:1  <b>bac</b> 46:3  <b>backed</b> 65:1          102:13 103:22          104:2  <b>background</b> 4:19          6:11 9:12 17:14          18:2 83:3  <b>backing</b> 77:7          181:14  <b>backpack</b> 62:6  <b>backwards</b> 64:16  <b>bacterial</b> 103:5  <b>bad</b> 40:22 45:11          48:9 51:3 53:6          55:12,22          57:19,20 63:9,14          80:14 81:3 83:12          91:12 95:14</p>	<p>97:14 115:11          118:18 126:5          131:14 140:20          143:6  <b>badly</b> 67:1  <b>bag</b> 72:6 91:15          121:22 122:1          123:17 160:1,4  <b>bagful</b> 50:14  <b>baggies</b> 91:14  <b>bags</b> 93:16  <b>Baker-Wong</b> 83:7  <b>bakery</b> 55:5  <b>balance</b> 97:16          194:8  <b>ball</b> 44:3 70:21          75:22  <b>balloon</b> 165:5  <b>banned</b> 126:10  <b>barely</b> 116:1          168:22  <b>barrier</b> 155:3  <b>base</b> 17:10 43:15  <b>baseball</b> 54:10,12          57:18  <b>based</b> 18:22 19:2          47:11 78:19  <b>basically</b> 20:16          22:12 31:2 47:18          51:4 53:2 114:18          128:20 169:15          181:6,17  <b>basis</b> 22:9 48:6,11          56:12 73:20          74:22 79:2,8          88:19 98:17          117:4 145:19  <b>bathroom</b> 42:5</p>	<p>57:22 105:8,13          106:12  <b>bathrooms</b> 54:13  <b>bathroom's</b> 57:21  <b>battery</b> 158:21          159:5  <b>battle</b> 98:12  <b>bay</b> 130:16  <b>Bears</b> 63:13  <b>beautiful</b> 123:21  <b>became</b> 60:13          118:17 133:1          147:12  <b>become</b> 42:1          114:1,21 115:14          119:10 131:19          152:6 192:5          196:12  <b>becomes</b> 133:19          179:4  <b>becoming</b> 46:6          133:9  <b>bed</b> 41:1 44:3          88:8,20 154:11  <b>bedridden</b> 131:15  <b>bedroom</b> 57:20,22  <b>begin</b> 67:8 106:15  <b>beginning</b> 88:12  <b>behalf</b> 36:22 176:7  <b>behavior</b> 189:19  <b>behind</b> 7:12 51:5          177:10  <b>belief</b> 167:14  <b>believe</b> 11:7 20:4          42:13 76:4,5          94:19 123:9          134:9 191:6</p>	<p>194:1  <b>believes</b> 114:14  <b>belly</b> 42:19 78:3  <b>Beltway</b>          35:17,18,20  <b>beneficial</b> 34:8,9          166:19  <b>benefit</b> 25:4          155:17,21 163:5          195:20  <b>benefits</b> 9:18,22          11:19 12:17          17:11 24:20  <b>Bens</b> 2:8 44:9,13          51:9  <b>bent</b> 76:17  <b>Bentyl</b> 115:18  <b>Berger</b> 3:3 175:14          192:14,15  <b>besides</b> 156:3  <b>best</b> 27:4 41:5          46:20 70:18 98:9          101:8 121:5          199:3 201:7  <b>beta</b> 127:7  <b>Bettemarie</b> 2:10          59:2,3 65:9          66:12 76:11          103:17 138:14          150:19 172:1  <b>better</b> 27:14 38:6          48:1 63:7 65:12          66:10 72:7,10          115:2,3 116:8          121:3 122:10          136:7,12 158:16          159:10 166:7          168:8 188:21,22          189:14,17</p>
--	--	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 6

<p>193:17 195:13  <b>better-informed</b>          13:22  <b>beverages</b> 7:12          50:5  <b>beyond</b> 39:4  <b>bicarbonate</b>          122:22  <b>biggest</b> 54:7 65:21          139:14 142:3          189:2  <b>bile</b> 119:3 133:12  <b>biliary</b> 59:13 63:2          76:22  <b>billion</b> 22:10,17  <b>billions</b> 179:2  <b>biochemical</b> 24:16  <b>biomedical</b> 123:22  <b>biopsies</b> 119:22  <b>biopsy</b> 118:14          119:17  <b>birthday</b> 54:2  <b>bit</b> 4:20 6:1,9 7:18          9:1,12 11:15          15:21 29:7,11          32:16 57:15 61:1          63:1,6 66:10          67:19 73:6 99:15          101:10 104:16          114:4 126:16          137:15 159:6          163:9 180:16          181:4  <b>bite</b>          65:14,16,18,20  <b>bites</b> 65:17 131:9          133:16 135:2  <b>bits</b> 138:21</p>	<p><b>black</b> 132:1  <b>blacklisted</b> 182:8  <b>blackout</b> 40:4  <b>bladder</b> 120:11,14  <b>blades</b> 64:19  <b>blank</b> 150:11  <b>blessed</b> 141:1  <b>blind</b> 183:18,22  <b>bloated</b> 122:1  <b>bloating</b> 21:14          45:9,11,16          48:8,9,21 64:12          68:20 69:11 70:5          77:6 102:6          103:13 111:20          114:3 122:12          130:6 135:2  <b>block</b> 170:8  <b>blocker</b> 127:7          170:5  <b>blockers</b> 23:10  <b>blood</b> 119:4 120:7          125:3 150:3  <b>bloodstream</b>          181:14  <b>bloody</b> 41:15  <b>blue</b> 40:9  <b>body</b> 68:1 124:22          160:2,5 173:7,10  <b>boil</b> 67:5  <b>bolus</b> 61:22  <b>Bond</b> 2:10 59:3          65:10 76:14          103:19 138:17          139:17 150:20          153:2 172:2  <b>book</b> 124:3</p>	<p><b>boots</b> 10:9  <b>boring</b> 140:19  <b>born</b> 117:22 119:6          124:11  <b>bother</b> 149:8  <b>bothersome</b> 39:15  <b>Botox</b> 41:12          126:17,21,22          129:3 131:22          159:15 162:11  <b>bottom</b> 51:18          122:1  <b>bout</b> 111:18  <b>bowel</b> 9:7 19:9          20:6 23:17,21          37:9,22 44:12          45:17 47:19          64:20 73:9 103:5          107:19,20 133:5          181:22          185:19,21          187:12 188:2  <b>bowels</b> 128:1  <b>box</b> 132:2  <b>boys</b> 44:19  <b>brain</b> 21:3 184:3          194:7  <b>brain/gut</b> 18:18          20:12,14 21:1          155:3  <b>break</b> 7:8,15,19          27:6 99:17,19          107:1          109:1,18,19          175:3  <b>breakfast</b> 56:16          89:21 144:18  <b>breaks</b> 40:8  <b>breath</b> 40:2 125:4</p>	<p>192:3  <b>breathe</b> 53:7  <b>breathing</b> 112:21          124:19  <b>Brezoczky</b> 2:21          107:2,3 108:21          175:14 187:1,2,4          189:22  <b>brief</b> 18:1 28:2          100:8  <b>briefly</b> 157:5  <b>bring</b> 4:13 27:20          185:8  <b>bringing</b> 175:20  <b>broader</b> 11:11  <b>broth</b> 125:19  <b>brought</b> 46:17          184:17  <b>Brown</b> 187:8,9  <b>Bruce</b> 3:4 175:15          194:13 195:21  <b>brutal</b> 88:11 132:9  <b>bucket</b> 58:19  <b>buckled</b> 75:21  <b>build</b> 28:8 32:17          69:22 97:12          127:14 138:7          164:2  <b>built</b> 97:9  <b>bullet</b> 144:17          149:21 150:15          179:13  <b>bumped</b> 139:2          146:16  <b>bunch</b> 146:20  <b>burden</b> 33:15          176:12,16</p>
--	--	---	--



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 7

<b>burning</b> 39:4 82:10 83:16 87:7 <b>burp</b> 133:18 <b>burping</b> 131:12 <b>businesses</b> 43:4 <b>butter</b> 55:20 <b>butterfly</b> 187:17,19 <b>button</b> 5:3 29:10 31:3 39:2 94:14 <b>buy</b> 63:7 167:15 <b>buying</b> 55:8 63:5 <hr/> <p style="text-align: center;">C</p> <hr/> <b>caffeine</b> 46:3 <b>cages</b> 53:9 <b>calcium</b> 170:4 <b>campaign</b> 186:20 <b>Campus</b> 1:10 8:17 <b>Canada</b> 146:6 158:8 195:10 <b>cancer</b> 124:2 <b>candy</b> 63:12 <b>caplets</b> 114:6 <b>capsule</b> 90:9 <b>capture</b> 28:15 <b>captured</b> 30:7 <b>car</b> 58:19 <b>Carafate</b> 132:3 <b>carbohydrates</b> 114:18 <b>cardiac</b> 181:7 196:17 <b>cardiologist</b> 127:2 <b>care</b> 33:18 45:20 55:1,8 58:11	62:12 94:13 120:8 142:14 149:7 155:19 168:9 172:6,20 179:7 189:1 194:22 <b>carefully</b> 185:2 <b>caregivers</b> 25:12 27:17 28:7 <b>Cares</b> 180:8 <b>caretaker</b> 36:21 <b>Caretakers</b> 32:12 <b>caring</b> 168:1 <b>Carissa</b> 2:19 175:13 180:5,6 182:17 184:10 <b>Carol</b> 2:15 87:21 131:7 135:11 153:21 <b>Carrie</b> 2:9 52:4,5 58:13 59:1 76:11 78:22 96:10 97:2,3 <b>carried</b> 93:15 <b>carries</b> 123:16 <b>carry</b> 50:13 123:17 <b>case</b> 46:12 48:2 141:11 169:16 176:22 <b>cases</b> 50:13 <b>catch</b> 169:22 <b>catch-22</b> 161:4 <b>category</b> 20:1 <b>CATHERINE</b> 144:3 <b>catheterizing</b> 122:20	<b>cause</b> 18:13 20:19 65:20 83:4 95:9 103:13 104:3 115:11 155:4 176:15 188:7,8 <b>caused</b> 116:20 132:22 134:18 143:6,9 152:20 <b>causes</b> 63:20 105:4 132:11 134:1 154:2 <b>causing</b> 51:19 120:10 <b>cc's</b> 122:8 <b>ceasing</b> 74:2 <b>Ceciel</b> 80:5,6 <b>cecum</b> 161:13 <b>celiac</b> 178:4,6,8,10,21, 22 179:6 185:14,15,17 186:1,5,13,21 193:12,13,18 <b>cell</b> 105:20 <b>cells</b> 106:9,13,15 118:3 119:17,22 192:21 <b>center</b> 4:4 5:15 58:12 190:14,15 <b>centered</b> 130:19 <b>central</b> 21:5 182:9 <b>cereal</b> 122:11 <b>certain</b> 51:13 81:4 99:5 115:15 146:7 <b>certainly</b> 150:15 <b>CERTIFICATE</b> 201:1 202:1	<b>certify</b> 201:3 202:4 <b>cervical</b> 120:21 <b>cetera</b> 111:3 138:12 <b>chain</b> 63:20 <b>chairs</b> 135:13 <b>challenge</b> 136:19 <b>challenges</b> 141:4 <b>challenging</b> 55:3 62:10 63:18,22 <b>chance</b> 7:3 174:11 198:18 <b>change</b> 26:18 128:5 140:7 195:14 <b>changed</b> 130:22 <b>changer</b> 130:9 <b>changes</b> 49:3 124:9 <b>channel</b> 170:5 <b>characteristic</b> 189:12 <b>characterized</b> 9:3 18:10 177:3,7 <b>charcoal</b> 114:12 115:22 <b>chart</b> 47:5 <b>check</b> 68:8 119:17 <b>chemicals</b> 127:11 <b>chemotherapy</b> 132:15 <b>chew</b> 41:20 <b>chewable</b> 98:1 <b>chicken</b> 125:18,19 <b>child</b> 92:19
--	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 8

<p>119:3,6 120:1          190:21,22          191:1,5,7,9,11</p> <p><b>children</b> 75:4          190:12,13,16          191:3,12,17,21</p> <p><b>children's</b> 61:13          190:10,20</p> <p><b>Chilson</b> 2:13          124:15,16</p> <p><b>chime</b> 166:3</p> <p><b>Chinese</b> 112:4,13          113:19</p> <p><b>chips</b> 164:15</p> <p><b>chiropractic</b> 112:4</p> <p><b>choice</b> 35:9,15</p> <p><b>choked</b> 91:21</p> <p><b>cholesterol</b> 150:5</p> <p><b>choose</b> 35:8 37:8          69:5 100:12          101:1 156:7</p> <p><b>chores</b> 131:19</p> <p><b>Chris</b> 31:21,22</p> <p><b>chronic</b> 9:7,10          18:5,10 19:11          20:8 23:18          37:10,14 38:2          59:15 73:12          79:4,13 82:15          83:3 91:4,6,9,10          95:16 102:18          128:17 131:8          132:22 144:14          176:18 177:6,20          181:10</p> <p><b>cisapride</b> 24:6</p> <p><b>clarifying</b> 39:3,5</p> <p><b>Clark</b> 162:13</p>	<p><b>class</b> 96:19,20          99:9</p> <p><b>classes</b> 23:11</p> <p><b>classification</b> 19:6</p> <p><b>classwork</b> 89:7</p> <p><b>clean</b> 41:4 55:9          122:6</p> <p><b>cleaned</b> 106:11</p> <p><b>cleaning</b> 41:3</p> <p><b>clear</b> 122:17          189:19</p> <p><b>clearly</b> 199:22</p> <p><b>click</b> 31:3          35:11,14</p> <p><b>clicker</b> 36:19,21</p> <p><b>clickers</b> 29:9 35:7          36:15,17 37:1,2          137:3 198:16</p> <p><b>Clinic</b> 121:19          192:19</p> <p><b>clinical</b> 5:11,19          10:11,17,19 12:3          15:15 17:9,16          78:11 81:15 87:2          107:3 134:16          162:16 187:11          196:19 197:6</p> <p><b>clock</b> 171:4</p> <p><b>clogged</b> 147:3</p> <p><b>close</b> 7:7 37:13          88:3 136:8</p> <p><b>closed</b> 46:19          120:4,12</p> <p><b>closely</b> 10:14</p> <p><b>closer</b> 4:13</p> <p><b>closest</b> 91:19</p> <p><b>closing</b> 198:22</p>	<p><b>closure</b> 118:16</p> <p><b>clothes</b> 48:10</p> <p><b>clothing</b> 53:10,11</p> <p><b>club</b> 124:3</p> <p><b>CNA</b> 139:7</p> <p><b>coached</b> 84:20</p> <p><b>coaster</b> 42:8 81:8</p> <p><b>coat</b> 63:16</p> <p><b>COBRA</b> 151:18</p> <p><b>cognition</b> 194:8</p> <p><b>cold</b> 49:20</p> <p><b>collaboration</b>          187:8</p> <p><b>collapsed</b> 125:1</p> <p><b>colleagues</b> 4:22          6:10 30:18          101:16 175:6</p> <p><b>collect</b> 12:2</p> <p><b>collected</b> 175:2          178:20</p> <p><b>collecting</b> 30:3</p> <p><b>collection</b> 17:8</p> <p><b>collectively</b> 68:4          138:3</p> <p><b>colo</b> 120:5</p> <p><b>colon</b> 39:12          105:16,18,20          106:3,6,8 120:20          121:1 133:2          159:18 183:10</p> <p><b>colonic</b> 39:11</p> <p><b>colonoscopy</b> 18:21          47:6,16 104:1          106:2</p> <p><b>Colorado</b> 144:4</p> <p><b>colorectal</b> 119:19</p>	<p><b>colostomy</b> 118:16          120:3,4</p> <p><b>combination</b> 50:6          98:16 114:22          136:9</p> <p><b>combinations</b>          115:21 177:7</p> <p><b>comes</b> 48:19 62:13          93:10 101:3          107:10 162:9          168:14,19          185:20 188:15          191:7</p> <p><b>comfortable</b> 8:1          34:21 47:2 66:14          135:13 162:20</p> <p><b>comforting</b> 194:21</p> <p><b>coming</b> 13:18 14:1          17:19 27:18          28:10 36:5 70:16          117:6 144:15          167:11,12 173:5          174:7 183:6,7</p> <p><b>commend</b> 108:10          192:9</p> <p><b>comment</b> 6:21          7:2,4,5 14:16,17          31:1,3,4 33:3          80:5 85:13 94:13          146:2 148:16          163:9,14 171:2          173:15,21          174:3,8,15,21          188:4</p> <p><b>commenting</b> 30:12</p> <p><b>comments</b> 27:22          30:12,14,15,20          31:7 32:3 56:4          77:19 78:4 85:12          92:13,15,22          94:12 100:4,5</p>
---	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 9

<p>103:10 111:6,12          136:6 142:13          161:9,12 174:16          176:4,5 182:18          194:12</p> <p><b>committed</b> 14:10</p> <p><b>common</b> 9:2 19:18          20:9 21:11,18          68:11 78:13          85:14 177:5          187:13 189:11</p> <p><b>commonalities</b>          26:9</p> <p><b>commonly</b> 23:5,7</p> <p><b>Commonwealth</b>          201:19</p> <p><b>communicated</b>          200:11,12</p> <p><b>communication</b>          18:19 20:13,14          21:1 199:11          200:3</p> <p><b>communities</b>          10:12</p> <p><b>community</b> 13:6          22:3 124:1          176:11          200:4,7,14</p> <p><b>compacted</b> 160:7</p> <p><b>companies</b>          10:11,15,17 14:1          78:10 189:4          191:20 192:16          200:14</p> <p><b>company</b> 12:1          63:10,15 197:15</p> <p><b>compare</b> 25:9</p> <p><b>comparing</b> 25:7</p> <p><b>Compazine</b></p>	<p>132:11 155:2</p> <p><b>compelled</b> 187:22</p> <p><b>complementary</b>          112:1,12          116:10,11          163:17</p> <p><b>complete</b> 129:15          130:8 140:9          147:8 166:15          202:9</p> <p><b>completely</b> 67:14          113:21 126:16          147:11 183:10</p> <p><b>complex</b> 27:9</p> <p><b>complexity</b> 136:9</p> <p><b>composure</b> 66:20</p> <p><b>compounded</b>          179:22</p> <p><b>compounding</b>          146:8 158:9          179:21 194:15          195:11,16 197:7</p> <p><b>Compro</b> 196:9</p> <p><b>computer</b> 46:17</p> <p><b>concentrate</b> 82:19          86:21 89:5</p> <p><b>concentrating</b>          115:13</p> <p><b>conceptualization</b>          s 103:1 104:18</p> <p><b>conceptualize</b>          101:18</p> <p><b>conceptualizing</b>          109:14</p> <p><b>concerned</b> 185:16</p> <p><b>concerns</b> 24:2</p> <p><b>concise</b> 174:2</p>	<p><b>concluded</b> 200:22</p> <p><b>condition</b> 26:8          36:7,20 50:21          59:6 70:11          110:18,20          121:20 134:20          144:14 166:21          171:9 177:1</p> <p><b>conditions</b> 9:16          19:15 21:20 23:5          24:15 26:5 28:16          32:15 70:11          177:2,5 180:18          187:13 188:8          190:17 191:22</p> <p><b>conduct</b> 10:13</p> <p><b>conducted</b> 176:8</p> <p><b>conducting</b> 10:10</p> <p><b>conference</b> 80:10</p> <p><b>conflict</b> 13:10</p> <p><b>confluence</b> 116:21</p> <p><b>Congress</b> 124:4</p> <p><b>conjunction</b> 195:3</p> <p><b>connect</b> 109:7</p> <p><b>connected</b> 62:3</p> <p><b>connecting</b> 172:14</p> <p><b>connection</b> 120:6</p> <p><b>consequences</b>          92:2,8</p> <p><b>Consequently</b>          118:2</p> <p><b>consider</b> 78:19          85:7</p> <p><b>consideration</b>          79:12 116:5          186:16</p> <p><b>considered</b>          158:4,14</p>	<p>186:5,13,18</p> <p><b>constant</b>          79:9,13,20 92:16          93:21 98:12          103:6 124:18          131:13</p> <p><b>constantly</b> 41:11          86:5 97:17 98:7</p> <p><b>constipated</b>          118:12 119:15</p> <p><b>constipation</b> 9:11          19:10,12 20:7,8          21:14 23:9,17,18          37:15 41:15          48:20 59:15          64:11,14 76:6,7          118:5 120:13,15          121:7 131:8,13          132:20,22          133:1,3 134:2          167:7 176:18          177:18</p> <p><b>Constituent</b> 31:12</p> <p><b>consulted</b> 114:9</p> <p><b>contact</b> 32:6 33:11</p> <p><b>contacted</b> 127:13</p> <p><b>context</b> 6:10 12:4          13:21 14:8 34:12</p> <p><b>continue</b> 32:3 35:2          72:3,9 87:12          111:18 115:10          147:14</p> <p><b>continued</b> 3:1          61:17 120:14</p> <p><b>continues</b> 72:14          123:9</p> <p><b>continuing</b> 127:21</p> <p><b>continuous</b> 61:22          71:7,8</p>
---	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 10

<p><b>continuously</b> 60:13 147:15</p> <p><b>contract</b> 165:13</p> <p><b>contracting</b> 135:9</p> <p><b>contractions</b> 20:18</p> <p><b>contradicted</b> 169:16</p> <p><b>contribute</b> 30:11,20 32:3,4,10 33:4 168:12</p> <p><b>contributed</b> 190:15</p> <p><b>contributing</b> 102:7</p> <p><b>contribution</b> 29:20</p> <p><b>control</b> 89:1 107:20 120:17 122:17 152:14</p> <p><b>controlled</b> 168:16</p> <p><b>controlling</b> 113:14</p> <p><b>conventional</b> 111:22 116:4,13</p> <p><b>conversation</b> 50:22 144:9</p> <p><b>conversations</b> 89:8</p> <p><b>cook</b> 41:5 55:9</p> <p><b>cookie</b> 52:18 63:8,11</p> <p><b>cooking</b> 41:3</p> <p><b>coordinate</b> 15:11</p> <p><b>corn</b> 128:4</p> <p><b>correct</b> 102:10 202:9</p>	<p><b>correlate</b> 85:16 107:19</p> <p><b>corresponds</b> 35:9</p> <p><b>cosmetic</b> 159:16</p> <p><b>cost</b> 22:18 151:7</p> <p><b>costs</b> 22:6,8,11,12,16, 20 176:17</p> <p><b>cough</b> 49:20,22</p> <p><b>counsel</b> 201:8,12</p> <p><b>count</b> 95:18</p> <p><b>counter</b> 149:17 156:12,13</p> <p><b>counting</b> 93:7</p> <p><b>country</b> 42:22 61:10 145:8,10 195:10,12,16</p> <p><b>couple</b> 40:3 57:7 91:18 92:7 97:10 131:1 135:16 148:20 167:6 183:11 186:10</p> <p><b>coupled</b> 45:16</p> <p><b>courage</b> 34:18 66:19</p> <p><b>courageous</b> 175:20</p> <p><b>course</b> 18:11 19:7 23:19 24:3 25:1 45:21 47:6 58:2 91:1</p> <p><b>Court</b> 202:5,7</p> <p><b>cover</b> 22:22 101:6 110:1 132:14 151:16,17</p> <p><b>covered</b> 144:1</p> <p><b>covering</b> 14:18 15:2 111:1</p>	<p>126:20 151:13 152:8 160:18</p> <p><b>covers</b> 95:4</p> <p><b>cramp</b> 78:3</p> <p><b>cramping</b> 45:9,10,16 48:8,21</p> <p><b>created</b> 170:7</p> <p><b>crippled</b> 72:11</p> <p><b>crippling</b> 70:20</p> <p><b>criteria</b> 19:3 47:18</p> <p><b>critical</b> 12:4 26:19 128:7 193:3</p> <p><b>crock</b> 125:19</p> <p><b>Crohn's</b> 47:12</p> <p><b>cross</b> 86:18</p> <p><b>crosses</b> 155:3</p> <p><b>cruciferous</b> 50:4</p> <p><b>crushed</b> 149:2</p> <p><b>crying</b> 56:5 141:15</p> <p><b>CT</b> 47:12</p> <p><b>cup</b> 56:16</p> <p><b>cure</b> 51:19 116:14 118:7 130:14 134:4 166:16 194:1,5</p> <p><b>curious</b> 94:21 144:6 198:6</p> <p><b>current</b> 6:19 15:7 27:7</p> <p><b>currently</b> 12:8 110:18 115:17 129:11 195:2</p> <p><b>curves</b> 123:16</p> <p><b>cut</b> 46:3 49:15 154:8 163:8</p>	<p><b>CUTTING</b> 202:4,13</p> <p><b>cycle</b> 102:14</p> <p><b>Cymbalta</b> 113:4</p> <p><b>Cynthia</b> 2:8 44:8,13 52:3</p> <p><b>Cytotec</b> 132:2</p> <hr/> <p style="text-align: center;"><b>D</b></p> <hr/> <p><b>D.C</b> 35:11 36:1 128:16</p> <p><b>daily</b> 10:3 24:22 45:10 46:8 48:6,11 50:17 52:15 56:12 73:19 79:2 87:2 88:19 98:17 111:19 116:6 122:9 129:16 145:19 176:20</p> <p><b>dairy</b> 115:16 128:2,3</p> <p><b>damage</b> 155:7,8</p> <p><b>dance</b> 54:10 57:17</p> <p><b>dangerous</b> 113:16</p> <p><b>dark</b> 52:12,13 140:20</p> <p><b>darn</b> 159:4</p> <p><b>data</b> 11:2 178:20</p> <p><b>date</b> 15:2 16:18 57:2,4</p> <p><b>daughter</b> 56:1</p> <p><b>daughters</b> 123:21</p> <p><b>dawned</b> 159:3</p> <p><b>day</b> 17:21 30:6 34:3,5 35:17,19 42:3 46:14 48:7 53:13</p>
--	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 11

<p>54:18,19,22          55:22          57:5,6,7,9,10,14,          20 58:15 62:6          66:10 73:21          78:15          80:10,11,15          81:16,17 83:2,10          84:1,6 87:13          88:1 89:16 91:13          92:3 93:6 95:11          97:14 99:6          114:6,7 120:16          123:1,6,14          124:11          131:10,16 132:5          133:3,12,16          139:9 141:19          144:18          146:15,17 147:2          160:3,6          164:20,22          173:17 180:13</p> <p><b>days</b> 22:18,19          27:4,5 40:22          41:6,10 48:8          51:2 52:13          54:19,20,21          57:19 72:14          95:15 96:15,16          97:10 99:10,13          115:11 120:2,9          121:11 123:9          129:15          131:14,15 132:8          134:6,7 154:4          165:1 182:15</p> <p><b>daytime</b> 84:10</p> <p><b>deactivated</b>          115:22</p> <p><b>dead</b> 105:21</p> <p><b>deal</b> 35:17 41:16          47:10 56:9</p>	<p>115:11 141:2          180:12</p> <p><b>dealing</b> 35:20          42:11 44:17 85:2          136:8 148:4,6          178:19 184:7          185:1</p> <p><b>deals</b> 35:18</p> <p><b>Debbie</b> 3:5 82:7          86:16 89:12          140:4 144:21          175:15 195:22          197:10</p> <p><b>debilitating</b> 82:18          89:7 90:3 116:5          129:1 176:19</p> <p><b>decades</b> 177:12</p> <p><b>decay</b> 92:5</p> <p><b>deceased</b> 157:22</p> <p><b>December</b> 121:12</p> <p><b>decided</b> 160:18</p> <p><b>deciding</b> 17:10</p> <p><b>decisions</b> 13:22</p> <p><b>decompression</b>          133:11</p> <p><b>decrease</b> 161:3</p> <p><b>decreased</b> 21:15</p> <p><b>decreasing</b> 145:14</p> <p><b>deemed</b> 52:8</p> <p><b>deeply</b> 33:20</p> <p><b>defecate</b> 119:16</p> <p><b>deficiencies</b> 96:7</p> <p><b>define</b> 156:13</p> <p><b>defines</b> 73:22</p> <p><b>definitely</b> 115:3          198:19</p>	<p><b>deflating</b> 165:5</p> <p><b>degree</b> 12:6 42:13          153:17</p> <p><b>degrees</b> 42:8</p> <p><b>dehydrated</b> 133:8</p> <p><b>delighted</b> 4:7,8</p> <p><b>delightfully</b>          184:19</p> <p><b>delivery</b> 119:3</p> <p><b>delve</b> 33:20 157:3          166:9</p> <p><b>demographic</b>          19:22</p> <p><b>demonstrate</b>          24:21</p> <p><b>demonstrating</b>          34:14</p> <p><b>demoralizing</b> 91:7</p> <p><b>dental</b> 92:5</p> <p><b>denying</b> 153:4,12</p> <p><b>department</b> 55:5</p> <p><b>depleted</b> 97:10</p> <p><b>depleting</b> 97:14</p> <p><b>deposits</b> 182:3</p> <p><b>depressants</b>          149:14</p> <p><b>depressing</b> 134:13</p> <p><b>depression</b> 115:12</p> <p><b>Deputy</b> 5:8</p> <p><b>describe</b> 18:5          26:21 70:2,8          87:18 107:7          109:9 144:12</p> <p><b>described</b> 33:14          93:12 104:15,18          157:17</p>	<p><b>describes</b> 78:3          92:20</p> <p><b>descriptions</b> 138:4</p> <p><b>descriptive</b>          83:8,15,21</p> <p><b>design</b> 35:2</p> <p><b>designs</b> 10:18,19</p> <p><b>Desipramine</b>          113:3 152:17</p> <p><b>desk</b> 7:6 35:4</p> <p><b>desperate</b> 154:10</p> <p><b>desperation</b>          125:14</p> <p><b>despite</b> 9:9 37:11          124:7</p> <p><b>detached</b> 183:11</p> <p><b>detail</b> 30:22</p> <p><b>details</b> 136:16</p> <p><b>determine</b> 25:15          61:11 148:11</p> <p><b>determined</b> 127:2</p> <p><b>devastating</b> 131:6</p> <p><b>develop</b> 96:7          122:4 193:17          196:12</p> <p><b>developed</b> 113:9          119:11          134:14,21 135:8          150:10,11 181:9          187:7,18 199:22</p> <p><b>developing</b> 51:11          154:18 181:13          197:6</p> <p><b>development</b> 1:5          4:16 8:9,22          10:8,10,15 11:12          13:22 14:2,5          33:8 35:3</p>
--	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 12

<p><b>device</b> 60:4 135:7          152:14 161:22          200:13</p> <p><b>devices</b> 111:2          136:10          157:13,16          161:9,19 198:1</p> <p><b>diabetes</b> 134:18,19          150:2</p> <p><b>diagnosed</b> 36:13          44:14,15 52:9          111:16 140:5          169:13          178:14,15,17          179:1 181:5          186:2</p> <p><b>diagnoses</b> 178:20</p> <p><b>diagnosing</b> 126:8</p> <p><b>diagnosis</b> 18:21          19:5 22:15 33:17          61:2 73:12 82:8          128:16,19          150:14 169:11          173:2 185:16</p> <p><b>diagnostic</b>          116:7,12</p> <p><b>dialog</b> 7:1 9:20          26:4 32:10</p> <p><b>diarrhea</b> 19:11          21:15 23:8,21          41:15          111:16,18,19          113:14,17          114:2,7 115:9          116:16,20          170:11 177:18</p> <p><b>die</b> 56:6 181:18</p> <p><b>died</b> 181:8</p> <p><b>diet</b> 43:9          49:3,12,16</p>	<p>112:10 114:18          115:1,4,6</p> <p><b>dietary</b> 23:4 49:14          112:2 129:4          140:7 156:16,19          157:1 198:1</p> <p><b>dietician</b> 127:13</p> <p><b>diets</b> 51:15</p> <p><b>difference</b> 27:4          59:9 66:7 139:14          151:5 187:22</p> <p><b>differences</b> 26:9</p> <p><b>different</b> 10:2          14:11 25:22          28:2,10 29:22          42:15 43:10,20          48:21 49:1,2          53:10,12 55:13          61:16 63:1 67:15          70:3 71:15          76:13,21          77:3,5,10 78:21          79:15 81:22 82:1          84:6 98:20          101:10 102:22          103:19          104:13,17 107:9          112:2 116:2          126:18 132:4,6          141:7,11 150:21          151:6,15,17          167:4 177:4</p> <p><b>differentiate</b>          70:18</p> <p><b>differently</b>          81:11,21</p> <p><b>difficult</b> 22:7,22          43:8 48:19 66:21          67:6 94:4 103:14          107:7 112:14          123:1 142:5</p>	<p>167:9 194:19</p> <p><b>difficulties</b> 21:16</p> <p><b>difficulty</b> 125:4          131:18 142:14</p> <p><b>diffuse</b> 82:10</p> <p><b>dig</b> 67:18</p> <p><b>digest</b> 52:17 97:20          114:21 125:17</p> <p><b>digestion</b> 116:18</p> <p><b>digestive</b> 71:20          114:20 115:19          124:4,10 125:17          131:7</p> <p><b>Diltiazem</b> 127:6</p> <p><b>Dimick</b> 5:16 83:20          84:3,6,11 93:18</p> <p><b>diminish</b> 135:2          177:8</p> <p><b>dinner</b> 90:10          144:18</p> <p><b>dip</b> 174:3</p> <p><b>direct</b> 5:14 22:11          24:20</p> <p><b>direction</b> 144:16          165:17,21 201:6</p> <p><b>directly</b> 22:15          25:1 32:6</p> <p><b>Director</b> 5:5 8:11</p> <p><b>disability</b> 151:12</p> <p><b>disabled</b> 151:11</p> <p><b>disabling</b> 18:12          82:14 83:22</p> <p><b>disastrous</b> 184:15</p> <p><b>disc</b> 120:21</p> <p><b>discharged</b> 146:18          147:1</p> <p><b>discomfort</b> 20:19</p>	<p>46:8 52:15          53:3,14 68:14,19          69:16,20          70:2,5,18,22          71:5,7,9          72:15,16,18          73:1,11,19,20          77:22          78:14,18,19,20          79:2,5,7,10,21          82:16 83:4,11          85:5 86:18          102:17 107:9          191:11</p> <p><b>discuss</b> 10:17,18          110:11 142:9          166:17 197:21          198:1,4</p> <p><b>discussed</b> 28:20          105:19,20 148:1          187:14 200:1</p> <p><b>discussion</b> 4:6          6:2,13,16,22          7:17 16:9 26:12          28:1,5,8          29:2,8,14,16          32:8 34:3,15          38:19,22 67:8          100:8 107:8          110:9,14,16          141:5 145:19          163:10          173:16,22          174:12</p> <p><b>discussions</b>          198:6,11</p> <p><b>discussion's</b> 33:14</p> <p><b>disease</b> 6:17 9:9          11:17,21          12:5,6,10,16,20,          21 13:13,15,20          14:8,11          15:5,15,21,22</p>
--	---	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 13

<p>17:1,14 25:12          47:13 53:22          71:19 117:22          118:1,8 119:21          124:12 150:12          178:4,6,9,10,21,          22 179:6 184:5          185:15,17          186:1,5,14,21          193:3,12,13,18</p> <p><b>diseases</b> 14:16,18          17:3 18:8 51:17          124:5,10 186:12          189:11,15</p> <p><b>disheartening</b>          142:11 196:6</p> <p><b>disorder</b> 17:22          19:21 20:21          28:16,17 36:13          37:7 49:5          59:10,14,18 61:4          75:8 117:21          137:10 156:6          160:22 188:11          189:18</p> <p><b>disorders</b> 1:3 4:18          6:12,20 7:2          8:9,15          9:2,3,6,13,15,17          10:1,5 15:3          18:2,4,6,14,15          19:2,6,17 20:4          21:7 22:7          23:2,10,15 24:15          25:13 26:7 27:8          28:17 37:4,6          75:9 83:4 96:6          131:7          176:2,8,15,17          177:3,10,11,13,1          5,21 179:2          185:12 186:7          187:14 190:13</p>	<p>192:7 198:9</p> <p><b>dissatisfaction</b>          177:16</p> <p><b>dissipate</b> 72:3          122:16 123:8</p> <p><b>distended</b> 133:19</p> <p><b>distention</b> 21:13          118:6 119:13</p> <p><b>distinguish</b> 70:4</p> <p><b>distracting</b> 60:16</p> <p><b>distressed</b> 46:7</p> <p><b>division</b>          5:5,8,12,17,19          8:11,13 9:12          15:10,17 17:17</p> <p><b>divisions</b> 16:20</p> <p><b>dizziness</b> 126:14</p> <p><b>docket</b> 16:11          30:21 31:6 33:21          36:8 38:17 78:7          87:11 92:12          109:9 110:12          164:1 182:18          186:18 194:12</p> <p><b>docket's</b> 32:21</p> <p><b>docs</b> 160:17</p> <p><b>doctor</b> 22:20          45:20 47:3,9          48:14 49:9 56:22          58:11 77:9 126:5          129:10 141:13          142:8 144:3          168:1,5          169:10,14,18          172:8,15,17          185:21 189:2</p> <p><b>doctors</b> 22:13          56:12 60:17          76:21 97:17</p>	<p>109:16 124:21          125:11 126:1          133:22 134:7          145:11 151:17          167:22 168:9          197:7</p> <p><b>doctor's</b> 133:15</p> <p><b>Doctors</b> 42:12          134:5</p> <p><b>document</b> 31:4</p> <p><b>documents</b> 16:12</p> <p><b>dog</b> 60:6</p> <p><b>dollars</b> 178:19          179:3</p> <p><b>domestic</b> 179:22</p> <p><b>domperidone</b> 24:6          90:7 129:2          132:17 139:22          140:1,8,20 141:9          142:9 143:11          144:7,16,20          146:3 147:7,14          152:15          179:13,16,19,20          180:1,2          195:2,3,4,14          196:5,14,21</p> <p><b>done</b> 17:9 22:9          40:11 62:7 90:6          99:4 103:4          107:13 108:2,14          123:12 125:14          153:9 158:5          162:2,3,19 163:2          165:8 170:14,21          182:14 192:9,18          196:14,16</p> <p><b>Donna</b> 2:3 4:20          5:4 8:5,10          11:13,14,18 19:8          74:13 80:6</p>	<p>143:20</p> <p><b>door</b> 47:22 57:21          159:21</p> <p><b>dosage</b> 132:19</p> <p><b>dose</b> 139:2 140:12          144:17</p> <p><b>doubled</b> 45:14          78:15 82:14</p> <p><b>doubted</b> 126:2</p> <p><b>download</b> 199:19</p> <p><b>downsides</b> 27:13          34:11 110:21          149:6,8 150:19          153:14 160:14</p> <p><b>dozens</b> 177:2</p> <p><b>Dr</b> 1:14 2:3,4,5,6          3:7 4:2          5:4,7,10,13,16,1          8,20,22 8:7 9:11          11:13 17:15          25:19 36:2          38:3,14 43:17          44:7 51:8 52:3          58:13,22 65:8          66:11 68:21          69:19 71:3,11          73:2 74:11,14          75:11 76:11          77:12 78:5,9,22          80:4 81:12,14          82:5 83:20          84:3,6,11,14          85:9,11          86:2,11,14 87:6          88:16 89:11          90:22 92:9          93:1,5,17,18          94:10,17 95:5          96:2,9 97:1          98:19 99:14          100:19 101:15          102:7,11,21</p>
--	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 14

<p>103:9,16 104:14          105:1,9 106:17          108:19,22          109:20 111:11          117:10,16          124:14 128:13          131:2 135:11          138:1 139:15,18          140:3,16 141:6          142:12          143:3,16,21          145:3,21 147:20          148:13 149:5,18          150:18 152:10          153:1,13          154:7,14,20          155:11          156:10,22          159:11 160:9          161:6,15,20          162:6,13          163:6,15 165:22          167:18 168:11          169:7,20 170:22          171:20 173:14          187:8,9 190:9          193:3 197:13          198:22 199:1          200:5</p> <p><b>dramatic</b> 49:3          186:6</p> <p><b>drank</b> 52:18 133:7</p> <p><b>drastic</b> 130:3</p> <p><b>drastically</b> 104:4</p> <p><b>drawing</b> 150:11</p> <p><b>dream</b> 124:10          129:20</p> <p><b>dressed</b> 40:22</p> <p><b>dried</b> 139:6</p> <p><b>drink</b> 53:3,4 65:4          126:19 129:21</p>	<p><b>drinks</b> 128:1</p> <p><b>drive</b> 54:17 146:11</p> <p><b>driving</b> 46:14</p> <p><b>drop</b> 63:3</p> <p><b>drove</b> 52:7 57:2</p> <p><b>drug</b> 1:5,9 4:4,16          8:8,21 9:19          10:8,10,11,15          11:11,21 13:7,15          14:5,9 31:19          33:8 35:3 58:6          76:1 78:12 90:20          106:14          134:20,22          137:6,9 140:11          141:3,6,7          149:17,21 150:2          156:3 170:10          192:16 195:17          197:8</p> <p><b>drugs</b> 5:15,21 8:14          10:14 14:2 23:6          25:15 51:11          58:10 82:22          83:14          132:10,12,16          134:3 150:16          155:1 167:7,9          168:19 170:2          181:9 191:18          194:6 195:4          196:8 197:21</p> <p><b>drug-seeker</b> 58:3</p> <p><b>dry</b> 48:18          101:5,12          164:11,12,18,22</p> <p><b>due</b> 59:18 63:2          127:14 131:16          151:10</p> <p><b>duller</b> 70:22</p>	<p><b>duodenum</b> 181:22</p> <p><b>duration</b> 93:20</p> <p><b>during</b> 16:13 17:9          41:13 42:3 45:3          62:6 66:9 84:1          89:16 119:2          120:4,9 123:12          147:16          150:10,13 175:3</p> <p><b>dying</b> 91:19 168:7</p> <p><b>dysautonomia</b>          184:4</p> <p><b>dysfunction</b> 59:11</p> <p><b>dysfunctional</b>          80:21</p> <p><b>dyskinesia</b> 59:13</p> <p><b>dyskinesia-type</b>          154:19</p> <p><b>dysmotility</b>          39:10,11 59:12          71:19 103:7,8          130:15</p> <p><b>dyspepsia</b> 19:12          20:6 167:2          193:15</p> <hr style="width: 50%; margin: 10px auto;"/> <p style="text-align: center;">E</p> <hr style="width: 50%; margin: 10px auto;"/> <p><b>eagle</b> 60:8</p> <p><b>earlier</b> 110:4          151:9 179:12</p> <p><b>early</b> 10:17,18          11:1 41:13 90:2          91:5 154:18          155:9</p> <p><b>earn</b> 34:20</p> <p><b>ease</b> 47:8</p> <p><b>easier</b> 39:14 65:11</p> <p><b>easily</b> 87:1</p>	<p><b>easy</b> 86:18 97:19          192:12</p> <p><b>eat</b> 39:16 40:12          41:17 43:12,21          50:10,11 51:3          52:22 54:4 55:7          60:21 63:9,21,22          65:12,13 69:17          71:21,22 86:22          96:22 97:4,6,9          98:14,15 99:12          106:7 121:21          122:15 125:18          126:20 129:19          131:9 133:16,17          135:3 140:2          141:22 142:1          144:19 147:6          148:5 165:12          179:14</p> <p><b>eaten</b> 133:18          164:15 165:10</p> <p><b>eating</b> 42:21 51:15          60:22 62:22 64:1          65:11 90:5          115:16 118:10          119:13 121:14          122:13 123:2          126:10,13          129:21          138:20,21          148:12,20 149:2          165:9,10</p> <p><b>economic</b> 176:17</p> <p><b>educate</b> 191:12,13</p> <p><b>educated</b> 75:7</p> <p><b>education</b> 76:5          169:10 189:2          191:14 200:8</p> <p><b>educational</b>          176:21 187:6          199:14</p>
--	--	--	---



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 15

<p><b>effect</b> 62:7          113:9,21 116:5,6          117:2 127:16,18          140:8 153:20          155:18 158:10          170:10 194:7</p> <p><b>effective</b> 13:1 32:8          112:14 113:1,13          130:2          158:4,11,13,15,1          7 177:6,14 195:4          196:22</p> <p><b>effectively</b> 50:13          51:7</p> <p><b>effects</b> 90:20          113:3,17 117:1          131:6 132:12          140:12 142:3          143:6 149:13,22          150:16 152:22          153:15 154:12          155:20 170:3          186:6 195:6          196:10,15</p> <p><b>efficient</b> 129:14          193:19</p> <p><b>efforts</b> 11:11          196:7 197:6</p> <p><b>Eggers</b> 2:6 4:2,3          5:22 25:19 36:2          38:3,14 43:17          44:7 51:8 52:3          58:13,22 65:8          66:11 68:21          69:19 71:3,11          73:2 74:11 75:11          76:11 77:12          78:5,22 80:4          81:12 82:5 84:14          85:9 86:2,11,14          87:6 88:16 89:11          90:22 92:9          93:1,17 94:10</p>	<p>95:5 96:2,9 97:1          98:19 99:14          100:19 101:15          102:7,11,21          103:9,16 104:14          105:1,9 106:17          108:19,22          109:20 111:11          117:10,16          124:14 128:13          131:2 135:11          138:1 139:15,18          140:3,16 141:6          142:12 143:3,16          145:3,21 147:20          148:13 149:5,18          150:18 152:10          153:1,13          154:7,14,20          155:11          156:10,22          159:11 160:9          161:6,15,20          162:6 163:6,15          165:22 167:18          168:11 169:7,20          170:22 171:20          173:14 199:4</p> <p><b>EGGERSReporte          d</b> 1:14</p> <p><b>eight</b> 82:21 114:5          118:17 123:14          126:1,4 158:3</p> <p><b>either</b> 54:13 92:16          94:19 97:20          148:19 155:14          195:7</p> <p><b>elaborate</b> 73:5          78:6</p> <p><b>electric</b> 133:6          135:4</p> <p><b>electrical</b> 24:11</p>	<p><b>electronic</b> 16:11</p> <p><b>elevated</b> 125:3</p> <p><b>elevations</b> 147:9</p> <p><b>eliminate</b> 50:4</p> <p><b>elimination</b> 115:6</p> <p><b>Elizabeth</b> 73:7          140:17,18 169:8          171:12,21</p> <p><b>Ellen</b> 2:18 139:21          144:11 175:13          179:9 180:4</p> <p><b>eloquently</b> 69:21</p> <p><b>else</b> 42:20 43:13          50:3 59:8 78:20          86:8 125:13          139:18 145:1          148:2,8 156:4,21          158:1 167:18          171:1</p> <p><b>email</b> 31:6 33:12</p> <p><b>embarrassing</b>          103:13</p> <p><b>embellish</b> 74:4</p> <p><b>embracing</b> 184:19</p> <p><b>emergency</b>          58:1,11 159:2</p> <p><b>emesis</b> 195:5</p> <p><b>emotional</b> 45:3</p> <p><b>emotionally</b> 22:1          46:7</p> <p><b>employed</b>          201:9,12</p> <p><b>employee</b> 197:14          201:11</p> <p><b>employers</b> 50:20          51:1</p> <p><b>employment</b></p>	<p>176:21</p> <p><b>empowering</b>          199:7</p> <p><b>empty</b> 89:18          133:12 148:18</p> <p><b>emptying</b> 52:11          90:5 128:21          149:16 192:22</p> <p><b>enable</b> 135:3</p> <p><b>enabled</b> 60:4</p> <p><b>enables</b> 13:15</p> <p><b>encapsulate</b> 48:4</p> <p><b>encourage</b> 32:9          94:10 107:4          108:1 174:19          181:1 182:19</p> <p><b>encouraging</b>          116:9</p> <p><b>Endpoints</b> 5:21</p> <p><b>enema</b> 104:9</p> <p><b>enemas</b> 104:7          118:10 121:6          161:14</p> <p><b>energy</b> 41:9 57:15          60:8 62:11 95:8          127:8 194:8</p> <p><b>enforce</b> 180:2</p> <p><b>engage</b> 28:6</p> <p><b>engagement</b>          31:17,20</p> <p><b>engineers</b> 123:22</p> <p><b>enjoy</b> 64:8 65:13          89:8</p> <p><b>enjoying</b> 64:1</p> <p><b>ensure</b> 9:18</p> <p><b>enteric</b> 21:2 188:9          189:9</p>
---	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 16

<p><b>Enterra</b> 152:14 160:12 197:14</p> <p><b>entire</b> 41:14 59:12 71:20 121:1</p> <p><b>entitled</b> 200:21</p> <p><b>enzymes</b> 115:20</p> <p><b>episode</b> 80:8,14,18,22 81:3,6 93:10 115:17 117:6</p> <p><b>episodes</b> 50:7 62:8,9 72:9 94:3 114:2</p> <p><b>equate</b> 91:9</p> <p><b>ER</b> 72:13,22 79:21 127:12</p> <p><b>erode</b> 85:5</p> <p><b>Error</b> 17:18</p> <p><b>Errors</b> 5:6,9 8:12</p> <p><b>ERs</b> 75:17</p> <p><b>erythromycin</b> 132:1 152:19 181:7 196:13</p> <p><b>esophageal</b> 39:10 59:12</p> <p><b>esophagus</b> 18:9 134:10</p> <p><b>especially</b> 4:8 16:22 58:11 70:3 90:16 138:7 169:18 188:8,14</p> <p><b>established</b> 19:4</p> <p><b>estimate</b> 22:8</p> <p><b>estimates</b> 19:19 22:17</p> <p><b>et</b> 111:3 138:12 194:2</p>	<p><b>ethnicity</b> 20:2</p> <p><b>evaluate</b> 93:19</p> <p><b>evaluated</b> 25:5 83:1</p> <p><b>evaluating</b> 81:20</p> <p><b>evaluation</b> 4:5 33:10 35:4 83:14 198:17</p> <p><b>evening</b> 72:22 200:20</p> <p><b>event</b> 151:12</p> <p><b>events</b> 130:18,19</p> <p><b>eventually</b> 104:7 129:5 183:9</p> <p><b>everybody</b> 17:18 58:2,5 62:15 95:1,4 108:8 188:18 196:4</p> <p><b>everybody's</b> 43:10 62:21</p> <p><b>everyday</b> 62:15 131:18</p> <p><b>everyone</b> 4:2 11:9 32:19 34:18 35:6 36:7 42:20 55:16 68:22 89:5 96:18 135:17 174:6 198:15 200:12</p> <p><b>Everyone's</b> 137:4</p> <p><b>everything</b> 32:20 42:21 49:15,19 58:17 62:22 67:5 98:16 131:21 133:7 134:8 141:17 151:16 169:15,16</p> <p><b>evidence</b> 11:22 17:10</p> <p><b>exact</b> 86:9</p>	<p><b>exactly</b> 84:2,5 138:8 149:7</p> <p><b>example</b> 18:20 63:7 153:11 193:7</p> <p><b>examples</b> 19:14 26:20</p> <p><b>exams</b> 121:7</p> <p><b>exceed</b> 17:11</p> <p><b>except</b> 137:17</p> <p><b>excessive</b> 127:9</p> <p><b>excessively</b> 127:1</p> <p><b>Excuse</b> 194:10</p> <p><b>exercise</b> 96:18 124:19</p> <p><b>exhausting</b> 93:15 96:8 98:12</p> <p><b>existing</b> 196:17</p> <p><b>exiting</b> 144:15</p> <p><b>expand</b> 34:11 96:12 126:19</p> <p><b>expect</b> 20:18 26:1 131:15</p> <p><b>expend</b> 95:8</p> <p><b>expensive</b> 132:16 151:14</p> <p><b>experience</b> 7:3 12:15,19 18:6 21:8 44:11 68:22 69:1 71:14 75:21 82:9 87:16 91:8 96:5 100:6 108:7 139:19 144:19 145:4 147:19 148:13 166:5,12 171:9 184:22 188:2,10,20 199:8</p>	<p><b>experienced</b> 68:7,18 90:11 92:5 100:11,14,15,21 107:16</p> <p><b>experiences</b> 15:7 26:5,10 28:3 29:15 36:10 47:15 67:11 69:21 92:10 102:22 136:15 137:19 166:10</p> <p><b>experiencing</b> 12:18 13:12 45:8 95:1</p> <p><b>experts</b> 19:4</p> <p><b>explain</b> 33:22 70:19 88:4 94:9 101:21 104:14 156:11 164:1</p> <p><b>explore</b> 107:6 143:17</p> <p><b>exposures</b> 127:18</p> <p><b>expressed</b> 34:13</p> <p><b>extent</b> 50:15 84:19 86:19 87:3 158:17</p> <p><b>extraordinarily</b> 102:2</p> <p><b>extreme</b> 127:11 134:22</p> <p><b>extremely</b> 9:20 132:16</p> <p><b>eye</b> 106:2</p> <p><b>eyes</b> 46:19</p> <hr/> <p style="text-align: center;">F</p> <hr/> <p><b>fabulous</b> 167:7</p> <p><b>face</b> 33:17 98:16</p>
--	---	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 17

<p>152:2 183:14 189:3</p> <p><b>faces</b> 76:16</p> <p><b>facilitated</b> 28:5</p> <p><b>facilitator</b> 1:14 4:6</p> <p><b>fact</b> 50:21 158:9 180:2</p> <p><b>factor</b> 62:11</p> <p><b>factors</b> 146:20 196:17</p> <p><b>fail</b> 128:20 183:8</p> <p><b>failed</b> 24:10 182:1</p> <p><b>failing</b> 180:1 188:6</p> <p><b>failure</b> 183:14</p> <p><b>faint</b> 132:22</p> <p><b>fair</b> 98:19</p> <p><b>fairly</b> 103:6 158:19</p> <p><b>fall</b> 76:19 86:20 114:9</p> <p><b>familiar</b> 21:12</p> <p><b>family</b> 44:18 52:7 53:21 54:1 55:17 56:19 60:1 124:5 139:12 175:19 176:21</p> <p><b>Farkas</b> 1:18 201:2,18</p> <p><b>Farrugia</b> 193:3</p> <p><b>fast</b> 150:5</p> <p><b>fat</b> 63:7,10</p> <p><b>father</b> 178:13,17</p> <p><b>fatigue</b> 65:22 94:20 95:5,6,9,12,16 96:5,15,17,21</p>	<p>97:3 110:7,11 126:12,15 127:1</p> <p><b>fatigued</b> 41:8</p> <p><b>fats</b> 63:3</p> <p><b>fatty</b> 129:22 130:20 182:3</p> <p><b>favorite</b> 40:12</p> <p><b>FDA</b> 4:5,22 6:10 10:7,14 25:19 27:1 31:10,11,17,19 33:6,8 44:9 59:4 70:16 73:13 74:19 106:22 107:5 131:5 132:2,17 135:10 137:7 143:16 146:8 164:6 176:11 179:18,20 180:1,9 189:8 190:2,18 191:14 192:9 194:16 195:9,13,14 196:8 197:16 198:6,10</p> <p><b>FDA-approved</b> 141:3</p> <p><b>FDA-regulated</b> 198:4,8</p> <p><b>FDA's</b> 8:21 9:18 11:19</p> <p><b>fear</b> 89:3 155:10</p> <p><b>features</b> 177:5</p> <p><b>February</b> 126:17</p> <p><b>fecal</b> 47:13 72:7 105:12 108:14 120:17,18</p> <p><b>fed</b> 131:10 133:14 134:2</p>	<p><b>feed</b> 55:21 181:11,17</p> <p><b>feedback</b> 34:22 152:15</p> <p><b>feeding</b> 24:12 56:13 71:21 121:21 129:6 130:12 133:14 148:3 181:11 183:12</p> <p><b>feedings</b> 59:20 121:14</p> <p><b>feel</b> 7:20 24:22 34:21 44:16 48:11 50:7 51:2,7,14 54:5 65:11 66:14 72:7,11,15 97:5 99:19 102:17 107:10 115:22 116:3 117:6 121:22 126:18 130:21 135:13 141:1 150:14,22 164:1 165:12 166:7,18 168:16 180:15</p> <p><b>feeling</b> 43:15 48:1,7 68:12 69:17 82:11 85:6 87:19 89:22 92:20 109:12,15 143:15 148:9</p> <p><b>feelings</b> 70:1</p> <p><b>feels</b> 55:17 64:19 165:4</p> <p><b>felt</b> 89:16 90:2 91:8 125:19,21 162:20 187:22</p> <p><b>female</b> 36:4</p> <p><b>fermented</b> 114:22</p>	<p><b>fiber</b> 50:4 112:11 129:20</p> <p><b>field</b> 167:22</p> <p><b>fifth</b> 120:21</p> <p><b>fighting</b> 56:12 62:2 95:15 193:5</p> <p><b>figure</b> 61:10 109:11 163:3</p> <p><b>figured</b> 173:8</p> <p><b>figures</b> 194:5</p> <p><b>fill</b> 65:17 72:6 78:18 81:15 198:18</p> <p><b>filled</b> 180:21</p> <p><b>final</b> 43:17,18 51:8 58:13,14 65:8,9 106:22 171:5</p> <p><b>finally</b> 4:7 16:6 24:10 34:22 52:9 61:5,15,18 119:7 121:3 126:5 159:3 173:8 180:14,17 181:18 183:9 196:18 197:11 198:21</p> <p><b>financial</b> 174:19</p> <p><b>financially</b> 189:5 201:13</p> <p><b>finding</b> 38:16 145:9</p> <p><b>findings</b> 176:10</p> <p><b>fine</b> 60:14 183:2</p> <p><b>finish</b> 183:4</p> <p><b>first</b> 4:22 6:9 7:8,17 14:17,18,22 26:14 27:16 28:13,14 40:18</p>
---	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 18

<p>45:19 59:22          60:18 68:3,15          70:9,10,15 71:4          89:1,17 90:4          91:5 96:15          100:10 101:22          102:8 112:9          118:8 119:3          125:21 135:17          136:3,21 153:5          157:21 158:18          164:17 169:19          175:16 178:15          179:1 187:6          190:20 194:15          197:15 199:4</p> <p><b>fiscal</b> 14:13,15</p> <p><b>fish</b> 115:20</p> <p><b>Fisher</b> 3:5 175:15          195:22 196:2</p> <p><b>fit</b> 48:9</p> <p><b>five</b> 14:11 19:20          79:6,7,10,11,20          87:1 89:14          110:13 111:5          118:19 120:2,9          158:18 164:18          181:20</p> <p><b>five-organ</b> 181:21</p> <p><b>five-plus</b> 40:14</p> <p><b>fix</b> 64:9</p> <p><b>flare</b> 27:3 79:3          95:11 126:5</p> <p><b>flares</b> 129:18</p> <p><b>flare-up</b> 46:15          50:20</p> <p><b>flare-ups</b> 45:18          83:12</p> <p><b>flatulence</b> 100:16          101:3,13,19</p>	<p>103:1,4,12,20</p> <p><b>flesh</b> 30:22</p> <p><b>floating</b> 31:21</p> <p><b>floor</b> 17:22 44:3          70:21</p> <p><b>Florida</b> 117:20</p> <p><b>flu</b> 88:6</p> <p><b>fluids</b> 98:4</p> <p><b>focus</b> 6:22 15:4          26:7 51:12,17          69:20 77:11          89:6,7 96:21          153:15 180:19          188:6</p> <p><b>focused</b> 4:17 28:19          31:5 33:15 68:2          76:22 82:3 171:7</p> <p><b>focuses</b> 26:15</p> <p><b>focusing</b> 115:13</p> <p><b>FODMAP</b> 114:18          115:1,4</p> <p><b>FODMAPs</b> 114:18</p> <p><b>foggy</b> 123:5</p> <p><b>folks</b> 6:4 29:21          77:15 174:13          184:21 186:2,10</p> <p><b>follow-up</b> 47:16          74:12 78:9 95:6          143:21 144:21</p> <p><b>food</b> 1:9 7:11          41:17 42:11,22          43:1 49:6,7 50:9          53:15,18,19 54:4          62:22 65:3,14,15          102:5,16 106:6          125:17 130:19          131:10 133:17          135:3 138:21          147:5 150:6</p>	<p>165:10 194:7</p> <p><b>foods</b> 43:21 49:11          50:4 63:5          115:6,15          129:20,22          130:20 197:15          198:5,8,11</p> <p><b>Foore</b> 175:13          182:22 183:1</p> <p><b>foot</b> 118:19</p> <p><b>forced</b> 45:4</p> <p><b>foregoing</b> 201:3</p> <p><b>foregoing/          attached</b> 202:8</p> <p><b>forever</b> 152:1</p> <p><b>forgot</b> 71:8 73:17          169:3,4</p> <p><b>form</b> 37:6 95:15          193:15,22</p> <p><b>format</b> 6:15 25:21          26:1 110:2,3,4</p> <p><b>formation</b> 193:6</p> <p><b>formed</b> 118:4          120:6</p> <p><b>forms</b> 33:10 35:4          198:18</p> <p><b>formula</b> 122:9          123:5</p> <p><b>formulating</b>          103:18</p> <p><b>Fort</b> 117:19</p> <p><b>forthright</b> 171:16</p> <p><b>fortunate</b> 129:18          166:11 182:6</p> <p><b>fortune</b> 166:6</p> <p><b>Forty-three</b> 37:21</p> <p><b>forum</b> 192:10</p>	<p>199:13</p> <p><b>forward</b> 29:2          200:17</p> <p><b>foster</b> 26:3</p> <p><b>foundation</b> 28:1          48:16 60:3 176:1          178:4,9,21          185:14,15 187:6</p> <p><b>founder</b> 180:7          187:4,17</p> <p><b>four-hour</b> 52:10</p> <p><b>four-legged</b> 136:3          173:18</p> <p><b>fourth</b> 65:18</p> <p><b>framing</b> 26:12</p> <p><b>free</b> 7:20 55:4          63:7,10 99:19          164:1 193:5</p> <p><b>frequent</b> 10:16          100:16 101:11          111:19          156:17,18</p> <p><b>frequently</b> 81:14          101:4 118:12</p> <p><b>fresh</b> 169:14</p> <p><b>Friday</b> 80:13</p> <p><b>friendly</b> 107:12</p> <p><b>friends</b> 39:20,22          53:21 60:1 86:22          131:20 136:3          139:13 173:18          191:2</p> <p><b>friend's</b> 40:10</p> <p><b>front</b> 27:19 89:5          109:21 168:7</p> <p><b>frozen</b> 63:7</p> <p><b>frustrated</b> 74:16</p> <p><b>frustrating</b> 141:12</p>
---	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 19

<p>153:3,10 196:6  <b>frustration</b> 46:9          141:2  <b>full</b> 6:8 22:22          69:17 80:10 92:6          107:20 118:14          119:16 125:1          127:15 182:2  <b>fullest</b> 124:7 186:3  <b>fullness</b> 68:12          69:17  <b>full-time</b> 130:17  <b>fully</b> 9:15  <b>fun</b> 52:11  <b>function</b> 24:22          85:14,19,21          86:1,5,8          106:15,16          127:20 132:9          191:5  <b>functional</b> 1:3          4:18 6:11,20 7:1          8:9,15 9:2,15          10:5 11:17 15:3          17:21 18:4,14          19:1,6,12,13,17,          21 20:6,7,20          21:7 22:6 24:15          25:13 27:8 36:13          37:3,5,7 49:4          61:4 62:11 80:8          82:15 91:11 96:5          156:6 167:2          176:1,8,15          177:3,10,21          178:7,19 179:2,5          185:12 186:7          187:14 188:11          190:13 192:7,17          193:15  <b>functioning</b> 9:5</p>	<p>43:3 85:13 86:3          94:1 105:21          106:3,9 118:4  <b>fundoplication</b>          119:7  <b>funerals</b> 53:19  <b>funny</b> 158:22  <b>furiously</b> 30:2  <b>furthering</b> 31:17  <b>future</b> 10:6 35:2          59:9 183:14          198:11</p> <hr/> <p style="text-align: center;">G</p> <hr/> <p><b>Gaekano</b> 2:16          175:12,18,21  <b>gain</b> 117:7 121:4          124:19 128:6          152:3  <b>gained</b> 12:17          150:4  <b>gall</b> 120:14  <b>game</b> 54:12 57:18          130:9 151:3  <b>games</b> 54:10  <b>ganglion</b> 118:3          119:17,21  <b>gas</b> 72:6 100:16          101:3,13,19          102:2,16          103:1,4,12,20          114:3  <b>gases</b> 144:15  <b>gastric</b> 24:11          52:10 90:5          121:22 128:21          133:6 135:4          149:15 152:13          158:1 160:12</p>	<p><b>gastritis</b> 89:19  <b>gastro</b> 161:12  <b>gastroenterologist</b>          46:22 91:5          179:15 190:10          200:5  <b>gastroenterologist</b>          s 46:18 116:2          196:21  <b>Gastroenterology</b>          5:6,8 8:12 17:17  <b>gastroesophageal</b>          9:8 37:10  <b>gastrointestinal</b>          1:3 17:21 19:2          20:21 21:7 22:7          157:8 176:2          187:14 188:11          193:2,14  <b>gastroparesis</b> 9:7          19:13 23:20          24:11 37:9 38:1          39:9 52:10 59:11          70:15 71:18 73:8          82:8 83:12 84:18          87:22 89:2,13          91:3,20 94:22          95:3 102:3          124:17 126:3,7,8          128:6,8,19          130:6,10 131:9          134:5,15,18,19,2          2 140:6 141:12          144:11          157:15,22          159:14 167:3          169:16          176:19,22          179:13,17 180:8          181:5 183:5          184:14 192:4          195:5</p>	<p><b>gather</b> 30:14  <b>gathering</b> 4:17  <b>Geller</b> 2:17 175:12          178:2,3,4  <b>gender</b> 20:1  <b>general</b> 23:4          34:8,11 58:17          77:20 80:12  <b>generally</b> 18:7,20          34:11 41:1          72:5,7 76:12          77:22 80:16 81:6          99:3 196:22  <b>genetic</b> 117:21  <b>gentle</b> 116:22  <b>GERD</b> 37:12,14          38:1 73:9 83:13          84:21 89:20          118:22 131:8          176:18  <b>GES</b> 128:8  <b>gets</b> 53:6 103:22          106:12 137:5          151:2 162:4          189:13  <b>getting</b> 13:14          14:19 33:18          41:22 54:12 61:2          62:4 65:1 69:13          77:16,18 97:7          100:17 101:9          102:11 113:21          118:9 127:22          142:14,15,19          144:4 146:19          152:11 160:5,15          162:6,7 163:11          180:17          195:7,8,10  <b>GI</b> 4:18 5:17</p>
--	---	--	--

<p>6:12,20 7:2                  8:9,15 9:2,4,5,15                  10:5 11:17 15:3                  18:4,5,14                  19:6,17,21 20:17                  21:4 24:15 25:13                  26:6 27:8 36:13                  37:3,5,7 49:4                  59:6,12,18 61:4                  64:22 68:3,6                  69:2 77:3,5                  80:21 82:8,15                  89:14 96:5 98:22                  103:7,8                  107:11,15                  114:16 125:11                  126:4,6,7 128:10                  129:9 130:14                  137:10 142:8                  144:15 156:6                  160:17 162:20                  176:8,15                  177:3,4,10,21                  178:7,19 179:2,5                  185:12 186:7                  190:13 192:7,17                  198:9</p> <p><b>GIAMBONE</b>                  68:17 69:14                  142:22 143:4                  152:12 161:11</p> <p><b>gift</b> 123:20</p> <p><b>Ginter</b> 2:20                  175:14                  184:11,12</p> <p><b>GI-related</b>                  100:9,13 107:5</p> <p><b>girls</b> 187:21</p> <p><b>given</b> 11:20,21                  100:21 123:19                  166:4 170:11</p> <p><b>gives</b> 7:2 60:8</p>	<p>132:18</p> <p><b>giving</b> 131:5                  146:12</p> <p><b>G-J-tube</b> 121:17</p> <p><b>glands</b> 150:12</p> <p><b>glass</b> 52:17</p> <p><b>glew</b> 52:12</p> <p><b>glow</b> 52:12</p> <p><b>gluconate</b> 122:22</p> <p><b>glutamine</b> 114:12                  115:20 122:11</p> <p><b>glutathione</b> 193:8</p> <p><b>gluten</b> 193:21</p> <p><b>goal</b> 26:7 124:6</p> <p><b>godsend</b> 140:11</p> <p><b>golden</b> 15:19</p> <p><b>gone</b> 141:15</p> <p><b>goodness</b> 60:11,21                  61:19 64:14                  65:13 173:4</p> <p><b>gotten</b> 152:15                  160:8 167:6                  198:18</p> <p><b>government</b> 13:9                  26:2</p> <p><b>GP</b> 192:19,20</p> <p><b>G-PACT</b> 180:7</p> <p><b>Graham</b> 77:16</p> <p><b>granddaughter</b>                  40:14</p> <p><b>grandmother</b>                  41:19</p> <p><b>grateful</b> 8:15                  123:19                  130:7,16,21</p> <p><b>great</b> 9:16 34:6</p>	<p>37:17 42:18 48:7                  57:3,6 75:4                  80:19 111:5                  115:11 127:21                  138:20 140:22                  141:2 151:6                  173:15 200:20</p> <p><b>greatly</b> 177:8</p> <p><b>green</b> 129:21</p> <p><b>grew</b> 119:8,14</p> <p><b>Griebel</b> 2:3 4:20                  5:4 8:7,10 74:14                  78:9 143:21</p> <p><b>grocery</b> 55:3</p> <p><b>ground</b> 10:9 30:11                  32:7 109:22</p> <p><b>group</b> 9:6 18:5                  19:4 25:13                  117:12 194:21</p> <p><b>groups</b> 16:1 30:19                  112:19</p> <p><b>growing</b> 46:9</p> <p><b>growled</b> 164:21</p> <p><b>G-tube</b> 133:10</p> <p><b>guess</b> 35:5 37:12                  39:21 43:15 74:9                  106:12 145:6                  157:14</p> <p><b>guidance</b> 196:19                  197:6</p> <p><b>guiding</b> 110:16</p> <p><b>gummy</b> 63:12                  127:19</p> <p><b>gut</b> 21:3 59:11,20                  102:5 181:12,14                  184:8</p> <p><b>gut/brain</b> 194:4</p> <p><b>guys</b> 66:18 141:17</p>	<hr/> <p style="text-align: center;">H</p> <hr/> <p><b>H2</b> 23:10</p> <p><b>hair</b> 41:7                  139:6,7,9</p> <p><b>half</b> 22:10                  44:14,15 89:21                  90:11 91:1                  110:17 118:19                  138:18 140:10                  158:18 160:4                  164:15 165:11                  178:11 185:17                  193:12</p> <p><b>halfway</b> 54:17</p> <p><b>Hampshire</b> 1:11</p> <p><b>hand</b> 29:8 86:12                  108:9 137:3                  145:6 194:19,20</p> <p><b>handbag</b> 123:16</p> <p><b>handful</b> 49:16</p> <p><b>handle</b> 72:2 88:13                  127:17 128:3</p> <p><b>hands</b> 29:3 67:10                  71:13                  163:16,18,21                  166:1,2,11,15</p> <p><b>hang</b> 51:5</p> <p><b>happen</b> 20:19                  121:5 140:14                  148:22 185:13                  186:3 191:16</p> <p><b>happened</b> 80:8,9</p> <p><b>happens</b> 61:8 81:7                  192:11 194:9</p> <p><b>happier</b> 167:17</p> <p><b>happiest</b> 122:1</p> <p><b>happy</b> 26:3 121:17</p> <p><b>hard</b> 53:9,20</p>
--	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 21

<p>54:11 55:6,9          56:1,6,14,19          57:13 58:10,17          60:17 64:18          66:19 80:21          96:17,20 97:16          98:5 101:5,12          115:4,12 146:3          156:12</p> <p><b>harder</b> 64:4          114:16</p> <p><b>hardest</b> 148:4          169:12</p> <p><b>Haston</b> 2:19          175:13 180:5,6          182:20 183:4</p> <p><b>hated</b> 59:22</p> <p><b>hats</b> 124:2</p> <p><b>haven't</b> 7:6 30:16          40:13,14 41:2          87:20 104:15          130:10 133:18          148:2 155:15          162:1,2 167:15          198:18</p> <p><b>having</b> 9:19 13:16          36:13 41:16,17          42:19 44:10          46:3,15 48:18          55:22 57:11          58:18,21 60:12          70:17 78:15          88:10 89:15          92:13 97:13 98:4          102:4 111:16          126:12 127:1          128:11 144:19          148:8 153:6,21          155:8 159:9          169:2 173:4</p> <p><b>Haynes</b> 107:15</p> <p><b>head</b> 71:11 73:3</p>	<p>102:11 122:17          123:5 135:12,15</p> <p><b>headband</b> 139:5</p> <p><b>heads</b> 117:13</p> <p><b>heal</b> 114:16</p> <p><b>health</b> 31:12 43:2          73:10,14 74:18          76:8 151:8,16          187:17 197:14</p> <p><b>healthcare</b> 151:15          171:13,18          176:10</p> <p><b>healthy</b> 106:1          179:19 187:5</p> <p><b>hear</b> 4:19 9:21          10:2,4 15:14,18          16:9 26:19 27:16          32:11,13,17          34:19 36:11          69:22 73:16 77:9          79:18 87:15          101:21 108:13          110:10 136:15          138:13 141:9          143:19 157:3</p> <p><b>heard</b> 8:10 17:3          28:9 67:10,11          69:20 84:9 87:20          94:19,21 101:20          104:15,16          136:5,6 138:4,7          142:12 148:2          151:21 152:12          157:2 162:2          164:2 176:14          187:20</p> <p><b>hearing</b> 28:2          78:14 82:12          125:10</p> <p><b>heart</b> 125:2          127:2,9 170:8</p>	<p><b>heartbeat</b> 170:9</p> <p><b>heartburn</b> 21:13          68:13 111:20          114:3 177:18</p> <p><b>heartburn-related</b>          23:12</p> <p><b>heartwarming</b>          199:14</p> <p><b>heat</b> 64:4,5</p> <p><b>heating</b> 133:20          154:5</p> <p><b>heavy</b> 107:19</p> <p><b>Heidi</b> 187:8</p> <p><b>Hello</b> 174:6          197:13</p> <p><b>help</b> 9:21 15:11          29:1 35:1 38:16          51:19 57:1 59:8          65:7 66:8 94:7          96:18 104:5          109:4 113:5          127:20          132:8,10,13          133:4 134:21          135:7 137:7,10          139:7 141:21          142:8,13 145:17          149:3,13,15          151:1,2 154:1          156:5 159:15          165:17 172:9,18          180:22 188:17          189:16 192:17          198:7</p> <p><b>helped</b> 16:3 60:3          127:22          132:5,19,21          138:22 139:5          145:16 160:20          172:8,11</p> <p><b>helpful</b> 16:20</p>	<p>17:5,19 25:11          38:18 82:22          90:21 94:8</p> <p><b>helping</b> 13:7 16:2          88:3 139:9          141:10 145:20          159:17 163:1          181:3 193:10</p> <p><b>helps</b> 13:21 34:11          62:13 123:15          127:14 133:12          141:19 153:4          161:4</p> <p><b>heme</b> 193:1</p> <p><b>hemin</b> 192:18</p> <p><b>herbal</b> 112:5          115:20 132:3          163:16</p> <p><b>herbals</b> 167:15          198:2</p> <p><b>herbs</b> 112:13          113:19</p> <p><b>hereby</b> 201:3          202:4</p> <p><b>Here's</b> 47:10</p> <p><b>hereto</b> 201:13</p> <p><b>herniated</b> 120:21</p> <p><b>Hershey</b> 182:8</p> <p><b>he's</b> 31:21,22          162:21</p> <p><b>hesitate</b> 171:16</p> <p><b>Hi</b> 5:13 39:8 52:5          59:3 70:14 71:17          82:7 87:21 107:2          124:15 128:15          147:22 159:13</p> <p><b>hide</b> 56:10 76:15</p> <p><b>hiding</b> 60:13</p>
---	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 22

<p><b>high</b> 41:17,18 50:4 98:8 125:3 127:1 129:20 177:15</p> <p><b>higher</b> 79:22 80:2,13 193:6</p> <p><b>highly</b> 195:4</p> <p><b>hill</b> 65:19</p> <p><b>Hippurate</b> 122:18</p> <p><b>Hirschsprung's</b> 71:19 117:22 118:8 119:21 124:11</p> <p><b>hit</b> 45:6 46:15 61:22 94:13</p> <p><b>hits</b> 105:3</p> <p><b>hold</b> 42:19 43:14 134:13 197:4</p> <p><b>holding</b> 179:11</p> <p><b>holistic</b> 132:3</p> <p><b>Holt</b> 2:14 128:15</p> <p><b>Holter</b> 194:2</p> <p><b>home</b> 55:14 147:2 181:17 191:7</p> <p><b>homeopathy</b> 112:4</p> <p><b>homework</b> 94:11</p> <p><b>honest</b> 199:11</p> <p><b>honey</b> 49:18</p> <p><b>honored</b> 59:5 117:20</p> <p><b>hook</b> 121:22 159:22</p> <p><b>hope</b> 28:22 30:2 34:20 36:3 134:13 180:16 185:20 190:2 197:2</p>	<p><b>hoped</b> 47:21</p> <p><b>hopefully</b> 200:18</p> <p><b>hopeless</b> 180:14,15</p> <p><b>hopes</b> 195:18</p> <p><b>Hopkins</b> 146:5,6 162:3</p> <p><b>horrible</b> 53:10 54:15 55:11 73:20 90:3 97:21</p> <p><b>horribly</b> 55:3</p> <p><b>horrifically</b> 178:16</p> <p><b>horror</b> 151:21</p> <p><b>hospital</b> 61:13 74:6 130:9,10 146:13 168:17,20 181:18 190:10</p> <p><b>hospitalization</b> 74:6 121:18 129:8</p> <p><b>hospitalizations</b> 22:13</p> <p><b>hospitalized</b> 41:11 146:6</p> <p><b>hotel</b> 56:16</p> <p><b>hour</b> 41:6 54:12 72:1 89:17,20,21 123:2 131:16 160:4</p> <p><b>hours</b> 40:1 52:7 53:14,15 54:16 57:5,8,11 62:14 72:4 81:19 82:17 84:1 89:18 122:15 123:3,9,14 160:4 182:15</p>	<p><b>house</b> 40:10 51:4 57:17 154:4</p> <p><b>huge</b> 64:12 66:6 138:22 139:10 149:11 151:12 169:11 190:18,19</p> <p><b>human</b> 91:7 168:16 169:3,4</p> <p><b>humans</b> 192:19</p> <p><b>humor</b> 47:7</p> <p><b>hunched</b> 164:16</p> <p><b>hunger</b> 39:17 143:15 148:4,6,9,10,12 164:21</p> <p><b>hungry</b> 52:21,22 53:1 148:22 149:1</p> <p><b>hurt</b> 77:6 79:17</p> <p><b>hurts</b> 53:1,5,6,7,8</p> <p><b>husband</b> 40:9 55:13</p> <p><b>hyoscyamine</b> 48:15 122:13</p> <p><b>hyperglycemia</b> 150:1</p> <p><b>hypersensitive</b> 49:18</p> <p><b>hypnosis</b> 112:20 113:19</p> <p><b>Hypoglycemia</b> 59:16</p> <hr style="width: 20%; margin: 10px auto;"/> <p style="text-align: center;">I</p> <hr style="width: 20%; margin: 10px auto;"/> <p><b>IBS</b> 44:14 83:13 111:17 112:21 113:22 114:22 115:18,22</p>	<p>116:15,21 167:1 170:11 176:18</p> <p><b>ICC</b> 192:21</p> <p><b>ice</b> 133:21 148:20 149:2 164:15</p> <p><b>iceberg</b> 67:21</p> <p><b>I'd</b> 17:12 44:9 45:13 47:22 48:1 60:21 63:9,14 69:21,22 74:14 117:6 131:4 164:12 174:6 175:18 186:9 190:1 194:15,17 197:15,17 198:15,21</p> <p><b>idea</b> 14:7 165:8</p> <p><b>ideal</b> 110:22 134:20 164:4</p> <p><b>identification</b> 75:5</p> <p><b>identified</b> 199:17</p> <p><b>identify</b> 26:8 32:4 109:5</p> <p><b>identifying</b> 74:10 75:1</p> <p><b>idiopathic</b> 9:10 19:12 20:8 23:18 37:14 38:2 131:8 192:20</p> <p><b>IFFGD</b> 176:2,6</p> <p><b>ignorance</b> 200:4,6</p> <p><b>ignore</b> 71:1</p> <p><b>III</b> 19:3</p> <p><b>ileostomy</b> 120:6,12 121:3,4,8,10 183:12</p> <p><b>I'll</b> 4:12 11:9 29:2 84:15 105:14</p>
--	--	---	---



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 23

108:15 136:6 137:13 156:7 174:1 175:10 183:4 199:3,16 <b>illegal</b> 142:2 144:5 <b>illness</b> 43:14 171:15 176:13 186:6 <b>illnesses</b> 95:16 124:7 192:17 <b>I'm</b> 4:3,5,8,22 5:4,10,11,13,16 8:10 11:14 17:16 25:19 27:18 37:12 39:13 40:16,17,22 41:8 42:9,13 43:5 44:2,3 45:14 46:11 48:12 49:18 50:7 51:7,14,15,16,20 ,22 52:19,20 53:2,5,13 54:4,21 55:15 56:5,12 57:11,22 58:5 59:5 61:18 62:22 63:20,22 64:1,17,19 66:12 67:13 68:14 71:11,21 72:2 73:14,17 74:11 75:7 77:14 78:14 79:17,22 80:1,18,19 81:1,10 82:12 83:13 84:17 87:6,9,10 88:21,22 90:7 91:1 92:6 93:1 95:3 96:20 99:3 101:15 102:11 103:16,18 104:1 105:15 106:21	110:1 111:7 115:18 117:19 121:17 124:16 128:15 129:18 130:7,16 133:20 135:15 138:20,21 139:21 140:13 142:8 145:14 147:13,15 148:1,5 149:16,20 150:1,10 151:6,18 154:10,11 155:22 157:14,21 160:9 161:4 163:11 165:15,20 166:1,22 167:14 171:4 173:4 178:3 179:12 183:11,12,22 184:3,13 185:4 186:15 190:9,11,12 192:15 194:14 195:13 197:13,14 200:5 <b>imagining</b> 173:6 <b>immediate</b> 90:8 114:13 117:4,5 140:9 <b>immediately</b> 90:6 125:21 126:9 140:13 144:22 191:9 <b>Imodium</b> 112:11 113:7,20 114:6,14 115:21 <b>impact</b> 19:22 21:21 26:16 33:15 46:5 52:14	69:4 90:19 101:1 <b>impacted</b> 21:22 172:6 <b>impactful</b> 12:21 <b>impactions</b> 120:18 <b>impacts</b> 15:6 187:11 <b>impaired</b> 21:8 <b>impairment</b> 193:22 <b>imperative</b> 179:4 <b>implant</b> 158:1 <b>implement</b> 35:2 <b>implying</b> 20:16 <b>importance</b> 34:15 <b>important</b> 9:14 10:4,7 15:6 17:20 24:18 25:10,16 36:11 38:15 52:8 70:6 94:15 108:16 109:13 122:16 157:19 158:12 163:20 184:18 192:5 197:2 <b>importantly</b> 19:14,22 184:19 <b>impossible</b> 4:10 <b>improve</b> 62:2 108:18 124:9 139:11 173:13 <b>improved</b> 166:20 <b>improvement</b> 125:21 126:2 127:17 138:11 139:1,10 146:16 163:1 <b>improves</b> 24:21	<b>improving</b> 185:6 <b>inability</b> 39:16 69:17 87:4 124:18 <b>inadvertently</b> 120:10 <b>Inborn</b> 5:6,9 8:12 17:17 <b>incapacitating</b> 73:18 74:1 <b>inch</b> 122:7 <b>inches</b> 118:20 <b>include</b> 9:6 93:11 128:6 157:5 179:6 198:10 <b>included</b> 20:3 31:8 112:19,21 128:8 129:1 156:14 <b>includes</b> 41:7 <b>including</b> 18:17 22:18 131:22 132:7 187:13 <b>inclusive</b> 19:8 21:18 <b>incontinence</b> 21:17 105:13 107:11,18 108:4,14 111:21 114:2 116:16 <b>incorrect</b> 22:4 <b>increase</b> 44:4 104:4 135:1 193:8 <b>increased</b> 16:4 161:1 <b>increasing</b> 127:8 150:4 160:15 177:12
--	---	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 24

<p><b>incredible</b> 89:15</p> <p><b>incredibly</b> 19:18 47:14</p> <p><b>IND</b> 146:4 195:9</p> <p><b>independence</b> 152:3</p> <p><b>independent</b> 152:6</p> <p><b>indicate</b> 37:16</p> <p><b>indicated</b> 23:16,19,20,22</p> <p><b>indication</b> 144:2</p> <p><b>indirect</b> 22:15</p> <p><b>indiscernible</b> 86:10 93:22 94:2 95:13 147:12 156:9 161:19 183:1 184:3 193:1</p> <p><b>individual</b> 176:16</p> <p><b>individuals</b> 13:5</p> <p><b>individual's</b> 21:21</p> <p><b>industries</b> 191:19</p> <p><b>industry</b> 11:4 17:1 33:1 187:20</p> <p><b>inertia</b> 39:11 126:9</p> <p><b>infarcted</b> 150:12</p> <p><b>infections</b> 119:5,10 122:20 123:11 159:19 181:13 183:21</p> <p><b>inflammation</b> 116:19</p> <p><b>inform</b> 12:14</p> <p><b>informal</b> 7:20,21</p> <p><b>information</b> 9:13</p>	<p>11:1,8 12:2 13:3,14 14:7 16:12,15 17:8 30:4 31:18 32:5 73:13 105:18 112:21</p> <p><b>informed</b> 179:15</p> <p><b>ingredient</b> 63:17</p> <p><b>ingredients</b> 63:13</p> <p><b>inhaled</b> 91:20</p> <p><b>inhaler</b> 127:19</p> <p><b>inhibitor</b> 137:21</p> <p><b>inhibitors</b> 23:10 132:4 137:16</p> <p><b>initial</b> 115:5 158:3</p> <p><b>initially</b> 158:14,18</p> <p><b>initiative</b> 4:17 6:11 9:1 11:16,18 187:6</p> <p><b>injected</b> 126:18</p> <p><b>injections</b> 41:12 129:3 131:22</p> <p><b>inpatient</b> 129:8</p> <p><b>input</b> 10:19 13:12 14:20 24:17 25:14 29:5 173:18 200:17</p> <p><b>insight</b> 29:7</p> <p><b>insights</b> 17:20 25:11</p> <p><b>insignificant</b> 102:1</p> <p><b>inspire</b> 124:6</p> <p><b>instance</b> 99:7</p> <p><b>instantaneous</b> 145:2</p> <p><b>instigate</b> 76:2</p>	<p><b>instigates</b> 40:5</p> <p><b>instructed</b> 125:18</p> <p><b>insulted</b> 72:16</p> <p><b>insurance</b> 46:19 112:16 126:20 132:13 144:2 151:8,12,20 153:2,4,7,12 159:15 191:20</p> <p><b>intake</b> 49:15 194:7</p> <p><b>intended</b> 8:14</p> <p><b>intense</b> 95:11 143:10</p> <p><b>intent</b> 26:3 34:4</p> <p><b>interactions</b> 21:8 64:8</p> <p><b>interconnected</b> 65:1</p> <p><b>interest</b> 13:10 78:8 174:20,22 177:12</p> <p><b>interested</b> 31:16 95:3 192:11 201:13</p> <p><b>Interestingly</b> 189:18</p> <p><b>interfere</b> 84:7,12 93:22</p> <p><b>interferes</b> 91:10</p> <p><b>intermittent</b> 93:21</p> <p><b>international</b> 19:4 176:1 187:10</p> <p><b>interpretation</b> 75:6</p> <p><b>interrelated</b> 65:5</p> <p><b>interrupts</b> 42:5</p> <p><b>intervention</b> 150:7</p>	<p><b>interventions</b> 9:10 37:11</p> <p><b>intestinal</b> 18:17,18 20:12,15,17 39:11 59:13 64:13 77:8 118:6,15 119:5,9 120:2 121:9 122:21 123:11 124:7 181:10</p> <p><b>intestine</b> 106:8 126:9 133:13 134:10 164:14 165:20</p> <p><b>intestines</b> 118:2 165:7</p> <p><b>intolerant</b> 128:3</p> <p><b>introduce</b> 49:16,17</p> <p><b>introduced</b> 158:14</p> <p><b>investigate</b> 189:4</p> <p><b>investigating</b> 159:8</p> <p><b>investigational</b> 137:9</p> <p><b>invite</b> 54:1,5 66:12 148:15</p> <p><b>invited</b> 54:2 178:5</p> <p><b>inviting</b> 44:11</p> <p><b>involve</b> 13:5</p> <p><b>involved</b> 32:9 199:6</p> <p><b>involves</b> 74:2</p> <p><b>irregularity</b> 45:9</p> <p><b>irreversible</b> 196:10</p> <p><b>irritable</b> 9:7 19:9 20:5 23:17,21</p>
---	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 25

<p>37:9,22 44:12          46:7 47:19 73:9          185:19,21  <b>isn't</b> 57:5 80:19          97:8 107:20          170:14  <b>isolated</b> 131:19  <b>issue</b> 43:2 64:12          76:8 87:13          151:13 152:7          178:7  <b>issues</b> 18:16 33:17          43:11 63:2 65:21          73:10 79:1 82:9          89:14 104:12          112:16 120:15          122:21 124:20          126:12 127:1,8          128:10 150:5          152:2,18 155:4          170:13 174:11          184:2,6 199:18  <b>item</b> 198:15  <b>items</b> 64:7  <b>it's</b> 7:8 9:17 10:3,7          15:13 17:2,20          22:7,22 23:22          25:10,16 27:9          29:13 30:6 34:4          35:8 36:10,18          37:17 38:14          39:4,13 40:10          42:16 43:2,8,13          46:12 48:15,22          49:19 50:2          51:6,19          52:8,16,17,21          53:7,19,20          54:10,13,15,18,1          9 55:5,9,12          56:1,14          57:5,7,10,12,13</p>	<p>58:10,16,17,18          60:19 61:7 62:16          63:11,16,18          64:4,14,18          65:4,11,19          66:7,19 67:6          69:15 70:22          71:1,2,6,7 75:3          76:2,4 77:4          78:11 79:1,15          80:21 81:3 83:2          84:6 85:4          88:6,9,11,15          89:9,10 94:15,18          96:7,15,17,20,21          97:11,15          98:2,5,15,18          102:2,4,7,14,19          103:13 104:13          105:19 106:10          108:10 109:13          113:8 115:5,16          136:12          138:2,8,22          141:10,11,18          142:1          144:1,5,13,14          148:6 149:11          152:16,21          153:10 154:6          156:2 158:12          159:7,16          160:3,22          161:18,19          162:9,10 163:2          167:3,8,10,22          168:4,10 169:18          172:19          173:1,2,9,11,12          178:12,21          183:22 184:7          185:10 189:14          190:5 191:9          194:5,6 196:5</p>	<p><b>IV</b> 40:18 42:2          59:18 61:20 98:4          152:7 168:20,22          183:20 192:18  <b>I've</b> 19:6 20:2 22:9          39:21 40:2 41:14          44:16 48:22          59:5,18 61:16          62:7,8,10 63:5          84:22 90:12          91:19 92:5 96:13          108:14 111:21          114:1 116:1          128:18 129:2          135:18 140:9,21          141:15,16 149:3          151:21 153:9          159:13,14 162:1          168:9 179:11          186:10 199:17</p> <hr/> <p style="text-align: center;"><b>J</b></p> <hr/> <p><b>jam</b> 7:17  <b>January</b> 159:17  <b>jelly</b> 55:20  <b>Jillian</b> 84:17          102:1,10,13  <b>jittery</b> 155:5  <b>job</b> 11:19 46:1          48:19 50:11          55:13 152:6          187:2  <b>John</b> 162:13  <b>Johns</b> 146:5 162:3  <b>Johnson</b> 160:1  <b>join</b> 52:20  <b>joined</b> 8:19 136:3  <b>joining</b> 13:19  <b>joke</b> 79:16</p>	<p><b>joked</b> 52:12  <b>jokes</b> 60:16  <b>joking</b> 60:15  <b>jot</b> 94:14  <b>Journal</b> 187:10          196:20  <b>journey</b> 48:3  <b>J-tube</b> 121:14,21          122:3 133:13,14          148:3  <b>judgment</b> 95:21  <b>juiced</b> 44:1  <b>Julian</b> 2:13 124:15          128:13 163:19          169:9,10,21  <b>July</b> 31:7 52:9          121:18 142:8  <b>June</b> 121:15  <b>justified</b> 200:10</p> <hr/> <p style="text-align: center;"><b>K</b></p> <hr/> <p><b>Katharine</b>          70:13,14 71:6          88:17,18 96:9,12          97:1 104:21          105:2 141:9          149:10,11 162:1          167:19,21  <b>Kelly</b> 2:21 107:2          108:21,22          175:14 187:1,4          189:21 190:7  <b>key</b> 171:19 194:1  <b>kick</b> 110:13          111:13  <b>kickoff</b> 17:7  <b>kicks</b> 127:16  <b>kidney</b> 183:14</p>
--	---	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 26

<p><b>kids</b> 52:12          54:1,6,8          55:8,14,17 56:18          58:20 79:16          190:11</p> <p><b>kid's</b> 57:17</p> <p><b>kilter</b> 127:3</p> <p><b>kinds</b> 81:22 82:1</p> <p><b>kiosk</b> 7:11,13</p> <p><b>knew</b> 27:1 36:5          47:19 68:22          138:9 146:7</p> <p><b>knit</b> 124:2</p> <p><b>knot</b> 165:13,14</p> <p><b>knowledge</b>          192:4,6,8 201:7</p> <p><b>known</b> 135:5          165:17</p> <p><b>Komichers</b> 2:18          175:13 179:10</p> <p><b>KORVICK</b> 144:6</p> <p><b>Kovacs</b> 5:20 93:5</p> <hr/> <p style="text-align: center;">L</p> <hr/> <p><b>lab</b> 150:22</p> <p><b>labeled</b> 58:4</p> <p><b>labeling</b> 63:6</p> <p><b>lack</b> 76:5 136:7</p> <p><b>lactating</b> 196:16</p> <p><b>ladies</b> 73:7</p> <p><b>lady</b> 73:17 122:2</p> <p><b>lagged</b> 177:10</p> <p><b>laid</b> 47:9 72:5</p> <p><b>language</b> 73:15          107:6 108:17          185:6,8,9,10</p> <p><b>laparoscopic</b></p>	<p>119:6</p> <p><b>laparoscopically</b>          160:19</p> <p><b>laparoscopy</b> 106:2</p> <p><b>laps</b> 99:8</p> <p><b>Lara</b> 5:16 93:17          94:15</p> <p><b>large</b> 119:8 157:15          178:14</p> <p><b>largely</b> 44:19          48:17</p> <p><b>larger</b> 13:16          107:22</p> <p><b>largest</b> 137:14</p> <p><b>last</b> 25:19 28:13          53:14 62:4,8          80:9 81:19 84:12          85:11 90:11 92:1          112:7 121:17          131:1 133:15          167:6 197:11          198:15</p> <p><b>lasted</b> 84:1 121:13</p> <p><b>lasting</b> 113:15</p> <p><b>Lastly</b> 200:9</p> <p><b>lasts</b> 71:9 82:16          123:2</p> <p><b>lately</b> 54:7</p> <p><b>later</b> 16:22 77:3          105:5 108:15          120:2,13 121:11          126:21 165:1</p> <p><b>Lauderdale</b>          117:20</p> <p><b>laugh</b> 42:19</p> <p><b>laughed</b> 47:7</p> <p><b>laughing</b> 169:2</p>	<p><b>Laughter</b> 135:20</p> <p><b>laundry</b> 41:2</p> <p><b>Laura</b> 81:13</p> <p><b>Laurie</b> 2:5 5:10          9:11 17:13,15          36:6 37:16 94:16</p> <p><b>laxatives</b> 120:16          121:5</p> <p><b>lay</b> 51:4 72:1,5          122:14</p> <p><b>layer</b> 160:20</p> <p><b>lead</b> 22:3 116:8          117:2</p> <p><b>leading</b> 54:20          127:12</p> <p><b>leads</b> 160:18,20</p> <p><b>leakage</b>          107:14,17,22          108:7 187:12          188:2</p> <p><b>leaking</b> 123:17</p> <p><b>lean</b> 91:15</p> <p><b>learn</b> 6:1 18:13          35:1 42:11 176:9</p> <p><b>learned</b> 48:22          55:19 135:18          169:17 191:3</p> <p><b>learning</b> 46:11</p> <p><b>leash</b> 60:6</p> <p><b>least</b> 14:10 16:14          41:4 47:20 50:19          67:10,12 86:12          106:5 113:1          199:18</p> <p><b>leave</b> 16:11,14          51:4 57:20,21          188:4 198:16</p> <p><b>leaving</b> 51:16</p>	<p><b>led</b> 39:12</p> <p><b>leg</b> 154:2</p> <p><b>legally</b> 183:18,21</p> <p><b>legs</b> 120:12 154:5</p> <p><b>less</b> 40:21 61:21          102:16 104:8          126:13 149:20          160:8</p> <p><b>lessons</b> 54:10</p> <p><b>lethargy</b> 54:8</p> <p><b>let's</b> 50:3 69:19          93:8 100:20          101:21,22          123:16 138:6          142:22 149:5          157:4</p> <p><b>level</b> 74:1 79:21          83:11 177:16</p> <p><b>levels</b> 85:6          98:3,6,8 191:14          192:8 193:6</p> <p><b>Lewis</b> 187:4</p> <p><b>Lexapro</b> 113:4</p> <p><b>licensed</b> 146:4</p> <p><b>lies</b> 194:1</p> <p><b>life</b> 10:3 21:22          24:22 26:17          39:15 42:1          43:3,6 44:20          45:3,5,13          46:5,14 49:5,7          51:7 52:15          60:5,9 62:2,21          66:9,22 69:5          84:19 87:2 90:19          101:1 116:6          118:1,9 120:8          121:20 123:20          124:6,9,21          130:22</p>
--	---	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 27

<p>139:12,14          140:21 141:1          160:3 171:14          173:13 176:20          177:1,9 183:12          186:2</p> <p><b>lifelong</b> 178:16</p> <p><b>life's</b> 50:18</p> <p><b>lifesaver</b> 160:13</p> <p><b>lifesaving</b> 195:17</p> <p><b>lifetime</b> 188:19</p> <p><b>ligament</b> 130:4          150:8</p> <p><b>light</b> 144:8</p> <p><b>lightbulb</b> 12:12</p> <p><b>lightheadedness</b>          143:7</p> <p><b>likely</b> 189:20</p> <p><b>limit</b> 28:18 175:7</p> <p><b>limitations</b> 49:14</p> <p><b>limited</b> 23:14,22          27:2 55:16 100:3          195:6</p> <p><b>linaclotide</b> 23:16</p> <p><b>line</b> 58:8 122:1</p> <p><b>lines</b> 155:1 182:9</p> <p><b>Linzess</b> 133:3          143:9</p> <p><b>Linzess/          Linaclotide</b>          137:11</p> <p><b>Lipoic</b> 193:8</p> <p><b>liquid</b> 98:1,4          107:17 108:8</p> <p><b>liquids</b> 129:22          147:5</p> <p><b>list</b> 14:16,20,21</p>	<p>19:8 21:18 63:17          143:18 179:21          180:3 195:15</p> <p><b>listed</b> 19:7 63:13</p> <p><b>listen</b> 33:6,9          171:19</p> <p><b>listened</b> 185:2          189:22</p> <p><b>listeners</b> 74:20</p> <p><b>listening</b> 6:14 33:2          168:8 188:5</p> <p><b>lists</b> 15:1</p> <p><b>literally</b> 129:15          140:21 182:15</p> <p><b>literature</b> 189:19</p> <p><b>little</b> 4:19 6:1,9          11:15 15:20 21:3          29:7,8,9 40:19          48:1 57:15 61:1          63:1,6 65:7,20          66:7,10 67:18          73:6,15 76:21          91:14 97:15          99:12,13 101:10          103:21 104:16          114:3 115:7          118:11 127:18          133:21 137:15          138:17          139:11,13          153:11 159:6          163:8 180:16          181:4</p> <p><b>live</b> 8:3 15:5 17:20          35:10 42:12          44:13 60:5 61:14          73:19 79:9,20          83:10 88:8          124:6,21 128:16          162:17 164:21          182:16 186:2</p>	<p><b>lived</b> 66:22          84:18,22</p> <p><b>liver</b> 182:1 183:8</p> <p><b>living</b> 7:1 26:5          36:20 42:2 48:17          85:4 187:5          188:10</p> <p><b>lobby</b> 7:13 124:3</p> <p><b>local</b> 125:15          146:10</p> <p><b>locally</b> 44:13          179:22</p> <p><b>located</b> 5:2 7:12</p> <p><b>locations</b> 158:6</p> <p><b>logging</b> 51:22</p> <p><b>logistics</b> 162:18</p> <p><b>Lomotil</b> 112:10</p> <p><b>long</b> 12:13 43:5          48:3 57:14 71:10          85:3,7 90:9 92:7          112:8 124:17          127:4 138:12          177:10</p> <p><b>longer</b> 129:9          182:11</p> <p><b>longest</b> 113:15</p> <p><b>long-term</b> 92:2</p> <p><b>loose</b> 45:16 101:11</p> <p><b>loosing</b> 184:3</p> <p><b>lose</b> 4:11</p> <p><b>losing</b> 106:9</p> <p><b>loss</b> 107:19 128:7          192:21</p> <p><b>lost</b> 4:10 22:18          39:21 62:10          96:13 120:7,16          181:15,16</p>	<p><b>lot</b> 11:3 14:17          18:13 19:15 22:8          42:9,14 45:8,9          46:3,12 49:1          50:10 51:16          53:22 61:3,4,15          62:10 65:20 66:7          73:3 75:16 77:18          78:4 81:5,18          82:14,16 83:4          88:12 92:15,22          94:21 96:4,17,22          102:11 104:3          108:14 109:22          110:8,9 119:13          130:18 136:5          141:10 148:19          164:7 165:3          167:2,13 168:9          170:16 172:18          180:14 184:2,6          195:19</p> <p><b>Lotronex</b> 137:18</p> <p><b>lots</b> 81:4 96:3          118:7 145:4          156:12</p> <p><b>love</b> 41:4 60:21          63:22 111:13</p> <p><b>loved</b> 32:12          36:12,16 38:4          68:7 100:13</p> <p><b>low</b> 82:10 92:21          114:17 115:3          184:1</p> <p><b>lower</b> 9:5 65:2,5          77:21 98:22          100:9,13 103:7          107:5,11,15          150:3 197:1</p> <p><b>lubiprostone</b>          23:16</p> <p><b>luck</b> 139:22 140:1</p>
--	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 28

<p><b>Luckily</b> 57:20  <b>lucky</b> 57:22  <b>lunch</b> 90:10  <b>luncheons</b> 50:11  <b>lung</b> 124:20  <b>lungs</b> 53:8 119:10      125:1  <b>Lustgarten</b> 190:14  <b>Lynn</b> 2:12 71:17      73:2 99:1      117:17,19      124:14 147:21      148:14</p> <hr/> <p style="text-align: center;"><b>M</b></p> <hr/> <p><b>magic</b> 144:16      149:21 150:15      179:13  <b>magnesia</b> 118:9  <b>magnesium</b>      122:22  <b>main</b> 6:17 174:12  <b>mainly</b> 157:7  <b>maintain</b> 66:20      115:5  <b>major</b> 45:18 46:15      50:7,19 130:15      152:2  <b>majority</b> 178:22  <b>male</b> 36:4  <b>malfunctions</b>      162:19  <b>malnourished</b>      133:8  <b>malnutrition</b>      96:13,22 120:22  <b>manage</b> 121:20</p>	<p>156:6  <b>manageable</b> 78:1  <b>managed</b> 88:13      116:1 136:12      165:15 166:8      168:20,22 169:1      179:12  <b>management</b> 23:4      156:16,19 157:1      163:21 198:9  <b>managing</b> 51:7,14      62:1  <b>manner</b> 193:19  <b>March</b> 159:20  <b>marijuana</b> 141:20      145:8,10,13,17  <b>Marilyn</b> 2:17      175:12 178:2,3      179:8 185:14,20  <b>Marinol</b> 129:4,17      132:2 141:20      143:22      145:6,7,15  <b>mark</b> 175:9  <b>market</b> 12:8      129:11 132:20      150:15 151:16  <b>married</b> 118:20      123:20  <b>Mary</b> 3:3 83:5      84:2,5,9 146:2      147:20 160:11      161:6 162:13      175:14 192:14      194:10  <b>massage</b> 99:10,11  <b>math</b> 124:2  <b>matter</b> 6:18 26:15      42:17 53:19</p>	<p>54:18 72:7      133:17 141:14      200:21  <b>matters</b> 13:8  <b>Mature</b> 187:5  <b>maximum</b> 132:18  <b>may</b> 1:7 33:6,7      39:3 73:15 77:5      85:3 86:7 95:2      97:9 103:20      114:15 116:8      121:15 170:17      172:19      174:20,22 177:1      179:22 187:19  <b>maybe</b> 15:15 17:6      42:6 64:2      66:3,4,22 75:11      83:20 93:11 94:6      95:11,20      106:5,14 137:11      159:4 171:7      185:22 197:6  <b>Mayo</b> 121:19      192:19 193:3  <b>MD</b> 1:12  <b>meal</b> 64:1 69:18      90:1 125:2,6  <b>meals</b> 86:22 140:7  <b>mean</b> 49:20 53:5      58:6,9 70:7 83:9      85:1 88:4 94:4      97:20,22 106:11      109:11 110:3      140:10 147:10      148:17 154:5      156:11 169:2,12      170:5  <b>means</b> 38:7 92:21      95:22 114:19</p>	<p><b>meant</b> 29:12 130:5      150:17  <b>measure</b> 24:20      78:12 85:12  <b>measurements</b>      25:4  <b>measures</b> 18:20  <b>measuring</b> 78:21  <b>mechanism</b>      188:7,17,21      189:4  <b>med</b> 116:22 134:1  <b>median</b> 130:4      150:8  <b>Medicaid</b> 151:17      152:4  <b>medical</b> 5:17 12:7      22:2 56:20 75:7      123:22 151:10      157:13 167:22      169:17 185:1,9      197:15      198:5,7,8,11      200:4,10  <b>Medicare</b>      151:21,22 152:5  <b>medication</b> 24:3      48:14 52:20      61:18,20,21 66:4      123:3 129:12      148:7,9 153:17      168:21 169:1      172:13 197:4  <b>medications</b>      22:14,21 61:16      65:7 104:3,5      118:22 132:6,7      145:12 150:21      151:7 153:9      158:7,10 172:22</p>
--	---	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 29

<p>183:15 191:22  <b>medicine</b> 49:20,22        88:2 111:22        112:1,13        116:4,10,11,14        117:4 127:6        154:1 191:4  <b>medicines</b> 157:7        170:15  <b>meditate</b> 49:2  <b>meditation</b> 112:22  <b>meds</b> 75:2 112:3        116:17 183:16  <b>Medtronic</b> 160:16  <b>meet</b> 12:9  <b>meeting</b> 1:4 4:7,15        6:14 7:4,21        8:2,9,20 9:14        11:7,17 13:16,18        15:3 16:7,13        25:22 26:2 29:21        30:17 35:1 44:10        54:3 69:15 70:17        128:12 172:16        175:3 197:16        199:20  <b>meetings</b> 8:22        10:16 13:13        14:6,10 15:11,20        16:3,7,19 17:4        25:10 35:3 80:10        81:5 136:4        197:20 198:4  <b>members</b> 175:19  <b>memory</b> 80:14  <b>men</b> 36:9,11  <b>Mend</b> 132:13  <b>mention</b> 76:20        110:4 148:2</p>	<p>158:1,12 170:4  <b>mentioned</b> 19:8        20:10,15 29:18        33:3 36:7 60:12        61:12 62:15,21        93:5 100:7 101:4        104:11 151:9        152:19,21  <b>menu</b> 50:10  <b>Meredith</b> 2:14        91:2,3 93:5,11        96:3 103:2,3        128:14,15 131:3        138:8 149:19,20        153:21        154:15,16 166:6  <b>Mestinon</b> 132:3        138:18 139:17  <b>metabolism</b> 127:3  <b>metabolizer</b>        168:18  <b>Methenamine</b>        122:18  <b>methods</b> 193:17  <b>Metoclopramide</b>        196:22  <b>Metocloprimde</b>        23:19  <b>metro</b> 35:11,12  <b>Michael</b> 1:18        201:2  <b>MICHALE</b>        201:18  <b>microphone</b> 4:13        66:16  <b>microphones</b>        28:11  <b>mid</b> 178:13  <b>middle</b> 4:11</p>	<p>38:8,20 88:21        127:4  <b>mike</b> 5:3 17:12        175:16  <b>mikes</b> 70:9  <b>milk</b> 118:9  <b>milligrams</b> 144:17        146:14,17        147:1,8,10  <b>million</b> 178:9,11        185:17  <b>millions</b> 188:12  <b>mind</b> 33:8 68:14        151:2 174:15  <b>mine</b> 139:8  <b>minerals</b> 112:6        114:11  <b>Mine's</b> 167:21  <b>minimal</b> 132:18  <b>minimally</b> 121:21  <b>minimize</b> 122:12  <b>minimum</b> 99:2  <b>Minnesota</b> 121:19  <b>minorities</b> 167:1  <b>mint</b> 41:20  <b>minutes</b> 4:21 7:10        9:2,13 27:6 28:4        67:5 68:9 101:7        111:12 125:16        163:10 171:3        175:4 178:1        194:11 199:2  <b>misdiagnosed</b>        179:1  <b>misdiagnoses</b>        179:4  <b>misdiagnosis</b> 22:3</p>	<p><b>miserable</b>        90:14,18 154:11  <b>misery</b> 90:15  <b>misinterpret</b>        74:17  <b>mispronounce</b>        175:11  <b>miss</b> 45:15 140:12  <b>misses</b> 135:17  <b>missing</b> 95:22  <b>mission</b> 186:1  <b>misunderstanding</b>        22:2 75:10  <b>mitochondria</b>        193:9  <b>mitochondrial</b>        184:4  <b>mitrochondrial</b>        59:10  <b>mix</b> 146:21  <b>mixed</b> 19:11  <b>moan</b> 92:21  <b>mode</b> 33:2  <b>models</b> 192:20  <b>modification</b>        198:1  <b>modifications</b>        129:5  <b>modify</b> 43:9  <b>mold</b> 63:16  <b>mom</b> 54:9 146:11  <b>moment</b> 88:19        134:2 184:16  <b>Mommy</b> 79:17  <b>mommy's</b> 55:22  <b>Monday</b> 1:7</p>
---	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 30

<p>81:9,10  <b>money</b> 124:3          190:15  <b>month</b> 16:14          129:7 151:19  <b>month-long</b>          111:17  <b>months</b> 61:14          115:8 119:14          120:12 123:13          126:1,4 130:13          133:20 142:9          168:3 182:11  <b>mood</b> 194:8  <b>moody</b> 46:9  <b>moon</b> 40:9  <b>morning</b> 55:12,14          56:15 88:20 99:7          139:4 189:8  <b>mornings</b> 55:11  <b>mostly</b> 44:21 46:9          49:10 94:5,6  <b>mother</b> 157:21          184:13 187:21  <b>motile</b> 136:7  <b>motility</b> 18:17          61:7 64:15          134:10 135:1          190:15  <b>motivation</b> 115:14  <b>motor</b> 193:14,22  <b>mouth</b> 48:18          93:13 123:18          144:14 153:7          168:21  <b>move</b> 25:20 28:5          29:2,16 38:21          39:5 53:6 65:7          68:14 70:21 76:1</p>	<p>87:8,10 88:7          92:9 96:11 98:21          102:4 103:21          106:6,22 109:1          125:4 128:1          143:19 153:15          156:1 164:8          173:21  <b>movement</b> 64:20          133:5  <b>movements</b> 45:17          107:19  <b>movie</b> 139:4  <b>moving</b> 64:15,16          65:6 92:6 102:19          165:5 174:8  <b>Mulberg</b> 3:7 5:7,8          85:11 198:22          199:1  <b>Muldowney</b> 2:5          5:10 9:11          17:15,16 81:14          94:17  <b>Mullin</b> 2:4 5:13          8:22 11:10,13  <b>multi</b> 136:7  <b>multiple</b> 37:17          62:9 94:12 114:1          119:9 120:16          127:12 129:2          177:8 194:6  <b>muscle</b> 59:14          132:1  <b>muscles</b> 41:8          139:1 165:6,12  <b>myoclonus</b> 59:16  <b>myself</b> 40:15          51:16 55:2 57:13          60:16 62:13          97:22 124:20</p>	<p style="text-align: center;">—————          N          —————</p> <p><b>NAC</b> 193:7  <b>naked</b> 106:1  <b>name's</b> 70:14 82:7  <b>Nancy</b> 2:20 175:13          184:11 186:22  <b>nap</b> 99:2 123:7  <b>narrowly</b> 33:15  <b>national</b> 185:13          190:4  <b>nationally</b> 190:3  <b>naturopath</b>          114:9,14,17  <b>nausea</b> 21:9,14          39:16 41:21          42:10 58:16,18          68:12,18          69:10,15          87:15,17          88:1,4,14,15,18          89:6,8,13,16          90:9,11,14          91:2,4,5,6,9,11,1          9          92:2,11,14,17,20          93:19 94:5 97:4          114:4 120:13          124:18 126:14          128:17          129:1,12,14,18          130:1,2 131:11          132:8,9,13          134:22 135:7          144:22 145:15          152:14,16 154:1          168:15,16 169:1          177:19  <b>nauseated</b> 121:22  <b>nauseating</b> 144:13</p>	<p><b>nauseous</b> 52:19          88:7,22 89:22          98:15 102:14          140:13 142:1  <b>navigating</b> 26:6  <b>nearest</b> 91:16  <b>nearly</b> 188:19  <b>necessarily</b> 24:17          51:6 107:21,22          149:7  <b>necessary</b> 24:13          97:7  <b>needless</b> 140:13  <b>needling</b> 163:16          164:11,12,18,22  <b>negative</b> 42:17          141:8 196:15  <b>neither</b> 143:9          201:8  <b>nerves</b> 21:4          120:10  <b>nervous</b> 21:2,5          44:21 188:9          189:9  <b>networks</b> 30:18  <b>neuro</b> 160:12          161:12  <b>neurogenic</b> 120:11  <b>neurological</b>          152:21 155:4,7,8          189:10 196:10  <b>neurologist</b>          138:19  <b>neuropathy</b>          120:11  <b>Neuropeptides</b>          194:2  <b>newer</b> 158:20</p>
--	--	--	---



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 31

<p><b>Nexium</b> 153:6  <b>nice</b> 38:7 49:9,13      64:2 146:11      187:2  <b>nicely</b> 157:2  <b>nicer</b> 151:11  <b>niece</b> 139:2  <b>night</b> 42:4 54:17      57:2 62:4 72:22      84:7,13 88:21      139:3 159:22  <b>nighttime</b> 84:10  <b>NIH</b> 107:13  <b>nine</b> 38:11 54:8      56:3 82:21      133:15  <b>Ninety</b> 35:22  <b>Nissen</b> 119:6  <b>nitrate</b> 122:5  <b>NJ</b> 146:18 147:2  <b>nobody</b> 54:14 57:1      88:14 108:12,13  <b>nodding</b> 117:13  <b>nods</b> 71:11 73:3      102:12  <b>nominations</b>      186:11,12  <b>non-celiac</b> 193:21  <b>none</b> 112:6 116:2      125:12 132:4      161:7  <b>non-functioning</b>      120:20  <b>non-invasive</b>      192:2  <b>non-pharmaceutical</b></p>	<p>99:15  <b>non-profit</b> 187:5  <b>nor</b> 201:9,13  <b>normal</b> 20:17,18      40:3 43:2 54:9      61:5 124:21      135:3 173:5      182:2 188:15  <b>normally</b> 129:19  <b>Notary</b> 201:1,19  <b>note</b> 68:4 103:19      174:19 196:19      197:20  <b>notes</b> 196:21 202:7  <b>nothing</b> 43:1 46:4      49:7 53:18 72:10      116:10 119:2      122:6 123:12      124:22 125:13      140:7 145:1      156:20 159:10      167:12  <b>notice</b> 151:5 163:7  <b>noticed</b> 138:11  <b>nourished</b> 134:4  <b>novel</b> 192:16  <b>Nowadays</b> 64:4  <b>NPY</b> 194:3,6,9  <b>nudge</b> 175:9  <b>numerous</b> 61:17      134:3  <b>nurse</b> 123:14  <b>nurses</b> 74:7  <b>nutrition</b> 40:19      42:2 59:19      98:5,17 128:1      152:7</p>	<p><b>nutritional</b> 96:6  <b>nutritious</b> 51:15  <hr/> <b>O</b>  <hr/> <b>Oak</b> 1:10 8:17  <b>objective</b> 18:19  <b>obsessed</b> 115:14  <b>obstruction</b>      121:9,15 181:10  <b>obstructions</b>      118:6  <b>obtain</b> 179:22  <b>obtaining</b> 146:3  <b>obviously</b> 93:19      116:14  <b>occasion</b> 45:15  <b>occasionally</b> 30:9      86:1  <b>occasions</b> 149:1  <b>occur</b> 9:4 115:10  <b>occurrence</b> 45:10  <b>occurs</b> 123:13  <b>o'clock</b> 7:16,19      99:3,18  <b>October</b> 124:22  <b>offer</b> 7:3  <b>office</b> 4:3 5:14,21      8:13 15:11      31:12,13,14      49:10 199:5  <b>officer</b> 201:2  <b>officially</b> 151:10  <b>Off-label</b> 24:3  <b>oh</b> 46:2 52:21 57:6      58:5      60:11,19,20,21      61:19 63:10</p>	<p>64:14 65:12 66:2      71:16 76:6 79:17      80:19 97:17      103:17 145:3      153:8 173:4  <b>oil</b> 63:13,15      115:20  <b>oils</b> 63:3  <b>okay</b> 35:5,16 61:6      62:17 66:3 77:4      78:5 83:16 98:20      101:6 103:9,16      105:2 106:19,20      137:4 143:4      145:22 149:18      154:14,20      161:19,20      166:14 181:19      183:2  <b>old</b> 49:13 78:3      118:17 119:18      169:12  <b>older</b> 38:18  <b>Oley</b> 60:3  <b>Olympic</b> 99:8  <b>omentum</b> 160:20  <b>one-drug</b> 194:5  <b>ones</b> 10:12      12:15,16 26:16      32:12 98:2      137:22 156:18      157:4 193:18  <b>one's</b> 38:4 71:4  <b>one-time</b> 97:8  <b>ongoing</b> 82:16      83:3 124:19      128:9  <b>onto</b> 59:22  <b>opaque</b> 179:18</p>
--	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 32

<p><b>open</b> 6:21 7:2          16:11,14 26:4          31:7 33:3          163:9,14 173:21          174:3,8</p> <p><b>opening</b> 4:21</p> <p><b>opens</b> 162:11</p> <p><b>opiate</b> 134:1</p> <p><b>opinion</b> 171:17</p> <p><b>opinions</b> 34:13,14</p> <p><b>opportunities</b>          189:3</p> <p><b>opportunity</b> 6:6          15:14,19 30:10          131:6 135:9          174:10,13 176:3</p> <p><b>option</b> 128:2</p> <p><b>options</b> 23:4,15          24:10 134:12          167:5,13,17          169:6 183:14          184:7 192:17</p> <p><b>oral</b> 50:1</p> <p><b>order</b> 7:9 19:5          61:10 175:10          176:12</p> <p><b>ordinary</b> 62:14          187:20</p> <p><b>organ</b> 105:22          106:16 181:20</p> <p><b>organization</b> 32:2          60:2 175:22</p> <p><b>organized</b> 15:8</p> <p><b>organs</b> 106:10          182:16</p> <p><b>originally</b> 59:20</p> <p><b>osmotic</b> 114:19</p> <p><b>osteoporosis</b></p>	<p>183:16</p> <p><b>ostomy</b> 72:6          121:16 123:17</p> <p><b>others</b> 11:5 16:1          30:16 32:14 33:1          37:19 38:15          76:19 109:16          113:1 124:6,10          131:14 136:13          152:21</p> <p><b>otherwise</b> 37:1          137:13 201:13</p> <p><b>outcome</b> 201:14</p> <p><b>outcomes</b> 22:5          24:14,19 108:18</p> <p><b>outlandish</b> 43:13</p> <p><b>outpatient</b> 22:9</p> <p><b>outside</b> 35:12,22          56:2 98:10,11          166:16 195:10</p> <p><b>outweigh</b> 11:20          57:19</p> <p><b>outweighs</b> 9:19</p> <p><b>overall</b> 59:11          163:21</p> <p><b>overgrowth</b> 103:6</p> <p><b>overlap</b> 19:15</p> <p><b>overlooked</b> 77:2</p> <p><b>over-the</b> 156:13</p> <p><b>over-the-counter</b>          23:6 112:3 133:4          156:20 157:4,10          197:22</p> <p><b>over-the-counters</b>          157:12</p> <p><b>overview</b> 23:3</p> <p><b>overwhelming</b>          94:20 110:6</p>	<p>179:19</p> <p><b>owned</b> 43:4</p> <p><b>oxidative</b> 193:4,10</p> <p><b>oxygenase</b> 193:2</p> <hr/> <p style="text-align: center;">P</p> <hr/> <p><b>p.m</b> 109:19</p> <p><b>PAC</b> 170:6</p> <p><b>pace</b> 135:5</p> <p><b>pacemakers</b>          152:14</p> <p><b>pacer</b> 135:5          158:2,12</p> <p><b>pacing</b> 154:4</p> <p><b>pack</b> 133:21</p> <p><b>packed</b> 7:17</p> <p><b>pad</b> 133:21</p> <p><b>pads</b> 154:5</p> <p><b>page</b> 2:2 26:13</p> <p><b>pain</b> 19:13 20:19          21:9,13 39:15,17          40:1 41:14          42:10,13 44:2          45:14          52:15,16,20          53:13,16          58:3,5,9,18          60:10,12,15,18          61:12,17,20,21          63:4 65:21          68:13,19          69:7,8,16,20          70:1,5,18,19,20,          22 71:7,10,12          72:9,11,13          73:16,22          74:1,5,8,9,12,15,          16,21,22          75:2,14,15,17,18</p>	<p>,19          76:2,3,6,7,15,16,          22          77:5,6,7,10,17,2          0,22          78:2,3,13,14,16,          17,18          79:3,4,5,10,14,1          5,19 80:9,12          81:1,19,21,22          82:3,13,20          83:1,7 84:20          85:1,5,7,12,16,2          0,21,22 86:5,6,9          87:8,18 91:10          92:18 98:14          101:12 102:6,18          104:4 105:4          107:9 111:20          113:14 114:3          116:17 118:7,13          119:12,13          120:13,17          122:15 123:1,8          124:18,20          130:1,5 131:12          133:22 134:1          135:2 143:7,10          145:14          148:5,11,12,18,1          9 149:4          152:17,20          164:21          168:15,20          172:12 177:19          191:6,11</p> <p><b>painful</b> 20:22          84:21 85:3 102:2          103:12 165:14</p> <p><b>pains</b> 72:1,2 82:1          115:9 119:9          121:14</p> <p><b>pain's</b> 42:20</p>
---	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 33

<p><b>palpitations</b> 113:13 170:6</p> <p><b>pancreas</b> 181:22</p> <p><b>pancreatic</b> 63:2 77:1 194:3</p> <p><b>pancreatitis</b> 59:14 63:4</p> <p><b>panel</b> 27:16,22 93:2 104:19 109:5 111:5 136:6 143:16 171:5 179:11 189:9</p> <p><b>panelists</b> 16:10 28:3 109:20 110:13 139:21 199:10</p> <p><b>panic</b> 189:12,18</p> <p><b>pants</b> 53:11</p> <p><b>Panus</b> 3:6 175:16 197:12,13,14</p> <p><b>papers</b> 49:9</p> <p><b>paralysis</b> 102:19 105:22</p> <p><b>paramount</b> 34:14</p> <p><b>parent</b> 43:5 190:22</p> <p><b>parents</b> 54:5 61:9 152:4 191:13,16</p> <p><b>park</b> 40:15</p> <p><b>Parkinson's</b> 189:15</p> <p><b>participants</b> 87:2</p> <p><b>participate</b> 7:5 176:20</p> <p><b>participating</b> 6:5 30:10 111:7 155:13</p>	<p><b>participation</b> 15:16 16:5</p> <p><b>particular</b> 13:7,8,15 14:9 15:21 26:8 107:4,10 108:3 144:9</p> <p><b>particularity</b> 13:11</p> <p><b>particularly</b> 20:5 24:18 32:1 95:2</p> <p><b>parties</b> 201:10,12</p> <p><b>Partnership</b> 191:16,19,20</p> <p><b>partnerships</b> 200:12</p> <p><b>party</b> 54:2</p> <p><b>Pasinkoff</b> 2:15 87:21,22 131:4,7 153:22 154:10</p> <p><b>pass</b> 42:14 128:20</p> <p><b>passing</b> 64:19</p> <p><b>past</b> 68:7 100:14 113:22 126:17 140:10 166:5 177:12</p> <p><b>pathways</b> 189:16,17</p> <p><b>patient</b> 4:17 6:19 8:16 10:12 13:4 16:1,16 18:22 20:20 25:2 28:7 29:17 31:5,15 32:2 44:12 47:21 60:2 74:21 80:16 107:12 157:21,22 171:13 174:14 175:22 179:12 180:8 182:4</p>	<p>184:20 185:3,22 200:14</p> <p><b>Patient-Focused</b> 1:5 4:16 8:8,21 11:11 14:4 35:3</p> <p><b>patient-reported</b> 24:14,19</p> <p><b>patients</b> 6:18 7:1 8:16 9:22 12:11,13,15 13:5,6,12 15:14,18 17:3 18:6,12 19:16 21:6,8 22:5 24:4,9,18,22 25:7,12,21 27:16,17 28:6 29:16 32:10,17 94:22 124:2 136:17 157:15 175:6,19 176:7 177:15 178:22 180:13,21 193:13 195:18 196:8 197:3,8,18</p> <p><b>patient's</b> 185:9</p> <p><b>Patients</b> 21:22</p> <p><b>pay</b> 57:8</p> <p><b>paying</b> 151:18</p> <p><b>PCA</b> 60:7 61:18 62:4</p> <p><b>PDUFA</b> 14:12</p> <p><b>peak</b> 147:16</p> <p><b>peanut</b> 55:20</p> <p><b>pebble</b> 72:18</p> <p><b>pediatric</b> 38:17 190:9 200:5</p> <p><b>peers</b> 30:18 67:16</p> <p><b>Pennsylvania</b></p>	<p>56:21</p> <p><b>people</b> 16:12 19:20 30:1 36:9 43:7,8 46:10,12 47:1 48:4 51:11,21 70:7 75:7,18,20 76:1,9 77:19,21 79:13,14 81:15 82:13 83:15 85:4,13,20 86:19 88:5 90:13 92:16 93:4 94:5,6 103:11 107:7,10,18 108:5 132:15 134:17 141:10 143:7,12 144:7,10 145:9,16 152:2,13 158:13 159:8 163:11,14 166:11 167:3 169:19 170:16 175:4 180:15 181:1 182:12 184:22 185:7 187:3 188:1,17 190:6 194:18,22 195:2,6 196:12,16 197:2</p> <p><b>people's</b> 26:4 85:16</p> <p><b>Peptamen</b> 122:8</p> <p><b>per</b> 133:15</p> <p><b>perceive</b> 20:21 102:15,16</p> <p><b>percent</b> 35:22 37:21,22 38:1,2,11,12,13 51:21 90:8 101:11,13,14 120:20 133:2</p>
---	---	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 34

<p>137:20,21          156:20 195:1  <b>perception</b> 18:18          20:12,16  <b>perceptions</b> 85:16  <b>perfect</b> 142:17  <b>perfectly</b> 106:1  <b>perforation</b> 106:5  <b>performing</b>          131:18  <b>perhaps</b> 26:9          75:6,9 135:7          157:20 185:10  <b>period</b> 40:7 85:3,8          159:20 196:11  <b>periodically</b> 29:2          30:6  <b>periods</b> 54:16          123:7  <b>peristalsis</b> 118:5  <b>perk</b> 159:5  <b>permanent</b> 112:7          116:11 121:2          155:7 162:10          163:4  <b>permission</b> 99:18          163:12 179:17  <b>peroxidase</b> 193:9  <b>persistent</b> 9:3,8          37:10  <b>persists</b> 9:9  <b>person</b> 6:3 25:19          30:1 36:19,20          38:8 39:6          43:10,15 78:2          91:14 92:19          126:19 135:3          152:17 161:12</p>	<p>172:9  <b>personal</b> 26:4          34:13 176:17          178:8,12  <b>personally</b> 102:15  <b>person's</b> 176:20  <b>perspective</b> 4:18          6:19 7:3 13:20          32:11 46:10          71:14 98:20          109:3 171:10  <b>perspectives</b> 16:10          26:10 32:13,16          38:16 76:12  <b>pharma</b> 200:13  <b>pharmaceutical</b>          27:11 111:2,4          136:22 138:15          149:9 156:2          171:8 189:3  <b>pharmacies</b> 146:8          179:21          195:11,16 197:7  <b>pharmacist</b>          194:15  <b>pharmacotherapi</b>  <b>es</b> 199:21  <b>pharmacy</b> 146:10          158:9  <b>Phenergan</b> 129:4          141:16 155:2  <b>Philadelphia</b>          56:22 57:3          190:11  <b>phobia</b> 191:10  <b>phone</b> 30:13,14          100:2,3,4 101:8          106:19,20          111:7,9 155:12</p>	<p>161:7,8 168:12          169:21 171:1  <b>phones</b> 30:8  <b>physical</b> 91:7  <b>physically</b> 4:9          22:1 64:16 93:8          119:15  <b>physician</b> 162:13          171:18 188:14          189:1 199:13  <b>physicians</b> 172:19          200:15  <b>pick</b> 41:20 48:11          146:11 198:17  <b>picked</b> 46:20          101:18  <b>pieces</b> 63:8,11          66:7  <b>pill</b> 47:22 50:1  <b>pilot</b> 14:6  <b>Pittsburgh</b> 172:10          181:19 182:8,9  <b>pivotal</b> 10:20  <b>placed</b>          133:9,11,13  <b>plan</b> 54:16,22          104:8 152:4  <b>planning</b> 109:3  <b>plans</b> 151:15  <b>plate</b> 50:9 122:7  <b>play</b> 57:18  <b>playing</b> 29:20  <b>please</b> 7:19          28:12,16,18          29:17 30:12          32:4,21 37:1          51:12,17 78:6          92:12 99:19</p>	<p>135:21 137:7          139:20 164:1          173:19 174:15          175:5,17          182:18,21          184:11 194:11          197:5 198:19  <b>pleasure</b> 35:19          53:16  <b>plug</b> 105:17          106:10 174:2  <b>plus</b> 115:21          122:10  <b>point</b> 31:11 48:18          49:6 55:12 90:1          92:1 109:13          110:6 133:19          142:16,17          160:22  <b>pointed</b> 84:3  <b>points</b> 43:18 91:18          150:20 164:18          165:2,4,18          184:17 186:9  <b>poisoning</b> 42:11  <b>polling</b> 29:6,9,13          35:6 67:20 137:1          156:1  <b>polypeptide</b> 194:4  <b>pool</b> 99:8  <b>poor</b> 116:18,19          168:18  <b>popular</b> 87:9  <b>population</b> 108:18          163:1 176:9          178:6 179:5          189:6 193:20  <b>populations</b> 38:18  <b>port</b> 54:13</p>
--	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 35

<p><b>position</b> 12:14</p> <p><b>positioned</b> 12:19</p> <p><b>positive</b> 42:16 116:9 119:20 179:21 180:3 195:15</p> <p><b>possibility</b> 117:1</p> <p><b>possible</b> 127:19 140:2 174:2</p> <p><b>possibly</b> 132:12 183:20</p> <p><b>posted</b> 16:18 32:6</p> <p><b>pot</b> 125:19</p> <p><b>pounds</b> 40:17,18,21 96:14 118:20 125:5 181:16</p> <p><b>powder</b> 122:5 146:9</p> <p><b>powerful</b> 199:8</p> <p><b>PPIs</b> 129:4 141:16</p> <p><b>practically</b> 168:6</p> <p><b>practice</b> 29:11 112:22 187:11</p> <p><b>pray</b> 171:17</p> <p><b>pre</b> 196:17</p> <p><b>pre-diabetic</b> 150:1</p> <p><b>predict</b> 50:16</p> <p><b>predominant</b> 19:11 111:17</p> <p><b>Preeti</b> 5:18</p> <p><b>prefer</b> 122:14</p> <p><b>pregnant</b> 53:5 119:5,14 133:20</p> <p><b>prep</b> 103:22</p> <p><b>prepare</b> 111:12</p>	<p>142:13</p> <p><b>prepared</b> 28:4 64:7 176:5 180:22</p> <p><b>prescribe</b> 48:14 133:22 141:13</p> <p><b>prescribed</b> 24:4 114:10 126:10 132:16 149:12</p> <p><b>prescriber</b> 146:4</p> <p><b>prescription</b> 23:13 112:3 120:16 137:9 197:22</p> <p><b>prescriptions</b> 195:7</p> <p><b>present</b> 95:12 119:22 176:3</p> <p><b>preservatives</b> 44:5</p> <p><b>president</b> 180:7</p> <p><b>pressure</b> 119:11 125:3</p> <p><b>pressures</b> 61:6</p> <p><b>pretty</b> 46:1 86:18 155:17 166:8</p> <p><b>pretzel</b> 52:18</p> <p><b>Prevacid</b> 119:1</p> <p><b>prevalence</b> 20:3</p> <p><b>prevalent</b> 190:6</p> <p><b>prevent</b> 116:18</p> <p><b>previous</b> 144:8</p> <p><b>Prilosec</b> 119:1 137:21</p> <p><b>primarily</b> 95:7</p> <p><b>primary</b> 6:22 28:17 45:20</p> <p><b>prior</b> 122:13 133:5</p>	<p><b>PRNs</b> 129:17</p> <p><b>probably</b> 7:9 39:5 45:7 46:2 55:18 113:15 157:11 166:16 193:21 195:8</p> <p><b>probiotic</b> 46:2 115:19</p> <p><b>probiotics</b> 114:10 127:20</p> <p><b>problem</b> 50:2 54:7 58:7 75:6 142:4 148:8 149:12 159:7 170:8 197:4</p> <p><b>problems</b> 41:14 76:14 82:15 104:12 140:15</p> <p><b>procedures</b> 22:4</p> <p><b>proceeding</b> 201:3 202:6,7,10</p> <p><b>proceedings</b> 201:4,6</p> <p><b>process</b> 6:15 10:8,16 14:19 164:13 167:8 174:19 179:18</p> <p><b>produce</b> 16:6</p> <p><b>producing</b> 199:6</p> <p><b>product</b> 63:19 139:16 145:20 155:14,16 187:19</p> <p><b>productive</b> 149:17</p> <p><b>products</b> 5:6,9 8:12 17:18 112:11 133:4 138:5 197:22</p> <p><b>profession</b> 73:14</p>	<p>185:1</p> <p><b>professional</b> 31:20 171:13</p> <p><b>professionals</b> 74:19 124:8</p> <p><b>profile</b> 197:1</p> <p><b>profound</b> 200:2</p> <p><b>program</b> 13:4 14:12,13 31:15 186:13,19 195:9</p> <p><b>programs</b> 4:4 5:14 14:1 24:9 199:5</p> <p><b>progress</b> 180:17 189:12</p> <p><b>progressed</b> 59:21 188:20</p> <p><b>progresses</b> 92:21</p> <p><b>progression</b> 190:1</p> <p><b>progressive</b> 160:22</p> <p><b>progressively</b> 114:1</p> <p><b>projectile</b> 118:12</p> <p><b>prolactin</b> 147:9</p> <p><b>promethazine</b> 132:11 141:16 153:22 154:3</p> <p><b>promise</b> 154:16</p> <p><b>promotility</b> 23:7</p> <p><b>pronounce</b> 137:6</p> <p><b>proof</b> 170:16</p> <p><b>properly</b> 114:16 125:18</p> <p><b>Propulsid</b> 181:7</p> <p><b>Pro-Stat</b> 122:11</p> <p><b>prosthetic</b> 92:6</p>
---	---	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 36

<p><b>protection</b> 187:18  <b>protocols</b> 112:2  <b>proton</b> 23:10            132:4 137:15,21  <b>Protonix</b> 119:2  <b>provide</b> 6:10            17:19 18:1 23:3            33:22 195:17  <b>provided</b> 31:6            116:12 172:17            173:18 197:18  <b>provider</b> 171:18  <b>providing</b> 9:12            25:4  <b>proving</b> 126:6  <b>pseudo</b> 181:10  <b>pseudo-</b>  <b>obstructions</b>            123:10  <b>psychological</b>            18:15  <b>psychotic</b> 129:12  <b>public</b> 1:4 6:21 7:2            14:16,19 26:2            30:21 33:3            163:9,14 173:21            174:3,8,17            176:10 178:8            199:10,12            201:1,19  <b>published</b> 187:10  <b>Pujita</b> 199:1  <b>Pujita's</b> 173:22  <b>puke</b> 58:19 88:22            91:15  <b>pull</b> 73:21 111:3  <b>pulled</b> 132:20            147:3</p>	<p><b>pulling</b> 114:20  <b>pump</b> 23:10 60:7            61:19 62:4 132:4            137:15,21  <b>puppy</b> 135:18  <b>purpose</b> 6:13            27:22 126:6            174:9  <b>purposes</b> 36:17  <b>pursue</b> 192:16  <b>push</b> 5:2 29:10            39:2 57:13 64:17  <b>pushed</b> 53:7 58:7            124:20  <b>putting</b> 14:20 41:7            109:10 154:5            197:16  <b>pyloric</b> 129:3  <b>pyloroplasty</b>            126:21 163:5  <b>pylorus</b> 126:18            131:22 162:5,11  <b>PYY</b> 194:3</p> <hr/> <p style="text-align: center;">Q</p> <hr/> <p><b>quality</b> 21:22 66:9            121:20 130:22            139:11 141:1            177:9 187:11  <b>quantify</b> 94:4  <b>quantity</b> 122:19  <b>quarter</b> 122:7  <b>question</b> 28:20            33:7,11,13 35:7            39:5 68:15 78:10            80:6 81:12,18,20            82:2 83:6 85:10            93:7,17 94:15            95:6 103:18</p>	<p>106:22 107:15            110:7 136:22            137:1 143:22            153:14 156:1            162:5 164:9            166:2  <b>questions</b>            15:12,17,19            26:11 29:6,12            30:3 32:1,2            35:6,14 36:15,18            39:3 67:20 74:12            81:9 82:2,4            84:4,15 87:7            93:2,20 94:8,12            110:16 155:14            164:5 171:5,15  <b>quick</b> 143:21            144:21  <b>quickly</b> 58:4            154:18  <b>quite</b> 25:22 39:17            75:14 87:9            126:16 158:4            169:22 178:21            184:1 192:11</p> <hr/> <p style="text-align: center;">R</p> <hr/> <p><b>race</b> 20:1  <b>radical</b> 172:11            193:5  <b>raise</b> 71:13 108:8            137:3  <b>raised</b> 93:4 145:7  <b>raising</b> 108:11            166:14  <b>range</b> 38:8,10            48:10 111:1  <b>ranging</b> 22:10  <b>rare</b> 117:21 149:1</p>	<p>150:9  <b>rarely</b> 39:16            148:22  <b>rat</b> 150:22  <b>rate</b> 61:22 82:20            86:7,9,19 87:3            125:2 127:2,9            160:15 161:2,3  <b>rated</b> 69:9 104:20  <b>rather</b> 83:6,18            109:12 147:4            194:6 195:9            197:8  <b>raw</b> 168:18  <b>Raymond</b> 3:6            175:15            197:11,13  <b>razor</b> 64:19  <b>reach</b> 30:17 36:9  <b>reaction</b> 147:15            153:20  <b>reactions</b> 63:21  <b>reading</b> 56:4            112:21 172:6  <b>ready</b> 75:15  <b>real</b> 39:4 41:19            50:2 52:2 79:19            137:5 164:21            180:19  <b>realistic</b> 171:14  <b>realize</b> 47:1 49:5            58:12 90:4            164:19 170:15            178:11 190:6  <b>realized</b> 12:11  <b>really</b> 7:1 12:5            13:20 15:4 16:3            17:19 18:4,22</p>
---	--	---	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 37

<p>20:13 21:4 22:16          24:18          25:9,11,14,16          26:3,12 27:2          28:1,8 29:16          32:9,11 33:9,15          44:16          45:2,3,4,14          46:4,6,8,13          47:4,7 48:3,15          50:12,15,16,17,2          2 51:7 54:21          55:12 60:17          63:16 66:6 74:20          80:21 82:13,22          83:12 87:9          90:2,4,14,17,18,          21 91:8 94:10,15          95:22 97:15 98:5          100:19 101:17          103:5 104:5          108:1,4,10,16          110:11 113:5          116:4 126:5          128:12 130:3,22          131:14          138:5,6,10          139:13          141:10,12,18          142:10 149:16          150:4 151:14          153:3,10          155:5,19 157:18          159:6 163:4          165:15,18          167:9,19,21,22          169:3 170:19          172:5,17 178:6          182:19 183:6          191:10 192:9,10          194:22 196:5          197:1 200:3,16  <b>reason</b> 102:5          125:10 143:22</p>	<p>150:9  <b>reasons</b> 24:8 75:14          151:10  <b>reauthorized</b>          14:12  <b>rebound</b> 113:9,21          117:2  <b>received</b> 143:1  <b>recently</b> 74:6          127:13 138:17  <b>recital</b> 57:17  <b>recommended</b>          134:12  <b>record</b> 174:17,22          187:17 201:7  <b>recorded</b> 8:3          201:4  <b>recordings</b> 202:8  <b>rectal</b> 101:12          118:14 119:16          121:7  <b>rectum</b> 18:9 120:5          121:2  <b>recurrent</b> 9:4  <b>red</b> 5:2 39:2 142:6  <b>reduce</b> 116:19          122:19 126:15          135:7 137:10          156:5 189:20  <b>reduced</b> 201:5  <b>refer</b> 14:5  <b>reference</b> 16:21  <b>referred</b> 125:11          126:3  <b>referring</b> 21:2  <b>reflect</b> 188:10  <b>reflected</b> 28:9</p>	<p>67:11 68:5  <b>reflecting</b> 188:19  <b>reflection</b> 37:18  <b>reflux</b> 9:8 37:11          118:18  <b>refractory</b> 176:18  <b>refreshing</b> 77:9  <b>refused</b> 126:4  <b>regard</b> 75:10  <b>regarding</b>          33:17,18 75:8          85:12 103:10          199:12  <b>regime</b> 128:10  <b>regimen</b> 27:9,12          48:16  <b>registration</b> 7:6,7  <b>Reglan</b> 119:1          126:11,15 129:5          132:1 143:5          147:13 152:20          154:16 155:2          196:9  <b>regular</b> 79:8 83:19  <b>regularly</b> 118:10          126:13 128:1  <b>regulated</b> 198:11  <b>regulations</b>          195:14  <b>regulators</b> 176:11  <b>regulatory</b> 200:16  <b>regurgitate</b> 133:18  <b>regurgitation</b>          93:12 131:12          153:7  <b>Reily</b> 2:9 52:5          58:15 79:1</p>	<p><b>reintroduce</b> 115:6  <b>reintroducing</b>          49:12  <b>reiterated</b> 156:3  <b>rejection</b> 183:16  <b>relapse</b> 189:20  <b>relate</b> 18:16 20:11          108:6  <b>related</b> 22:15          53:20 68:2 96:6          150:6 174:12,20          201:9  <b>relative</b> 80:7,20          115:8 201:11  <b>relatively</b> 91:12          129:19  <b>relay</b> 194:19  <b>relayed</b> 194:18  <b>release</b> 130:4          150:8 165:4,18  <b>released</b> 164:19          165:2,6  <b>releasing</b> 165:14  <b>reliable</b> 113:8          140:9  <b>relief</b> 90:8,20          112:6 113:8,15          114:13 117:3          132:18 134:7          140:9 145:10          159:9  <b>relieve</b> 45:22          144:10 145:2  <b>relieved</b> 87:5          144:22 152:16  <b>relieving</b> 83:3  <b>relying</b> 25:14  <b>remainder</b></p>
--	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 38

<p>36:14,18  <b>remarkable</b>          173:16  <b>remarks</b> 4:21 8:6          28:4 39:1 43:17  <b>remarried</b> 43:5  <b>remedies</b> 112:5          132:3 163:17  <b>remember</b> 10:7          44:6 124:18          138:1 163:19  <b>remotely</b> 30:10          155:12  <b>removal</b> 39:12  <b>remove</b> 49:11          121:1  <b>removed</b> 106:4          120:5,14 130:12          133:2  <b>repeat</b> 139:15  <b>repeated</b> 120:1          200:2  <b>replaced</b> 158:22          159:5  <b>report</b> 16:17 31:9  <b>reported</b> 202:5  <b>Reporter</b> 202:5  <b>Reporter's</b> 202:7  <b>reports</b> 16:18,20          17:5  <b>represent</b> 10:9          24:19 190:11,12  <b>representation</b>          30:1 36:6  <b>representative</b>          13:4 31:15          174:14 190:3</p>	<p><b>representatives</b>          11:4 29:17          160:17  <b>represented</b> 18:3          20:4 67:16          136:17  <b>representing</b> 13:6          188:19  <b>represents</b> 178:9  <b>rescue</b> 127:18  <b>research</b> 4:5 103:4          107:3,16          108:2,15 124:4          138:2 146:7          167:10,14          170:14,20          172:20 176:9          177:9 189:12          193:10  <b>researched</b> 125:15  <b>researcher</b> 193:1  <b>researchers</b> 10:12  <b>researching</b> 46:18  <b>resection</b> 118:15  <b>residency</b> 169:14  <b>residues</b> 127:12  <b>resonate</b> 92:10          136:14  <b>resonated</b> 92:11  <b>resonates</b> 71:15  <b>resources</b> 31:10  <b>respect</b> 34:14,16          43:16  <b>respectful</b> 175:5  <b>respiratory</b>          127:15  <b>responding</b></p>	<p>174:16  <b>response</b> 14:19          30:2 110:6 171:6  <b>responses</b> 28:19          127:15  <b>responsibility</b>          9:18  <b>rest</b> 40:8 41:7          54:16 57:12          62:18 99:4  <b>restaurant</b> 50:8  <b>restaurants</b> 64:7  <b>restless</b> 154:2          155:5  <b>restrict</b> 196:7  <b>restricted</b> 112:10  <b>restrictions</b> 24:1  <b>restrictive</b> 115:4  <b>restrooms</b> 7:12  <b>result</b> 9:4 117:6          120:22 127:10          129:8  <b>results</b> 10:18,22          35:16 47:17          100:18 116:9          118:5 196:5  <b>retail</b> 105:7  <b>retired</b> 151:10  <b>retrograde</b> 161:14  <b>return</b> 66:13  <b>review</b> 15:10,17          16:20  <b>reviewed</b> 31:8  <b>reviewer</b>          5:11,17,19,21          17:16  <b>reviews</b> 8:14</p>	<p><b>revising</b> 14:20  <b>revolve</b> 43:1 49:7          56:20 62:22  <b>revolves</b> 42:22          49:6 53:15  <b>rhythmic</b> 118:4  <b>rib</b> 53:8  <b>rice</b> 122:11  <b>rich</b> 16:9 107:8          164:7  <b>Richmond</b> 124:16          162:17  <b>ride</b> 42:8 81:8  <b>ridiculous</b> 168:4  <b>rising</b> 76:3  <b>risk</b> 10:1 196:17          197:1  <b>risks</b> 9:19 11:20          12:18 17:11  <b>Ritu</b> 3:2 175:14          190:8 192:13  <b>road</b> 66:3  <b>robust</b> 36:6 38:8          107:8  <b>role</b> 27:10 32:14          33:9 111:4 193:4  <b>rolled</b> 154:11  <b>roller</b> 42:8 81:7  <b>Rome</b> 19:3 47:18  <b>room</b> 11:5 13:19          28:7 29:14 32:18          33:1 34:18 56:18          58:1,11 69:15          100:11 117:11          136:17 137:2          138:4 143:5          153:16 156:17          159:2 167:1,3</p>
--	---	--	--



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 39

188:18	<b>Sara</b> 1:14 2:6 4:3 15:7 199:4	<b>seasick</b> 88:9	<b>sensation</b> 144:12
<b>root</b> 188:7	<b>Sarris</b> 73:5,8 74:18	<b>seat</b> 31:19	<b>sensations</b> 91:7
<b>roughly</b> 68:16	<b>Sarrit</b> 5:20	<b>seats</b> 66:14	<b>sense</b> 47:7 69:12 101:5 104:15,21 105:2,11 109:11 138:3 157:11,13
<b>round</b> 32:16 67:1 135:21 173:19 186:16	<b>sat</b> 139:3	<b>second</b> 26:13 66:17 71:4 91:1 110:17 119:6 120:3 140:4 171:17	<b>sensitive</b> 34:16 63:20
<b>routine</b> 40:5	<b>Saturday</b> 4:9	<b>secondly</b> 150:7	<b>sensitivity</b> 127:11 193:21
<b>row</b> 92:4	<b>save</b> 95:17	<b>seconds</b> 135:16	<b>sent</b> 109:4 142:13 172:10 181:17
<b>rubbing</b> 154:4	<b>saved</b> 140:21	<b>security</b> 117:7	<b>separate</b> 79:1,12
<b>rule</b> 47:12	<b>saw</b> 47:3 77:3 169:15	<b>seeing</b> 22:20 35:13 71:11 127:17 142:8 146:16	<b>separately</b> 187:16
<b>rules</b> 30:11 32:7	<b>scale</b> 74:8,9,15,16,22 75:1,14,17,18,19 76:4,17 78:16,18,21 79:6 80:16 83:7,19	<b>seekers</b> 76:1	<b>sepsis</b> 62:8,9 121:11
<b>run</b> 12:3 124:3 160:1,4 175:10	<b>scales</b> 79:13 81:16	<b>seem</b> 43:6 58:8 82:21 142:5	<b>September</b> 14:14 121:10
<b>running</b> 62:5 162:14	<b>scan</b> 47:12	<b>seemed</b> 114:13 115:1 119:2	<b>septic</b> 133:10
<b>runs</b> 31:14	<b>scared</b> 56:5 143:13	<b>seeming</b> 168:8	<b>series</b> 8:20
<b>rupture</b> 118:15 120:2	<b>scares</b> 169:18	<b>seems</b> 66:5 85:15 94:4 103:6 116:21 122:6 167:8 200:7	<b>serious</b> 9:16 117:1 186:5,12
<b>ruptured</b> 120:22	<b>scary</b> 91:22 113:3	<b>seen</b> 21:19 22:8,9 116:1 163:1 177:11 182:5	<b>seriously</b> 80:2 168:6 185:4,5 186:4,8,21
<b>ruptures</b> 118:7	<b>scheduled</b> 126:21	<b>segment</b> 193:20	<b>served</b> 7:8
————— S —————	<b>school</b> 22:18 41:17,18 45:2 54:3 55:14 123:22 141:21 169:17 191:1,5,8,10	<b>segments</b> 177:4	<b>service</b> 123:15
<b>sad</b> 168:10	<b>schools</b> 191:13	<b>segue</b> 163:3,4	<b>session</b> 102:9 174:8,10 175:5 190:3
<b>safe</b> 112:15 167:13 170:20 179:16 195:4	<b>scientific</b> 29:12 170:16	<b>self-sufficient</b> 55:18	<b>sessions</b> 15:8 112:20 165:2
<b>safely</b> 179:22 197:5	<b>scope</b> 166:16	<b>send</b> 21:5 41:19 63:3 65:18 94:12 126:6 148:15	<b>sets</b> 28:2 41:9
<b>safety</b> 10:22 11:1 24:2	<b>screening</b> 13:10 179:6	<b>sending</b> 30:20	<b>setting</b> 6:9 7:21 15:12
<b>sake</b> 87:8	<b>script</b> 47:22	<b>sends</b> 135:6	<b>seven</b> 39:21 116:2 133:20 140:22
<b>salad</b> 129:21			
<b>samples</b> 55:5			
<b>sampling</b> 190:4			
<b>sandpaper</b> 48:18			
<b>sandwiches</b> 55:20			

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 40

<p><b>seventh</b> 121:16</p> <p><b>seven-year</b> 78:2</p> <p><b>several</b> 19:8 29:1        40:11 61:15        73:10 82:8 92:3        93:19 112:19        114:10 120:9        125:11 137:16        152:18 163:21</p> <p><b>severe</b> 45:14 52:10        60:10,12,14        61:13 63:4 71:2        75:2 76:22        80:8,12,18,22        81:19 82:3,13,16        83:1,22 84:21        87:22 89:15 90:1        103:13 105:16        118:5 119:4,8        126:8,12,15        127:1,10 132:19        133:1 168:7        179:12 183:16        196:9</p> <p><b>severely</b> 119:15        133:8</p> <p><b>severity</b>        12:5,10,20 15:4</p> <p><b>sewer</b> 144:14</p> <p><b>shampoo</b> 160:1</p> <p><b>share</b> 32:19,20        33:5 34:18,21        36:10 39:1 58:14        87:19 131:6        139:19 164:12        166:5 177:5        189:11</p> <p><b>shared</b> 38:17        171:11 199:10</p> <p><b>sharing</b> 124:8        176:9 192:4</p>	<p>200:17</p> <p><b>sharp</b> 71:3        77:19,20 83:9,16</p> <p><b>sharper</b> 71:4,6        77:22</p> <p><b>sheet</b> 49:13</p> <p><b>she's</b> 56:2,3,5        92:21</p> <p><b>shocked</b> 119:20</p> <p><b>shocking</b> 160:21        161:2</p> <p><b>shocks</b> 160:15</p> <p><b>shoe</b> 72:18</p> <p><b>short</b> 196:11</p> <p><b>shortness</b> 40:2</p> <p><b>short-term</b> 113:8</p> <p><b>showed</b> 15:8 47:18        129:13 139:1</p> <p><b>shower</b> 62:12 74:3</p> <p><b>showers</b> 40:3</p> <p><b>showing</b> 29:19        154:16</p> <p><b>shown</b> 192:22        196:15</p> <p><b>shows</b> 20:13 195:1</p> <p><b>shut</b> 183:10</p> <p><b>sick</b> 47:7 54:12,14        56:11 89:10        92:20 125:10,12        127:3 159:18        160:2,5 182:15</p> <p><b>sickest</b> 182:4</p> <p><b>sign</b> 7:5 139:10</p> <p><b>signals</b> 21:5 135:6</p> <p><b>signed</b> 163:14        175:4</p>	<p><b>significant</b> 21:21        26:16 46:4 69:4        92:5 101:1 200:3</p> <p><b>significantly</b> 75:4</p> <p><b>signs</b> 18:15,22        21:11,18 199:12</p> <p><b>sign-up</b> 7:7 175:2</p> <p><b>silence</b> 188:12</p> <p><b>silver</b> 1:12 122:5</p> <p><b>similar</b> 28:8 38:10        43:11 69:14        76:12 91:10        92:15,22 100:18        137:22 143:4        178:21</p> <p><b>Similarly</b> 69:10</p> <p><b>similar-type</b> 77:19</p> <p><b>simple</b> 64:20,21        65:19 177:17</p> <p><b>single</b> 43:4 125:6        131:10 180:13</p> <p><b>Sirota</b> 2:11        111:10,15        117:15 161:18        170:1</p> <p><b>sit</b> 27:20 54:11</p> <p><b>sitting</b> 42:9,10,21        56:2 64:1 121:6</p> <p><b>situation</b> 47:4        102:15 184:15</p> <p><b>situations</b> 50:12        74:22 103:15</p> <p><b>six</b> 52:7 54:16        115:5 116:1        119:14 123:13        127:16</p> <p><b>Sixty-six</b> 101:13</p> <p><b>six-week</b> 159:19</p>	<p><b>size</b> 53:11 182:2</p> <p><b>sizes</b> 53:12</p> <p><b>skeletal</b> 138:22</p> <p><b>skills</b> 201:8</p> <p><b>skin</b> 122:4</p> <p><b>slashed</b> 120:10</p> <p><b>sleep</b> 39:22 42:6,7        54:22 84:8,12</p> <p><b>slide</b> 20:13 94:18        100:1</p> <p><b>slides</b> 32:5</p> <p><b>slightly</b> 29:22 70:3</p> <p><b>slip</b> 7:18</p> <p><b>slow</b> 149:15 170:8        181:12</p> <p><b>slowing</b> 106:8        134:11</p> <p><b>slowly</b> 64:15        188:13</p> <p><b>small</b> 39:10 71:22        103:5 106:7        126:9 129:13        133:13 134:10        140:7 144:17        164:14 165:19        181:21</p> <p><b>smaller</b> 107:22</p> <p><b>smells</b> 55:4</p> <p><b>smiling</b> 76:18</p> <p><b>smoke</b> 127:11        142:1</p> <p><b>smoking</b> 142:2</p> <p><b>smooth</b> 59:14</p> <p><b>smoothie</b> 43:22</p> <p><b>snacks</b> 50:14</p> <p><b>snake</b> 165:4</p>
--	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 41

<p><b>snap</b> 165:13</p> <p><b>snapshots</b> 28:2</p> <p><b>so-called</b> 10:20</p> <p><b>social</b> 50:12 53:16 64:8 94:1 103:14 130:18,19 131:20 176:21</p> <p><b>socializing</b> 82:19 86:21</p> <p><b>socially</b> 22:1 94:1</p> <p><b>societal</b> 176:16</p> <p><b>society</b> 53:15</p> <p><b>socio-economic</b> 20:2</p> <p><b>sodium</b> 122:21</p> <p><b>soft</b> 64:18</p> <p><b>solely</b> 51:12</p> <p><b>solid</b> 107:17 108:8 165:10</p> <p><b>solution</b> 162:10 163:4</p> <p><b>solved</b> 159:7</p> <p><b>somebody</b> 43:12,13 59:8 85:18,21,22 86:7,8 90:17</p> <p><b>someone</b> 4:13 29:4 31:13 36:22 69:22 85:4 101:21 111:6 154:15 158:1 171:7 185:5</p> <p><b>sometime</b> 154:9</p> <p><b>somewhat</b> 160:8</p> <p><b>somewhere</b> 7:15 75:19 80:1</p> <p><b>son</b> 57:17 158:17 178:12,15</p>	<p>184:14</p> <p><b>son's</b> 54:11</p> <p><b>sooner</b> 188:18 189:16 200:19</p> <p><b>sore</b> 122:4</p> <p><b>sorry</b> 73:17 81:1 139:21 177:22 182:17 194:10</p> <p><b>sort</b> 16:21 20:14 23:3 44:22 46:13,15 48:3,11 49:14 50:17 82:11 83:3 95:4 150:14 166:20</p> <p><b>sorts</b> 102:19</p> <p><b>sound</b> 103:20</p> <p><b>sounds</b> 74:16 77:14 86:11 87:12 93:18 102:2 104:9 110:7 151:11</p> <p><b>soup</b> 64:3,6,10</p> <p><b>sour</b> 82:11</p> <p><b>source</b> 11:8 98:9</p> <p><b>soy</b> 128:2</p> <p><b>spasmodic</b> 115:19</p> <p><b>spasms</b> 59:13 64:13 77:8 104:4</p> <p><b>speak</b> 4:12 25:20 28:14 44:11 48:17 74:9 108:15 111:16 117:9,21 174:11 178:5 184:16 194:17</p> <p><b>Speaker</b> 2:2</p> <p><b>speakers</b> 175:11 199:10</p>	<p><b>speaking</b> 28:18 80:17 109:15 117:12 135:10 160:16 194:21</p> <p><b>special</b> 15:13 24:9 158:6 179:17</p> <p><b>specialist</b> 125:9</p> <p><b>specialists</b> 61:9</p> <p><b>specific</b> 26:18,20 33:10 39:18 86:2 110:19 164:9</p> <p><b>specifically</b> 24:11 112:20 132:7,14 134:14 189:18</p> <p><b>spectrum</b> 23:1 26:6 37:19</p> <p><b>spells</b> 40:4</p> <p><b>spend</b> 6:9 54:17 72:21 139:8</p> <p><b>spending</b> 139:12</p> <p><b>spent</b> 87:13 118:8 139:3 178:18 179:3 188:1</p> <p><b>spirit</b> 199:2</p> <p><b>spoke</b> 189:8</p> <p><b>spoken</b> 186:10</p> <p><b>sponsor</b> 11:22 12:1</p> <p><b>sponsoring</b> 12:1</p> <p><b>sponsors</b> 17:1</p> <p><b>spoon</b> 95:17</p> <p><b>spoons</b> 95:18</p> <p><b>Springs</b> 1:12</p> <p><b>stack</b> 49:9</p> <p><b>staff</b> 28:10 198:17 199:6</p> <p><b>stage</b> 67:9 158:3</p>	<p>199:4</p> <p><b>stages</b> 41:13 105:16</p> <p><b>stakeholder</b> 31:20</p> <p><b>stand</b> 31:22 66:19 125:6 164:17,20 198:22</p> <p><b>standard</b> 9:9 37:11 128:10 179:7 185:10</p> <p><b>standardize</b> 19:5</p> <p><b>standpoint</b> 190:21 192:6</p> <p><b>start</b> 4:11 14:15 15:9 27:19 39:6 48:1 49:12 65:1 67:19,20 109:18 111:8 121:14 126:13 138:14,20 149:2,10 151:1 173:4 175:8,18 189:9</p> <p><b>started</b> 14:14 39:17 40:18 41:22 45:19 46:6,18 48:3 59:19 89:15,22 96:14 106:13 110:1 111:6 119:10,12 121:3,4 127:6 129:10 138:18,19 140:8 146:12 147:9 148:20 154:17,18 160:15 161:2 164:20 165:9 181:12 183:8 193:7,9 198:14</p> <p><b>starting</b> 130:13</p>
--	---	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 42

<p>147:6 180:15 183:22 <b>starving</b> 53:2 <b>state</b> 28:13,16 79:9,20 80:1 105:22 164:13 174:22 187:16 <b>states</b> 19:20 92:17 134:17 <b>status</b> 20:2 <b>stay</b> 33:2 42:3 66:13 135:12 179:19 <b>stayed</b> 125:1,2 <b>staying</b> 38:19 199:2 <b>steadily</b> 127:8 <b>stent</b> 162:4,9 <b>step</b> 169:19 <b>steps</b> 123:15 <b>steroids</b> 183:17 <b>stick</b> 175:7 <b>stimulating</b> 145:13 <b>stimulation</b> 24:12 <b>stimulator</b> 133:6 135:4 160:12 161:13 <b>stomach</b> 44:2,21 52:16,20 53:4,9 71:22 72:2 82:11 88:5,10 89:18 93:13 115:9 124:18 133:11,12 135:1,6,8 143:7 160:6 164:19,21 165:3 177:18</p>	<p>181:22 192:22 <b>stomach's</b> 52:21 148:18 <b>stomach's</b> 122:5 <b>stool</b> 107:17 108:8 <b>stools</b> 41:15 101:5,12 <b>stop</b> 57:12 112:17 113:17 147:11 155:6,9,18 163:8 181:8 183:9 <b>stopped</b> 93:14 119:7 133:10 147:13 153:16,19 154:20 <b>store</b> 55:3 <b>stories</b> 151:21 162:2 175:20 190:1 194:18,20 <b>story</b> 67:11 124:8 181:4 197:18 <b>straight</b> 164:17,20 <b>strange</b> 103:21 104:10 <b>strangling</b> 165:7 <b>Strategic</b> 4:3 5:14 199:5 <b>strength</b> 40:20 123:6 <b>stress</b> 42:16 45:22 56:9 60:19 193:4,11 <b>stressed</b> 47:4 <b>stressful</b> 45:2 46:1 <b>strictly</b> 167:16 <b>string</b> 85:11</p>	<p><b>striped</b> 82:6 <b>strong</b> 6:5 29:19 <b>stronger</b> 73:15 125:19 134:1 <b>struck</b> 200:2 <b>structural</b> 18:7 24:16 177:11 <b>struggle</b> 48:6 58:15 130:17 <b>struggled</b> 59:5 <b>struggles</b> 61:2 66:21 <b>struggling</b> 4:14 136:13 166:12 <b>stuffed</b> 79:14 <b>stuck</b> 102:3 <b>students</b> 124:2 <b>studies</b> 107:13 112:19 127:14 128:21 191:18 196:14 <b>stuff</b> 42:12 43:6 63:4,18 65:4 77:1,7 104:2 153:12 156:12 164:7 169:12 173:1 <b>stuff's</b> 173:7 <b>stumble</b> 137:7 <b>style</b> 26:1 <b>subdivided</b> 19:10 <b>submit</b> 10:13 16:13 182:18 186:13,17 194:11 <b>submitted</b> 10:21 11:22</p>	<p><b>subsequent</b> 89:22 <b>subside</b> 149:4 <b>substitutes</b> 128:4 <b>subtype</b> 19:11 <b>success</b> 16:4 127:22 140:22 147:8 162:15 170:18 191:15 <b>successful</b> 91:12 116:3 <b>sudden</b> 126:2 <b>suffer</b> 19:16 88:1 97:16 131:11 154:12 188:12 <b>suffered</b> 87:4 89:13 126:13,14 178:16 <b>suffering</b> 20:20 51:20 90:14,18 94:22 128:9 197:3 <b>sufficient</b> 192:22 <b>sufficiently</b> 189:6 <b>sugars</b> 114:19 150:3 <b>suggest</b> 19:19 103:17 <b>suggested</b> 45:21 46:1 <b>suggestion</b> 185:6 <b>suggests</b> 96:18 <b>summaries</b> 109:4 <b>summarize</b> 199:16 <b>summarized</b> 31:8 <b>summarizing</b> 30:4,5 <b>summary</b> 31:9</p>
--	---	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 43

<p><b>summer</b> 126:22 162:7</p> <p><b>sun</b> 98:10,12</p> <p><b>super</b> 130:21</p> <p><b>supplement</b> 116:22 117:5</p> <p><b>supplemental</b> 112:5</p> <p><b>supplements</b> 114:10,12 115:1 134:3 170:19 198:2</p> <p><b>supply</b> 97:11,15</p> <p><b>support</b> 10:21 30:19 33:18 34:19 38:16 56:8 60:2 112:19 114:11 120:8 172:18 198:7</p> <p><b>supposed</b> 97:13 98:13,18 149:14</p> <p><b>suppositories</b> 118:10 121:6</p> <p><b>sure</b> 32:8 42:7 43:18 55:1,2 58:19 75:7 77:13 99:21 104:17 106:18 112:15 145:14 164:3</p> <p><b>surgeon</b> 119:19,22</p> <p><b>surgeries</b> 22:14 61:17 118:13 136:10 161:10 172:22</p> <p><b>surgery</b> 120:1,3,4,9 121:1,8,9,16 130:3 150:10,13 159:16 172:11</p> <p><b>surgical</b> 111:2</p>	<p>150:7 157:14,16</p> <p><b>surprise</b> 26:22</p> <p><b>surprised</b> 143:18</p> <p><b>survey</b> 29:13 138:2 180:22 190:4 195:1</p> <p><b>sustain</b> 98:6</p> <p><b>swallowing</b> 21:16</p> <p><b>sweater</b> 82:6</p> <p><b>sweeteners</b> 49:19,22 128:4</p> <p><b>swelling</b> 131:12</p> <p><b>swim</b> 99:8,12 124:1</p> <p><b>swimming</b> 99:7</p> <p><b>switched</b> 98:1 153:6</p> <p><b>symptom</b> 28:21 68:18 69:1 70:9 78:13 95:10 100:6 101:16 107:20 108:4,17 128:7 149:13,14 166:20 167:21 171:15 187:12</p> <p><b>symptomatic</b> 9:8 37:10</p> <p><b>symptoms</b> 6:18 9:4 10:3 18:6,11,15,22 20:11 21:9,12,19 23:12 26:15,20 33:15 42:7 45:1,12,20 47:11 51:13,18 52:14 64:13 66:8 67:22 68:2,4,6 69:1,3 77:14 78:13 84:18 87:5 93:3 95:8 96:19 98:22</p>	<p>99:21 100:5,9,13,22 101:2 102:8 107:5,11 108:12 109:8 110:19 115:10,14 116:6,16,18,22 122:12 124:17 128:6 129:16 130:15 131:17 132:6 134:6,9,15 137:10 144:9 149:15 150:17 154:19 156:5 157:8,9 168:15 171:8 177:8,20 178:5,7,16 188:6 199:12</p> <p><b>syndrome</b> 9:7 19:9 20:6 23:17,21 37:9,22 44:12 47:19 73:9 154:2</p> <p><b>Syracuse</b> 52:6 56:21</p> <p><b>system</b> 21:3,6 64:22 68:1 97:9 114:16 127:15,20 144:15 188:9 189:9</p> <p><b>systematic</b> 13:2 17:7</p> <hr style="width: 20%; margin: 10px auto;"/> <p style="text-align: center;">T</p> <hr style="width: 20%; margin: 10px auto;"/> <p><b>table</b> 5:1 47:9 92:4 198:16</p> <p><b>tabs</b> 122:4</p> <p><b>tachycardia</b> 40:2 152:18</p> <p><b>Tagamet</b> 119:1</p> <p><b>tags</b> 27:20</p>	<p><b>tailor</b> 15:20</p> <p><b>tailored</b> 30:13</p> <p><b>taking</b> 7:19 22:20 75:11 90:12 99:17 113:10,12 114:5,14 115:18 118:9 120:15 123:7 132:18 134:3 137:17 149:16 154:17 155:15,18 170:6 176:19 185:4 186:8 193:7 195:2,3</p> <p><b>talk</b> 11:10 14:1 20:15 27:7 34:4 46:13 47:2 50:20 67:7 73:11 99:22 108:13 109:8 157:4 160:11 164:3 192:15</p> <p><b>talked</b> 28:21 31:16 87:17 102:8,17 145:8 155:15 164:10 184:21 192:1,2</p> <p><b>talking</b> 9:1 22:12 23:1 34:2 42:9 45:19 52:1 60:15 70:16 77:19,21 78:10 90:22 92:4,19 104:21 149:4 156:4 157:6 169:13,22 170:1,2 188:6</p> <p><b>Tan</b> 31:14</p> <p><b>Tanya</b> 2:7 39:7,8 43:17 44:7 75:12 105:9 106:17 108:11 145:21 167:20 168:11</p> <p><b>tape</b> 142:6</p>
---	---	--	---

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 44

<p><b>Tardive</b> 154:18  <b>target</b> 193:2  <b>task</b> 4:10 190:19      192:12  <b>tasks</b> 115:13      131:18  <b>taste</b> 65:14 97:21  <b>tastes</b> 65:15  <b>Taylor</b> 2:7 39:8,9      43:20 75:13      105:10 145:5      148:17 164:11      168:14  <b>tea</b> 56:16  <b>teacher</b> 191:6  <b>team</b> 109:3  <b>tease</b> 27:10 70:7      137:15  <b>technical</b> 109:12  <b>techniques</b> 62:1      112:22  <b>tee</b> 155:11  <b>teeing</b> 100:2,7  <b>teenager</b> 44:17      45:4  <b>teeth</b> 92:6  <b>Tegan</b> 2:16      175:12,16,21      177:22  <b>Temple</b> 158:5  <b>temporarily</b> 113:1      160:21 162:12  <b>temporary</b> 53:14      112:6  <b>ten</b> 22:10 82:21      83:19 85:19,22      86:6,9 87:1</p>	<p>121:11 132:5      144:17 163:10  <b>tend</b> 107:18      129:22  <b>tens</b> 180:12  <b>tepid</b> 129:9  <b>term</b> 18:5 92:8      176:16  <b>terminology</b> 83:15  <b>terms</b> 26:21 29:22      70:4,6,7 82:18      83:8,21 87:18      109:6,10,13  <b>terrible</b> 88:15      129:1 159:9  <b>test</b> 47:13,17      137:5 188:15  <b>tested</b> 100:19      167:16  <b>testing</b> 22:4 61:3      128:8,10 179:3,6      193:17  <b>tests</b> 61:4 173:5      192:2,3  <b>thank</b> 5:22 6:2      11:5,13 13:18      17:14,18 25:18      35:21 38:3 43:20      44:7,9 52:2,3      58:20,21,22 59:4      66:1,11,18 67:17      69:19 70:15 73:2      77:12 78:5 93:1      97:1 102:21      106:17      108:19,22      109:18      111:13,15      117:9,10,14,15      124:14</p>	<p>128:11,13      131:2,5 135:9,11      136:2 142:16,17      145:21 147:20      150:18 152:10      154:14 159:11      160:9 161:6,15      163:6 165:21,22      169:20 170:22      171:20      173:14,17      174:5,7 177:22      178:3 179:7,8,10      180:3,4,9,20,21      182:17      184:10,12      186:22 189:21      190:6,7,9      192:12,13      194:14,16,17      195:20,21      197:10,16,17      198:12,13      199:1,4,9 200:19  <b>thankful</b> 90:7  <b>Thankfully</b> 61:9      151:8  <b>thanking</b> 175:19  <b>thanks</b> 70:16      140:18  <b>that's</b> 13:13 14:5      21:17 22:17      25:2,18 28:20,21      29:4 31:2      32:10,11,21      39:20 43:11,21      44:6,18 45:7      46:10,12 47:2      48:12,17 50:9,17      52:1 53:1 59:15      61:1 65:2 66:2      70:6 73:13,22      76:18 79:8,20</p>	<p>80:20 81:6 82:13      85:1 88:2 91:22      93:15 98:7      102:5,17,20      107:12 108:2      138:22 141:5      142:9,10      151:6,19,22      153:11,15      156:14 162:5      166:16 170:10      181:2 183:2      184:18 185:8,11      188:18 195:20  <b>the-counter</b> 104:3      170:19  <b>theme</b> 45:7 94:19  <b>themes</b> 15:9 85:14  <b>themselves</b> 55:22      97:20 168:1  <b>theory</b> 95:17  <b>therapeutic</b> 9:9      37:11 200:18  <b>therapies</b> 23:13      24:5,7 137:9      151:13 152:8      156:4 198:2,3      199:21  <b>therapy</b> 24:21      112:20 165:16      200:18  <b>thereafter</b> 201:5  <b>Therefore</b> 9:19  <b>there'll</b> 66:4  <b>there's</b> 8:1 12:6      18:7,12 23:14      24:16 29:19      30:21 42:22      43:1,10 48:5      50:9 51:21 52:1</p>
--	--	---	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 45

<p>53:17 57:1,5          63:12 66:6          72:10,12,17          75:10 78:7 79:2          84:15 87:7 93:2          137:16 142:4,6          148:7,9 149:1          150:15 151:5          152:8 164:5          167:11,12          180:19 183:13          184:5,8          186:16,17          190:21,22 192:8          199:20 200:3  <b>Theresa</b> 2:4 5:13          8:22 11:10 31:15  <b>they'd</b> 63:15  <b>they'll</b> 43:9 70:9          72:14 74:7  <b>they're</b> 9:3 12:19          18:10 19:18          27:17 34:9,10          44:1 45:12 70:3          86:8 97:19,20          114:19 152:13          170:20 183:17  <b>they've</b> 143:8  <b>thick</b> 129:21  <b>thickness</b> 118:14          119:16  <b>thin</b> 120:18  <b>third</b> 35:18 171:17  <b>thirds</b> 35:17,19  <b>THOMPSON</b>          35:22 37:21          38:10 77:18          92:15 100:18          101:10 103:11          137:20 156:19</p>	<p>161:16 163:13  <b>thoughts</b> 25:17          33:22 34:21 51:8          58:13 65:8,9  <b>thousand</b> 180:13  <b>thousands</b>          178:18,19  <b>threatening</b> 42:1          102:16 177:1  <b>three-hour</b> 40:6          42:6  <b>threw</b> 56:17 125:2  <b>throughout</b> 10:15          21:4 34:3 68:1          195:12,16  <b>throw</b> 57:14 91:16          97:5,22  <b>throwing</b> 41:11          88:6  <b>thrown</b> 199:3  <b>Thursday</b> 80:9  <b>timer</b> 175:7  <b>tiny</b> 138:21  <b>tip</b> 67:21  <b>tired</b> 56:17 58:16          96:20 98:7          122:14 123:4  <b>today</b> 4:6,12,15          6:6 8:17 9:21          10:2 13:17 15:2          17:19 18:3 20:5          25:17 26:7,19          27:17 30:22          31:13 32:19          33:20 35:1 38:19          42:9 44:10 56:2          57:8 73:11 75:15          78:17 80:19 81:9          99:6 111:18</p>	<p>135:10 136:6          166:4,17          174:7,13 175:21          176:4,14 185:11          186:11          187:15,22          188:3,5,9,18          189:2,7,22          200:1,11  <b>Today's</b> 8:20  <b>toe</b> 79:14,17  <b>toilet</b> 93:9,10,14          121:6  <b>tolerable</b> 134:6  <b>tolerance</b> 113:10          117:3 196:12  <b>tolerate</b> 59:21          86:5 121:13          148:21  <b>tomorrow</b> 57:9          95:19  <b>ton</b> 150:4  <b>tools</b> 116:7,12  <b>top</b> 59:16 68:18          69:9 156:18          168:15  <b>topic</b> 26:14 27:19          28:19 30:13          38:22 67:8 78:7          99:22 109:20          110:9,14 136:20          185:20 190:5  <b>topics</b> 6:17 26:11          27:15 33:20          34:16 107:7          174:12 194:17  <b>tops</b> 169:5  <b>total</b> 120:17  <b>totally</b> 47:8 60:14</p>	<p>72:11 79:15          116:3 158:16  <b>touch</b> 34:15 87:14          105:11 193:20  <b>touching</b> 67:6  <b>toward</b> 7:13 38:20  <b>towards</b> 92:6          180:17  <b>TPN</b> 59:22 60:4,7          62:4,5 121:12          129:6 133:9,10          146:13 148:3          151:13          181:12,15          182:2,10 183:8  <b>track</b> 114:20  <b>tracking</b> 24:17  <b>tract</b> 9:6 20:17          21:5 59:12 71:20          107:11,15          125:17 177:4  <b>trade-offs</b> 15:16  <b>Tramadol</b> 133:21  <b>transcribed</b> 8:3          174:17  <b>transcript</b> 202:6,8  <b>transcription</b>          202:1,9  <b>Transcriptionist</b>          202:14  <b>transition</b> 141:8          151:20  <b>transparent</b>          174:18 199:11  <b>transplant</b> 164:14          165:20          181:20,21          182:6,10,13</p>
---	--	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 46

<p>183:15,18  <b>trap</b> 159:21  <b>trash</b> 91:16  <b>trauma/intensive</b>      120:8  <b>travel</b> 124:5  <b>treat</b> 8:15 12:10      23:8,11,17      110:18 116:15      129:12 132:6      134:5,8,14,17      150:17 157:7      183:17  <b>treating</b> 6:20 27:8      129:14 130:2      179:16  <b>treatment</b> 10:5      12:17 23:3      24:10,20 25:8      27:9,11 33:16      34:5 48:16 66:5      91:12 110:14,22      113:6 116:8      125:20 128:22      134:12,20      138:9,10,15      140:20 142:15      149:7 150:9      164:4 172:3,6      183:13 184:7      189:20 195:5      196:3  <b>treatments</b> 9:17      10:1,6 12:7,22      15:7,22 22:4      23:1 25:3 27:11      34:2,4,7 91:1      99:15 110:21      111:2,5 112:1,7      115:2      116:3,13,17      136:10,11,22</p>	<p>142:4,15,20      143:1 149:6,9      155:20 156:2      157:14,17 164:6      168:4 171:8      172:22      177:6,14,16      179:3 188:22  <b>treatment's</b> 34:6  <b>Treatments</b>      177:17 180:9  <b>treatment-wise</b>      172:5  <b>tremendous</b> 117:3      140:1 176:15  <b>tremendously</b>      199:11 200:9  <b>trepidation</b>      128:18  <b>trial</b> 10:17 15:15      78:11 129:10      162:14,17      172:14 192:18  <b>trials</b>      10:11,13,19,20      11:1 12:3 17:9      25:6 61:16 81:15      87:2 134:16      172:16,21  <b>tricky</b> 63:11      130:20  <b>tried</b> 63:5      112:2,3,9,12      113:2,18 118:22      121:12 122:5      131:21 134:8      140:6 143:8,11      149:9 150:21      152:17 153:5      181:6  <b>trigger</b> 50:6,15</p>	<p>129:22 164:18      165:2,4,18  <b>triggers</b> 104:12      115:17  <b>trouble</b> 31:5 76:19  <b>true</b> 73:22 91:9      170:17 201:6      202:9  <b>truly</b> 76:4,5      173:16 185:7      199:14  <b>try</b> 4:12 27:10      28:18 32:18      33:12 42:18      43:21 45:22      49:11 51:18      56:10 65:6,14      70:7 71:20,21      111:3 127:13      133:16 134:5      136:11 137:14      144:4 153:8      173:13 175:6,9      183:4  <b>trying</b> 14:7 15:11      52:17 66:1 98:2      138:3 150:22      152:3,5,6 157:9      163:3 172:21      180:11  <b>tube</b> 56:13 59:20      71:21 122:7,8      130:12 131:10      133:14 134:2      146:18 147:3      159:18,20      161:13 181:11      183:12  <b>tubes</b> 24:13 129:6  <b>tuned</b> 74:21  <b>turn</b> 5:3 8:5 11:10</p>	<p>17:12,22 44:1      101:16 108:6      188:14  <b>turnaround</b>      129:15  <b>turnout</b> 6:5  <b>tutor</b> 124:1  <b>twice</b> 133:10      144:18 182:2  <b>two-and-a-half</b>      129:7  <b>two-day</b> 104:1  <b>two-hour</b> 99:2      123:7  <b>two-minute</b>      175:7,8  <b>type</b> 31:3 42:16      43:14 138:13      157:6 165:16  <b>typed</b> 202:6  <b>types</b> 22:19 43:20      44:4 49:2      77:5,10 86:2      149:5 151:15      168:19 198:3  <b>typewriting</b> 201:5  <b>typically</b> 18:10  <b>typing</b> 30:2  <hr style="width: 20%; margin: 10px auto;"/> <p style="text-align: center;">U</p> <hr style="width: 20%; margin: 10px auto;"/> <b>unable</b> 40:3 64:17      119:15 125:3,6      128:3  <b>uncomfortable</b>      50:22 104:10  <b>unconventional</b>      141:18  <b>undergoing</b></p>
---	---	---	--



Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 47

<p>132:15</p> <p><b>underlying</b> 18:13</p> <p><b>understand</b> 8:18          9:15,21 12:4          13:21 21:20          23:14 43:7 53:22          58:8 60:18          76:7,10 79:9,19          81:16 85:15          107:14 148:17          181:3 188:21          197:2</p> <p><b>understanding</b>          76:19 176:12          181:2 189:17</p> <p><b>understands</b>          117:12</p> <p><b>understood</b> 25:5          185:7</p> <p><b>undertaken</b> 11:16</p> <p><b>underwear</b> 72:19</p> <p><b>underweight</b>          118:11,19</p> <p><b>undiagnosed</b> 96:8          178:11 193:16</p> <p><b>unexplained</b> 91:4          128:17</p> <p><b>unfair</b> 67:4</p> <p><b>unfortunate</b> 56:15</p> <p><b>unfortunately</b>          55:17 56:18 58:4          79:4 106:7 108:5          120:7 123:11</p> <p><b>unidentified</b> 85:17          86:4,13 95:13,14          128:9 154:22          156:9 157:20          162:8 166:22</p> <p><b>unique</b> 12:14</p>	<p>15:13</p> <p><b>uniquely</b> 12:19</p> <p><b>United</b> 19:20          134:17</p> <p><b>units</b> 120:7</p> <p><b>University</b> 158:5          181:19 187:9</p> <p><b>unless</b> 39:4 87:6          104:6 144:20</p> <p><b>unmet</b> 12:6 176:13          199:22 200:10</p> <p><b>unnecessary</b> 22:3</p> <p><b>unpleasant</b> 47:14</p> <p><b>unpredictability</b>          131:17</p> <p><b>unpredictable</b>          18:11 45:17</p> <p><b>unrelenting</b> 88:1          89:15 131:11</p> <p><b>unsuccessful</b>          130:7</p> <p><b>Unsurprising</b>          68:10</p> <p><b>unsympathetic</b>          44:20</p> <p><b>untreated</b> 96:8          189:14</p> <p><b>upload</b> 31:4</p> <p><b>upon</b> 34:16 69:22          87:14 173:15</p> <p><b>upper</b> 9:5 65:3,6          68:2,6 69:2          103:8</p> <p><b>upset</b> 191:7</p> <p><b>upwards</b> 91:13</p> <p><b>urgency</b> 21:15          101:6 104:15,22</p>	<p>105:3,11 111:19          114:2 116:16</p> <p><b>urgent</b> 58:11</p> <p><b>urges</b> 115:9</p> <p><b>urging</b> 179:20</p> <p><b>urine</b> 122:19,20</p> <p><b>useful</b> 17:2</p> <p><b>usually</b> 65:17          77:11 135:17          169:11 198:5</p> <hr/> <p style="text-align: center;">V</p> <hr/> <p><b>vacations</b> 56:20</p> <p><b>VAIDYA</b> 174:6          177:22 179:8          180:4 182:17,21          183:2 184:10          186:22 189:21          190:7 192:13          194:10 195:21          197:10 198:13</p> <p><b>validation</b> 173:9</p> <p><b>valuable</b> 9:20 11:8          29:20</p> <p><b>value</b> 10:4 200:16</p> <p><b>valued</b> 138:9</p> <p><b>valve</b> 129:3</p> <p><b>variable</b> 73:22          81:17</p> <p><b>variables</b> 146:21</p> <p><b>variety</b> 24:8          197:21</p> <p><b>various</b> 51:14          129:3 198:1</p> <p><b>vary</b> 42:8</p> <p><b>vast</b> 178:22</p> <p><b>vegetables</b> 43:22          44:1 49:17 50:5</p>	<p>126:11</p> <p><b>veins</b> 182:7,10</p> <p><b>Venkataraman</b>          5:18</p> <p><b>venous</b> 181:15</p> <p><b>Verapamil</b>          113:12,16 170:4</p> <p><b>Verma</b> 3:2 175:14          190:8,9 200:6</p> <p><b>versa</b> 21:6</p> <p><b>version</b> 78:2          158:21</p> <p><b>versions</b> 158:20</p> <p><b>versus</b> 71:3 79:14</p> <p><b>via</b> 8:19</p> <p><b>vice</b> 21:6</p> <p><b>vicious</b> 102:14</p> <p><b>view</b> 9:22</p> <p><b>Virginia</b> 124:16          162:17 201:19</p> <p><b>virus</b> 88:10</p> <p><b>vision</b> 184:1</p> <p><b>visit</b> 31:2</p> <p><b>visits</b> 22:13 127:12</p> <p><b>vital</b> 195:17</p> <p><b>vitamin</b> 97:18          98:8,9 114:11          115:19 122:18          127:13,20</p> <p><b>vitamins</b>          97:7,8,10,19          98:1 112:5          127:19</p> <p><b>Vivonex</b> 122:10</p> <p><b>voice</b> 4:8,11 16:16          85:17 86:4,13          95:13,14 154:22</p>
---	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 48

<p>156:9 157:20          162:8 166:22          184:20 185:2,3  <b>volumes</b> 107:22          108:1  <b>volunteer</b> 70:8  <b>vomit</b> 91:22 92:22          93:6,9  <b>vomiting</b> 21:14          68:12,17          69:10,15 74:2          87:14,16          88:12,13 89:1,4          90:16          91:4,13,18,21          92:1,3,14,18          94:2,6 97:4          118:6,12 119:3,7          128:17 129:2          130:1,2 133:7          135:7 160:7  <b>vulnerable</b> 51:16</p> <hr/> <p style="text-align: center;">W</p> <hr/> <p><b>wait</b> 58:5 105:4          135:18 182:11  <b>waiter</b> 64:9  <b>waitress</b> 64:9  <b>wake</b> 48:7 55:11          88:20  <b>waking</b> 82:17  <b>walk</b> 47:22 98:11          125:7  <b>walked</b> 47:3  <b>walking</b> 56:3          164:16  <b>wall</b> 7:13 46:16  <b>warning</b> 132:2  <b>washed</b> 40:6,7</p>	<p>41:6  <b>Washington</b> 35:11          128:16  <b>wasn't</b> 75:14 77:2          80:14 112:15          146:15,19,22          148:21 153:6          159:4 161:1  <b>watched</b> 139:4  <b>water</b> 4:14 40:5          52:18 114:20          126:19 129:9  <b>watery</b> 101:11  <b>ways</b> 10:2 51:14          100:6 107:9          113:7 192:16  <b>weak</b> 40:17 41:1  <b>weakness</b> 40:4  <b>wear</b> 48:12 121:21  <b>wearing</b> 48:12          53:9  <b>web</b> 6:4,5,7 8:19          11:5 32:5          35:13,21 36:2,8          37:20 38:9 51:22          68:5,15 69:12          77:15,17 87:11          92:13 94:7,13          100:17 101:9          103:10 109:10          110:5,10          137:2,19 139:20          142:19 148:15          152:11 153:16          156:17 161:9          166:3 167:4  <b>webcast</b> 8:3 13:20          16:8 29:18,19,22  <b>website</b> 8:4 16:17          31:2 180:22</p>	<p><b>we'd</b> 138:13  <b>weddings</b> 53:18  <b>wedgie</b> 72:19  <b>Wednesday</b> 80:11  <b>week</b> 46:21 62:14          72:14 99:10          146:15 147:5          159:3  <b>weeks</b> 97:12 115:5          123:9 127:6,16          147:2 168:3  <b>weighing</b> 48:22  <b>weight</b> 40:20          121:4 124:19          125:4 128:6,7          150:4  <b>weird</b> 54:5  <b>welcome</b> 4:2 8:8          11:9 100:5  <b>welcoming</b> 8:6  <b>we'll</b> 4:18 6:9          7:7,18,19 25:20          27:6 28:12          30:4,5 39:2,5          44:8 70:11,12          71:16 73:4          82:5,6 84:14,16          88:16 89:11          90:22 96:9,11          97:2 98:20          99:14,19 100:7          101:7 103:2          109:11,17 111:3          138:14,15          140:16 145:22          147:21          149:10,18          156:11 157:19          159:12 161:20          167:20 169:7,9</p>	<p>171:22 198:16  <b>Wellbutrin</b> 113:4  <b>well-controlled</b>          25:6  <b>WENDY</b> 202:4,13  <b>we're</b> 6:12 7:14          8:15,21 13:16          14:2,9,18,22          20:16 22:12 23:1          24:17 25:14 26:2          27:5,15 29:10          30:3,8,13 33:19          34:7 35:5 36:17          38:19,22 43:16          52:4 67:19 69:13          73:10 77:18          78:10 85:17          87:19 96:10          98:7,21 99:18          100:2,3,7,11          106:9 109:1          110:15 166:9          173:21 174:7          180:17 185:15          186:7  <b>we've</b> 11:16 16:19          17:2,4 40:11          111:11 145:7          152:12,15 156:4          164:6,10 167:6          178:20 180:10          191:3  <b>whack</b> 194:9  <b>whatever</b> 7:22          35:8 75:3 135:13          150:9  <b>whatnot</b> 160:17  <b>whenever</b> 99:20  <b>whereas</b> 20:19  <b>wherein</b> 192:19</p>
--	---	--	--

Capital Reporting Company  
 Functional GI Disorder Patient Focused Drug Development 05-11-2015  
 Page 49

<p><b>Whereupon</b> 200:21</p> <p><b>wherever</b> 66:14 117:7 192:6</p> <p><b>whether</b> 11:19 12:22 17:10 25:3 42:16 58:16 64:18 73:20 74:2 97:3,13 116:7 148:11,18 158:8</p> <p><b>White</b> 1:10 8:17</p> <p><b>whole</b> 6:13 13:6 47:4 54:22 63:20 64:22 66:22 141:5</p> <p><b>whom</b> 201:2</p> <p><b>who's</b> 29:14 36:22 85:4 109:5 155:12 178:13</p> <p><b>whose</b> 67:14</p> <p><b>wide</b> 111:1</p> <p><b>widespread</b> 13:12</p> <p><b>willingness</b> 34:17</p> <p><b>win</b> 186:14</p> <p><b>wings</b> 60:7</p> <p><b>Wisconsin-Madison</b> 187:9</p> <p><b>wish</b> 27:13 63:6 64:8 167:4 199:9</p> <p><b>wishes</b> 195:13</p> <p><b>woken</b> 88:21</p> <p><b>Wolfson</b> 2:12 71:17,18 117:18,19 147:22</p> <p><b>woman</b> 50:8</p> <p><b>women</b> 24:1 36:6 67:12 135:22</p>	<p>196:16</p> <p><b>wonder</b> 96:4 116:7 172:9 190:19</p> <p><b>wonderful</b> 16:8 55:4 60:2 61:20 123:14 172:17 185:5 190:3,14 199:17,19</p> <p><b>wonderfully</b> 140:15</p> <p><b>wondering</b> 103:3 144:8 148:7 165:15 173:4 188:12,13</p> <p><b>wonders</b> 155:16</p> <p><b>work</b> 10:14 22:18 45:15,22 48:9,13 51:2,6 52:17 81:3 82:19 86:21 108:17 109:21 112:12 113:20 114:7 115:1 119:2 122:6 130:17 131:18 142:21 143:1,5,9,13 152:20 165:9 175:21 177:17 185:13 192:8 196:4</p> <p><b>worked</b> 62:5 130:8 138:5,6,10,16 140:14 142:20 143:9,14 144:7,10 147:7 151:9 152:16 155:16 157:18 164:14 170:3</p> <p><b>working</b> 10:11 15:1 25:15 27:12 34:10 62:3 104:7 105:7 146:22</p>	<p>147:13 153:17 155:17 159:4 160:8 176:7 180:10,20 188:1</p> <p><b>works</b> 25:22 34:6 122:9 153:18 168:22</p> <p><b>world</b> 124:5</p> <p><b>worries</b> 149:16</p> <p><b>worse</b> 22:5 42:16,18 79:5 113:18 114:1 115:15 120:15 131:14 159:1 189:13</p> <p><b>worsen</b> 119:12</p> <p><b>worst</b> 27:4 41:10 78:17 172:12</p> <p><b>worth</b> 159:8 174:4</p> <p><b>wrap</b> 139:5 172:1</p> <p><b>wrap-up</b> 99:22</p> <p><b>write</b> 33:11 47:21 77:15 87:12 92:12 94:11 109:9 168:10</p> <p><b>writhing</b> 83:9</p> <p><b>written</b> 105:10</p> <p><b>wrong</b> 48:5 72:17 124:22 143:12 144:16 173:3,12</p> <p><b>wrote</b> 39:13</p> <hr/> <p style="text-align: center;">X</p> <hr/> <p><b>Xanax</b> 112:10</p> <p><b>Xifaxan</b> 143:6</p> <hr/> <p style="text-align: center;">Y</p> <hr/> <p><b>Y1</b> 194:9</p>	<p><b>Yep</b> 69:14</p> <p><b>yesterday</b> 80:18,20</p> <p><b>yet</b> 60:14 63:8,19 76:18 87:20 100:7 108:6 142:5 157:17 160:7 171:10 188:11 198:19</p> <p><b>yoga</b> 49:2 53:11 127:22</p> <p><b>yogurt</b> 63:8</p> <p><b>yogurt's</b> 63:10</p> <p><b>York</b> 52:6 57:1</p> <p><b>you'll</b> 7:5 16:17 149:12 174:4</p> <p><b>young</b> 41:19 73:17 152:2</p> <p><b>younger</b> 38:4 41:14 59:7 60:11 66:2</p> <p><b>yours</b> 30:5</p> <p><b>yourself</b> 172:3</p> <p><b>yourselves</b> 8:1</p> <p><b>you've</b> 8:10 36:20 66:21 76:7 83:2 100:19 136:11 149:9 154:8 166:5 171:9 200:10</p> <hr/> <p style="text-align: center;">Z</p> <hr/> <p><b>Zagnit</b> 3:4 175:15 194:13,14</p> <p><b>Zantac</b> 119:1</p> <p><b>Zegerid</b> 89:19</p> <p><b>Zelnorm</b> 24:6 132:19</p>
--	--	---	--

<p><b>Zev</b> 123:15 136:2 <b>zip</b> 91:16 <b>Zip-loc</b> 91:14,15 93:16 <b>Zofran</b> 126:10,16 129:4,17 130:1 141:16 143:8 <b>Zyprexa</b> 129:10,13,16 130:8,13,14,21 149:21 150:3,6</p>			
---	--	--	--